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NOVEL APPROACHES FOR THE SYNTHESIS OF C-5 MODIFIED PYRIMIDINE 
NUCLEOSIDES  
by 
Yong Liang 
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Professor Stanislaw F. Wnuk, Major Professor 
The antiviral or anticancer activities of C-5 modified pyrimidine nucleoside analogues 
validate the need for the development of their syntheses. In the first half of this dissertation, I 
explore the Pd-catalyzed cross-coupling reaction of allylphenylgermanes with aryl halides in the 
presence of SbF5/TBAF to give various biaryls by transferring multiple phenyl groups, which has 
also been applied to the 5-halo pyrimidine nucleosides for the synthesis of 5-aryl derivatives. To 
avoid the use of organometallic reagents, I developed Pd-catalyzed direct arylation of 5-halo 
pyrimidine nucleosides. It was discovered that 5-aryl pyrimidine nucleosides could be 
synthesized by Pd-catalyzed direct arylation of N3-free 5-halo uracil and uracil nucleosides with 
simple arenes or heteroaromatics in the presence of TBAF within 1 h. Both N3-protected and N3-
free uracil and uracil nucleosides could undergo base-promoted Pd-catalyzed direct arylation, but 
only with electron rich heteroaromatics. 
In the second half of this dissertation, 5-acetylenic uracil and uracil nucleosides have been 
employed to investigate the hydrogermylation, hydrosulfonylation as well as hydroazidation for 
the synthesis of various functionalized 5-vinyl pyrimidine nucleosides. Hydrogermylation of 5-
alkynyl uracil analogues with trialkylgermane or tris(trimethylsilyl)germane hydride gave the 
corresponding vinyl trialkylgermane, or tris(trimethylsilyl)germane uracil derivatives. During the 
hydrogermylation with triphenylgermane, besides the vinyl triphenylgermane uracil derivatives, 
vi 
 
5-[2-(triphenylgermyl)acetyl]uracil was also isolated and characterized and the origin of the 
acetyl oxygen was clarified. Tris(trimethylsilyl)germane uracil derivatives were coupled to aryl 
halides but with decent yield. Iron-mediated regio- and stereoselective hydrosulfonylation of the 
5-ethynyl pyrimidine analogues with sulfonyl chloride or sulfonyl hydrazine to give 5-(1-halo-2-
tosyl)vinyluracil nucleoside derivatives has been developed. Nucleophilic substitution of the 5-(β-
halovinyl)sulfonyl nucleosides with various nucleophiles have been performed to give highly 
functionalized 5-vinyl pyrimidine nucleosides via the addition-elimination mechanism. The 5-(β-
keto)sulfonyluracil derivative has also been synthesized via the aerobic difunctionalization of 5-
ethynyluracil analogue with sulfinic acid in the presence of catalytic amount of pyridine. Silver 
catalyzed hydroazidation of protected 2'-deoxy-5-ethynyluridine with TMSN3 in the presence of 
catalytic amount of water to give 5-(α-azidovinyl)uracil nucleoside derivatives was developed. 
Strain promoted Click reaction of the 5-(α-azidovinyl)uracil with cyclooctyne provide the 
corresponding fully conjugated triazole product.  
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1. INTRODUCTION 
1.1. Activities of purine and pyrimidine nucleosides and nucleotides 
It is known that both pyrimidine and purine nucleosides are the basic building blocks for 
DNA and RNA, which contain the genetic information that is passed from one generation to the 
next. The sugar linked purine and pyrimidine nucleosides were connected by phosphates to form 
the backbone for the DNA or RNA, whereas, the different heterobases interact with one and 
another in a certain pattern via hydrogen bond to form the double helix structure for DNA. The 
sequence of nucleoside bases in DNA is considered as the genetic information, which can be 
replicated by the DNA polymerase enzyme to RNA with high accuracy. In April 2003, the 
completion of the human genome sequence was announced.1 
Natural or synthesized purine and pyrimidine nucleosides are found to possess some 
important biological activities, which could be applied in biology, biotechnology or 
pharmaceutical development.2 With the research development, nucleoside analogues have 
attracted much more attention because of the wide application in the anticancer and antiviral area.  
The active nucleoside analogues of these compounds can be considered as “ prodrugs”, which 
need to be activated by normal metabolic process, such as phosphorylation. Both pyrimidine and 
purine nucleoside analogues are currently used clinically as antimetabolite drugs and share the 
similar mechanism. They cross into cells with the help of the nucleoside transporter and followed 
the metabolic pathway to be converted to nucleotide analogues, which could inhibit one or more 
enzymes that are critical for the DNA synthesis.3  
1.1.1. Anticancer activity of nucleoside analogues 
Until 2014, only 14 nucleoside-based drugs have been approved by the U.S. Food and Drug 
Administration (FDA) for the treatment of cancer (Table 1).4 Approximately 10% of the 
anticancer drugs are nucleoside analogues; six of these drugs were approved during the 1996-
2014 and there are more nucleoside analogues in the clinical trial stage. The approval of 
2 
 
nucleosides analogues as anticancer drugs by FDA indicates that synthesis of base/sugar-
modified nucleoside analogues is one of the most effective methods for the development of new 
drugs for cancer. 
Table 1. FDA approved anticancer purine and pyrimidine nucleoside analogues 
Drug Catagory Year 
5-aza-2'-deoxycytidine (Decitabine) 2′-Deoxycytidine 2006 
O6-methylarabinofuranosyl guanine (Nelarabine) Guanosine  2005 
5-aza-cytidine (Azacitidine) 2′-Deoxyadenosine 2004 
2'-fluoro-2'-deoxyarabinofuranosyl-2-chloroadenine (Clofarabine) Cytidine 2004 
N4-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine (Capecitabine) Cytidine 1998 
2,2-difluoro-2'-deoxycytidine (Gemcitabine) 2′-Deoxycytidine 1996 
2-chloro-2'-deoxyadenosine (Cladribine) 2′-Deoxyadenosine 1992 
2'-deoxycoformycin (Pentostatin) Adenosine 1991 
Arabinofuranosyl-2-fluoroadenine (Fludarabine) Purine analogue 1991 
5-fluoro-2'-deoxyuridine (Floxuridine) 2′-Deoxyuridine 1970 
Arabinofuranosylcytosine (Cytarabine) Cytidine 1969 
6-thioguanine (Lanvis) Guanine 1966 
5-fluorouracil (Adrucil) Uracil 1962 
6-mercaptopurine (Purinethol) Purine 1953 
Taking cytarabine (1-β-D-arabinofuranosylcytosine) as example, it is the anticancer drug in 
hematological malignanciesone, which is one of the first pyrimidine nucleoside analogs approved 
in 1969. Cytarabine is transported into the cell with the assistance of human Equilibrative 
Nucleoside Transporter 1 (hENT1),5,6 followed by the phosphorylation of deoxycytidine kinase 
(dCK) and nucleotide kinases to give 5'-arabinofuranosylcytosine triphosphate (5'-araCTP).7 The 
anticancer activity of 5'-araCTP is characterized as the inhibitor of DNA polymerase α8 and 
incorporation into DNA instead of deoxycytidine triphosphate (dCTP) to interrupt DNA synthesis. 
5'-Arabinofuranosylcytosine monophosphate is also able to incorporate into DNA to inhibit the 
DNA synthesis by preventing the DNA chain extension.9 However, the biological anticancer 
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activity could be disabled by cytidine deaminase and cytoplasmic 5'-nucleotidase to give inactive 
arabinosyluridine. 
1.1.2. Antiviral activity of nucleotides analogues 
During the past two decades, nucleoside analogues have become reliable antiviral agents in 
the treatment of different kinds of virus, such as herpes simplex virus (HSV), hepatitis B virus 
(HBV), human immunodeficiency virus (HIV) and others.2 Some of the antiviral nucleoside 
analogues are listed in Table 2.  
Table 2. Antiviral properties of purine and pyrimidine nucleoside analogues 
Drug Category Year 
2'-deoxy-2'-fluoro-2'-methyluridine-5'-phosphate (Sofosbuvir) Thymidine 2013 
Tenofovir disoproxil fumarate, mixture of purine analogues (Tenofovir) Purine 2008 
1-2-deoxy-β-L-erythro-pentofuranosylthymine (Telbivudine) Thymidine 2006 
5-fluoro-1-(2R,5S)-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine (Emtricitabine) Cytidine 2006 
(1S,3R,4S)-4-Hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentylguanosine (Entecavir) Guanosine 2005 
2',3'-didehydro-2',3'-dideoxythymidine (Stavudine) Thymidine 2001 
2',3'-dideoxy-3'-thiacytidine (Lamivudine) Cytidine 1998 
2',3'-didehydro-2',3'-dideoxythymidine (Stavudine) Thymidine 1994 
3'-azido-3'-deoxythymidine (Zidovudine) Thymidine 1987 
2-amino-1,9-dihydro-9-[(2-hydroxyethoxy)methyl]-6H-purin-6-one (Acyclovir) Guanosine 1982 
(E)-5-(2-bromovinyl)-2'-deoxyuridine (Brivudine) Uridine 1980 
9-β-D-arabinofuranosyladenine (Vidarabine) Adenosine 1976 
5-ethyl-2'-deoxyuridine (Edoxudine) Thymidine 1969 
5-iodo-2'-deoxyuridine (Idoxuridine) Uridine 1962 
The inhibition mechanism of the antiviral nucleoside analogues is similar to the anticancer 
agents mentioned above. First of all, the antiviral nucleoside analogues are transported into the 
cells by the Nucleoside Transporters (NTs), followed by the phosphorylation to give nucleotide 
analogues. Then, the resulting nucleotides repress the viral reproduction by incorporation into the 
nascent viral DNA chain which leads to the chain termination. The compound 3'-azido-3'-
deoxythymidine (AZT) is the first U.S. government-approved drug for the treatment of HIV, 
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which is a nucleoside analogue reverse-transcriptase inhibitor (NRTI). It can significantly inhibit 
the replication of the virus10 but cannot completely prevent viral replication.11 
1.2. Biological activities of 5-modified pyrimidine nucleosides 
Structure-activity relationship (SAR) studies indicated that the pyrimidine base bearing 
electron-withdrawing groups or conjugated substitutions at C5 position confer the biological 
activity of the nucleoside analogues,4,12-18 such as antiviral,19-24 anticancer,4,25 or antibacterial. 26,27 
Examples of pyrimidine nucleoside analogues with modification at C5 position include 5-
fluorouracil (1, FUra), 5-ethyl-2'-deoxyuridine (2, Edoxudine), (E)-5-(2-bromovinyl)-2′-
deoxyuridine22,28 (3, BVDU), 5-aza-2'-deoxycytidine4,25 (4, Decitabine) and 5-fluoro-1-(2R,5S)-
[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine (5, Emtricitabine) (Figure 1) which have potent 
antiviral properties. Pronounced cytotoxity and significant antiviral activity have been reported 
for 1-(-D-arabinofuranosyl)-5-ethenyluracil29 and 5-ethynyl-2'-deoxyuridine30 as well. 
 
Figure 1.Structure of anticancer/antiviral nucleoside analogues 
The 5-iodo-2'-deoxyuridine (1, Idoxuridine) is the first antiviral agent topically to treat herpes 
simplex keratitis. Later on, sugar and/or base modified nucleoside analogues have been 
synthesized and studied in detail.4,31 The 5-ethyl-2'-deoxyuridine (2, Edoxudine) was the first 
antiviral nucleoside analogue approved by the FDA in 1969, however it is not currently used 
clinically. The (E)-5-(2-bromovinyl)-2'-deoxyuridine (3, BVDU)28 and bicyclic 
furanopyrimidine-2-one nucleoside analogues which display remarkable antiviral potency against 
the varicella zoster virus (VZV),32 are highly potent and selective antiviral drugs. The 5-aza-2'-
deoxycytidine (4, Decitabine) was approved by FDA in 2006 for injection for the treatment of 
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patients with myelodysplastic syndromes (MDS).33 Emtricitabine (5) was approved by FDA in 
2006 as well and used for the treatment of HIV infection in adults and children. 
It is also worthy to note that the C5-aryl or C5-heteroaryl pyrimidine nucleoside analogues 
possess intrinsic fluorescence because of the extended conjugation system. These types of 
pyrimidine nucleoside analogues usually show special fluorescence with the irradiation by UV 
light, which could be employed as the molecular beacons for detecting the presence of abasic 
sites of oligonucleotide,34 determination of the RNA structure,35 exploring RNA folding and 
recognition,36 as well as studing the intramolecular electron transfer37 or electron injection in to 
DNA38,39 and so on.40,41 Among the 5-arylated pyrimidine nucleoside analogues, the 5-(2-
furyl)uridine and 5-(2-thienyl)-2'-deoxyuridine analogues display the strongest florescence, 
owing to the high conjugation between the electron rich furan or thiophene with the pyrimidine 
base. Thus they have been incorporated into RNA and DNA fragments using phosphoramidite 
solid support technology and used as fluorescent probes.34,36,42,43 The 5-aryl and 5-(2-thienyl) 
modified 2'-deoxyuridine (or cytidine) triphosphates can also be used as the substrates for DNA 
polymerases and for DNA staining and electrochemical labels.44-46 
1.3. Synthesis of the C-5 modified pyrimidine nucleosides via Pd-catalyzed cross-coupling 
reactions 
The transition metal catalyzed cross-coupling reactions have contributed significantly for the 
synthesis of biaryl compounds. One of the most important transition metal for the cross coupling 
reactions is the Palladium (Pd). With few exceptions, two different activated components are 
required. One is the organometallic, alkene (Heck reaction), or alkyne (Sonogashira reaction) and 
the other is the halides or triflates.  
The Pd-catalyzed reaction was first introduced by Dr. Richard Heck in 1970s.47 Later many 
Pd-catalyzed cross coupling reactions were published with different substrates, and the 
methodology became one of the most important methods to build the C-C bond. There are some 
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reasons for the popularity of the Pd-catalyzed coupling reaction. First of all, the coupling reaction 
can be carried out under mild conditions, which usually could inhibit the formation of the 
unwanted byproduct, or in other words, give the desired product in high yield selectively. Second, 
a wide range of functional groups could be tolerated by the Pd-catalyzed coupling reactions. 
Addition of ligands usually could increase the yield and decrease the reaction time or temperature 
by lowering the reaction barrier. Because of the important contribution of the Stille reaction, 
Heck reaction and Suzuki reaction in the organic synthesis, natural product synthesis or 
pharmaceutical application, 2010 chemistry Nobel Prize was awarded jointly to Richard F. Heck, 
Ei-ichi Negishi and Akira Suzuki.48  
1.3.1. Traditional Pd-catalyzed cross-coupling reactions 
1.3.1.1. General consideration 
The Pd-catalyzed cross-coupling reactions, such as Suzuki, Hiyama, Stille, Negishi and 
Kumada reaction, share some common similarity. They all need the organometallic 6 (e.g., B, Si, 
Sn, Zn, Mg) and aryl halides or pseudohalides 7 for the coupling reaction to work properly 
(Scheme 1). 
 
Scheme 1. General scheme for Pd-catalyzed cross coupling 
The general mechanism for the Pd-catalyzed cross-coupling reaction involves three basic 
steps (Figure 2). Initially, Pd insert into the sp2-hybridized C-X bond via a concerted three-center 
intermediate to give intermediate B, followed by transmetalation which involve the cleavage of 
the X-M bond and the formation of the new bond between the carbon of 6 and the palladium 
center to give intermediate C, and reductive elimination to give the coupled product 8 with the 
regeneration of the palladium catalyst A. Oxidative insertion step is usually considered as the rate 
determining step of the catalytic cycle. The presence of anionic ligands (e.g., OAc) could also 
7 
 
accelerate the oxidative insertion step by the formation of [Pd(OAc)(PR3)n]- to make the 
palladium more nucleophilic. 
 
Figure 2. General mechanism for Pd-catalyzed cross-coupling reaction 
1.3.1.2. Application of the traditional Pd-catalyzed cross-coupling reaction to the synthesis 
of C-5 modified pyrimidine nucleosides 
Since the C-5 modified pyrimidine nucleosides possess important biological activities, the 
synthesis of these pyrimidine nucleosides have been studied in detail. The Pd-catalyzed cross-
coupling reactions, which have developed rapidly during the last 40 years, are one of the most 
important methodologies used for the formation of new carbon-carbon bond. Thus, 5-aryl 
pyrimidine nucleosides have been directly synthesized by: i) aromatic photo-substitution of 5-
iodouracil nucleoside with poly substituted arenes or vice versa,49-51 ii) Pd-catalyzed coupling 
reaction employing 5-chloromercuripyrimidine nucleoside,51,52 or iii) Pd-catalyzed coupling 
reaction of 5-halopyrimidine nucleosides with organometallic, e.g., organolithium and organozinc 
compounds, which are required to be freshly prepared,49 as well as organotin, organosilican and 
organoboron. 12,30,37,53-60 The synthesis of numerous 5-substituted pyrimidine nucleosides via Pd-
assisted routes have been reviewed.12  
Heck Coupling 
The Heck reaction47 can build the C-C bond by coupling of an unsaturated halide (or triflate) 
with an alkene in the presence of base and palladium catalyst. It could also be employed to 
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synthesize the C-5 substituted pyrimidine nucleosides.61 Trans-3-(5-uridylyl)propenoate (10), 
which is an important precursor of BVDU, was first synthesized by Bergstrom62 with 5-
chloromercuriuridine and methyl acrylate in the presence of Li2PdCl4 in methanol. Later on, in 
order to eliminate the toxic mercury, Bergstrom56 employed the improved Heck condition63 to 
synthesize compound 10 in 53% with 5-iodo-2'-deoxyuridine 9. (E)-5-(2-Bromoethenyl)-2-
deoxyuridine 11, one of the most potent anti-herpes simplex virus (HSV) drug, was obtained from 
10 by basic hydrolysis followed by decarboxylation and bromination at 60 oC with NBS64 
(Scheme 2). 
 
Scheme 2. Synthesis of C-5 modified pyrimidine nucleosides via Heck reaction 
Sonogashira Coupling 
Sonogashira coupling65 is a useful tool to synthesize the alkynyl aryl or vinyl derivatives by 
the reaction of terminal alkynes with aryl or vinyl halides in the presence of Pd catalyst and 
copper(I) co-catalyst under the amine condition. Even though both 5-alkynyl- and 5-ethynyl- 2'-
deoxyuridines have been studied as potent inhibitor of HSV-1, HSV-2, and vaccinia virus (VV), 
the biological activity is too low to be considered as good antiviral agents.22,66 The 5-alkynyl 
pyrimidine nucleosides 13 could be synthesized by the Sonogashira reaction of 5-iodo-2'-
deoxyuridine 9 with several of terminal alkynes.30,67  
Further treatment of 13 with CuI and Et3N/MeOH at reflux condition gave the bicyclic 
furanopyrimidine derivative 12. Surprisingly, the parent bicyclic furanopyrimidine compound 
12a does not possess activity either against HSV-1, HSV-2, cytomegalovirus (CMV), or varicella 
zoster virus (VZV).68 However, the long chain bicyclic analogues display surprising and unique 
9 
 
biological profiles, especially for 12b bearing n-octyl group which is more active against VZV 
than the reference compound acyclovir.67 When R = TMS, desilylation of 13 with TBAF at 0 oC 
gave 5-ethynyl pyrimidine analogue, which could be converted to 11 by the selective 
hydrogenation (Scheme 3).30 
 
Scheme 3. Synthesis of C-5 modified pyrimidine nucleosides via Sonogashira reaction 
Suzuki Coupling 
The Suzuki reaction which couples organoboronic acid and aryl halides in the presence of 
palladium under basic conditions is another useful tool to build the carbon-carbon bond.69-71 5-
aryl pyrimidine nucleoside derivatives 15 could be obtained from the reaction of protected 5-iodo 
pyrimidine substrates 14 with organoboronic acid (Scheme 4).17,37,54  
 
Scheme 4. Synthesis of C-5 modified pyrimidine nucleosides via Suzuki reaction 
Hiyama Coupling 
Hiyama reaction72,73 is Pd catalyzed cross-coupling reaction of organosilanes with organic 
halides, which is promoted by fluoride ion.74-76 The organofluorosilanes could be used as the 
starting material directly or generated in vivo. C-5 Vinyl modified pyrimidine nucleoside 
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analogues 16 and 17 could be synthesized by the reaction of 5-iodo pyrimidine substrate 9 with 
fluorovinylsilane77 in the presence of TBAF at 60 oC (Scheme 5). 
 
Scheme 5. Synthesis of C-5 modified pyrimidine nucleosides via Hiyama reaction 
Stille Coupling 
Stille reaction,78,79 which involves the coupling of an organotin compound with organic 
halides or triflates via Pd-catalyzed coupling reaction, is another powerful tool to synthesize the 
C-5 modified pyrimidine nucleoside derivatives. It could tolerate different type of functional 
groups existed in the substrates. And various organotin reagents have been utilized for the 
synthesis of 5-substituted pyrimidine nucleosides 19 (Scheme 6).57 
 
Scheme 6. Synthesis of C-5 modified pyrimidine nucleosides via Stille reaction 
1.3.2. Direct activation and its application in Pd-catalyzed cross-coupling reactions 
With the research in progress, the Pd-catalyzed coupling-reactions can also occur with only 
one activated substrate under certain conditions (single C-H functionalization); sometimes 
activation was not required at all (double C-H activation).  
Direct arylation of aromatic rings with aryl halides or pseudo halides, which eliminate the 
usage of organometallic substrates, has been recently established as excellent protocols for the 
synthesis of biaryls and begun to compete with traditional Pd-catalyzed cross-couplings.80-85 It 
has been noted that both intra-86-88 or intermolecularly87,89-95 direct arylations can proceed 
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smoothly, especially with electron-rich heteroaromatics.83 One of the advantages is that either 
organic halides or organometallic reagents can be substituted by simple arenes as partners in 
cross-coupling processes. Such approaches are more atom efficiency in terms of sustainable 
chemistry. Extensive investigations have been made to improve our understanding of how the 
transition metals catalyze the cleavage and functionalization of the inert C-H bonds effectively. 
Since Pd is one of the most commonly used transition metal catalyst for the C-H functionalization, 
I will focus my dissertation on the Pd-catalyzed C-H functionalization. 
1.3.2.1. Single C-H functionalzation via Pd-catalyzed cross-coupling reactions 
As discussed above the 5-arylated pyrimidine nucleoside could be synthesized by the 
traditional Pd-catalyzed cross coupling reactions in good yield under the mild condition; however, 
multistep preparation of pre-activated organometallic substrates is required. Coupling products 
with toxic organotin residues might be a problem for biological studies as well. Thus, the C-H 
direct arylation of the pyrimidine nucleosides have been developed as an alternative method to 
avoid such problems. 
1.3.2.1.1. Direct arylation at C5/C6 position of uracil nucleosides 
Kim and coworkers reported that the coupling of 1,3-dimethyluracil 20 with electron rich aryl 
bromides 21 in the presence of Pd(OAc)2 and Cs2CO3 at 130 oC for 12 h gave 1,3-dimethyl-5-
aryluracil 22 in decent yield (35-79%) along with C6-arylated regioisomer 23 in 0-25 % (Scheme 
7).96 It’s the typical selectivity problem observed during the C-H functionalization of uracil base. 
Moreover, when 1-(tetrahydrofuran-2-yl)-3-benzyluracil was employed as the substrate to mimic 
the glycosidic bond of the nucleoside, the sever decomposition was observed under the regular 
coupling condition. Lowering the reaction temperature allowed the isolation of the corresponding 
product in 55 % with N3 protecting group.  
12 
 
 
Scheme 7. Direct C-H arylation of uracil analogues with aryl bromide 
Hocek and his group found that the 1,3-protected uracil analogues 20 could couple with aryl 
iodine in the presence of Pd catalyst and cesium carbonate to give the 5-arylated uracil analogues 
22, but with even higher temperature (160 oC) and longer time (48 h) (Scheme 8).68,69 
Interestingly, when the reaction was carried out with addition of CuI as the co-catalyst, the C6 
arylated product 23 was obtained as the major isomer but in low yield. If the reaction was carried 
out without Pd catalyst, 23 was observed as the only product.  
 
Scheme 8. Catalyst controlled single C-H functionalization of uracil analogues 
To obtain the natural uracil analogues, several of protecting groups (e.g., Bn, PMB) need to 
be installed at N3 position of 20 and later removed under different conditions; some of them were 
too harsh to give deprotected uracil in good yield. The application of methodology to nucleoside 
substrates was not discussed at all. It is believed that the coupling precede via concerted 
metalation deprotonation (CMD) mechanism, while the cupper catalyzed condition might proceed 
with deprotonation-cupration mechanism. 
Instead of coupling to aryl halides, 1,3-protected uracil 20 could also couple with boronic 
acid in the presence of Pd and ligand (1,10-phenanthroline) at 90 oC for 16 h to give 6-aryluracil 
analogues 23 as the exclusive product (Scheme 9).97 Interestingly, when the protected uracil 
analogues 20 coupled with simple arylboronic acid, 6-arylated products 23 were obtained in 
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moderate yield exclusively, whereas, when the heteroaromatic boronic acids were employed as 
the activated component, 20 was recovered unchanged. Similar results were obtained when 
protected uracil analogues were replaced with free uracil or protected uridine analogues. So, this 
optimized condition shows some limitations that only work for specific substrates. 
 
Scheme 9. Regioselective C-H arylation of uracil analogues with arylboronic acids 
1.3.2.1.2. Other C-H functionalization C5/C6 position of uracil nucleosides 
Iridium catalyzed C-H borylation of 20 in the presence of ligand at 80 oC gave unseparable 5-
borylated uracil intermediates 21 with 5,6-diborylated uracil analogue. Successive electrophilic 
trifluoromethylation with Togni reagent yielded 5-trifluoromethyluracil 24 in 21% (Scheme 10). 
Alternatively, 24 could also be obtained by the selective C-H trifluoromethylation of 20 with 
NaSO2CF3 in the presence of tert-butyl hydroperoxide.98 Another C-H direct arylation of 24 with 
aryl halide gave various products with 20 as the major component. C-6 Arylated products 23 and 
25 were only obtained in small quantity due to the instability of the trifluoromethyl group at C-5 
position under the basic condition.  
 
Scheme 10. Direct C-H borylation and arylation of 1,3-dimethyluracil 
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Selective C-H amination product could be synthesized by the coupling of 1,3-dimethyluracil 
20 and 4-bromoaniline in the presence of indolyliodonium tosylate (Scheme 11).99 The iodonium 
salt intermediate 25 was responsible for the regioselectivity (SEAr), followed by the amination 
gave the corresponding product 27 in 65 % yield (Scheme 8).  
 
Scheme 11. Direct C-H amination of uracil analogues 
1.3.2.2. Double C-H functionalization via Pd-catalyzed cross-coupling reactions 
1.3.2.2.1. Direct arylation at C5/C6 position of uracil nucleosides 
Double C-H functionalization reactions employ two unfunctionalized components, which 
could build the C-C bond without the pre-activation of any components. Pd-catalyzed cross-
coupling of 1,3-dimethyluracil 20 with arenes 28 in the presence of pivalic acid and silver acetate 
under the reflux condition gave 1,3-dimethyl-5-aryluracil 22 as the minor product and 1,3-
dimethyl-6-aryluracil 23 as the major product (Scheme 12).96 It is believed that reaction went 
through a concerted metalation-deprotonation (CMD) processes via PdII(L)(OPiv) species by 
deprotonation of the more acid hydrogen at C6 of uracil ring, followed by another concert 
metalation-deprotonation to give the 6-arylated uracil product 23. Analogously, the C5-C5' and 
C5-C6' dimer or even C5-C5' and C6-C5' trimer could be synthesized under the similar 
condition.100  
 
Scheme 12. Pd-Catalyzed double C-H functionalization of 1,3-protected uracil analogue 
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The Pd-catalyzed cross-couplings of unfunctionalized uracil analogues 20 with pyridine-N-
oxide 29 in presence of Pd(OAc)2 and silver carbonate at 140 oC for 12 h gave C-5 modified 
uracil product 30 with high regioselectivity and good yield.101 N-oxide analogue 30 was readily 
reduced by PCl3/pyridine to give the pyridine derivative 31 (Scheme 13). Comparing to the 
traditional Pd-catalyzed coupling reaction, the highly selective double C-H functionalization does 
not need to activate any component of the substrates. It is believed that the electrophilic 
palladation occurs preferentially at the C-5 position of uracil. Subsequent coordination with 
pyridine N-oxide to give active Pd(II) complex, followed by the reductive elimination to give 
coupling product 31. 
 
Scheme 13. Synthesis of 2-uracilyl pyridines via Pd-catalyzed double C-H functionalization 
1.3.2.2.2. Other C-H functionalization at C5/C6 position of uracil nucleosides 
Fully protected uracil could undergo the self-C-H functionalization to give a mixture of 5-5', 
6-6' or 5-6' dimmers in the presence of Pd(TFA)2 and AgOAc (Scheme 14).100 When the reaction 
was stirred at 120 oC for 4 h, the 5-5' dimmer 32 was the major regioisomer, whereas, when the 
reaction was stirred at 80 oC for 16 h, the 5-6' dimmer 33 was the major regioisomer. Interestingly, 
the reaction of 1,3,5-trimethyluracil or 1,3,6-trimethyluracil did not yield these dimmers under the 
similar condition. The steric effect of the methyl group either at C5 or C6 position of the uracil 
base might be responsible for the failure of the reaction. The sugar protected uridine and/or 2'-
deoxyuridine analogues also underwent these base-dimmer reactions.  
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Scheme 14. Synthesis of uracil dimmers via Pd-catalyzed double C-H functionalization 
The 5-alkenyl substituted uracil or uracil nucleoside derivatives could also be synthesized via 
the Pd-catalyzed double C-H functionalization.102 Thus, treatment of 1,3-protected uracil 
analogues 20 with terminal alkenes 34 in the presence of Pd(OAc)2, Ag2CO3 and pivalic acid at 
60 oC gave E-5-alkenyluracil derivatives 35 with excellent region- and stereoselectivity (Scheme 
15). However, it is worth to mention that these coupling conditions were only compatible with the 
fully protected uracil or uracil nucleosides and no examples of unprotected or N1 or N3 protected 
uracil were given. 
 
Scheme 15. Synthesis of 5-alkenyl uracil and uracil nucleosides via Pd-catalyzed double C-H activation 
The Pd-catalyzed intermolecular oxidative cross coupling of two different heteroaromatic 
rings to form the unsymmetrical hetero-biaryls has been reported recently by You.103 The 
methodology has also been applied to the purine analogues. Thus treatment of 1,3-diethyl 
xanthine 36 with 2-methylthiophene or furan 37 in the presence of Pd and Cu catalysts gave the 
bisheteroaromatic products 38 in excellent yield, which indicated the tolerance of free NH group 
at imidazole ring at purine skeleton (Scheme 16). Thiophene, furan or other fused electron rich 
heteroaromatics 37 not only couple with purine analogues but also the pyridine N-oxide. Thus, 
the different electron density between the two heteroaromatic components is believed to be the 
key point for the reactivity and selectivity in the two metalation104 steps of the catalytic circle.  
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Scheme 16. Substrate controlled intermolecular double C-H functionalization 
It has been proposed that the regioselective electrophilic C-H substitution (SEAr) with 
Pd(OAc)2 to give α-thienylpalladium(II) intermediate A (Figure 3). Followed by the concerted 
metalation-deprotonation (CMD) process to give the heterocoupling intermediate, which might be 
the rate determining step. The Cu salt seems to be crucial for the coupling reaction, since, both 
catalytic efficiency and regioselectivity were dramatically increased with the addition of 
substoichiometric amount the copper salt. 
 
Figure 3. Proposed intermediates for the oxidative double C-H activation 
Multi-fused heteroaromatics 40 could also be obtained via the intramolecular double C-H 
activation with benzimidazole or purine analogues 39 in the presence of Pd catalyst and silver salt 
as the oxidant (Scheme 17).105 With the addition of iodobenzene, it is possible to construct the 
seven, eight, or nine member ring bearing two phenyl groups with cooperation of iodobenzene, 
which is synthetically difficult. However, the double C-H activation was performed in the acidic 
mediates at 110 oC for 24 h, which will limit the scope of the substrates.  
 
Scheme 17. Substrate controlled intramolecular Pd-catalyzed double C-H functionalization 
18 
 
Catalyst/solvent controlled Pd-catalyzed oxidative heck reaction106 omit the need for pre-
activation of the substrates. According to the reactivity of indole, the palladation and Heck 
coupling reaction are preferred to take place at the C-3 position.107 However the reaction site 
could be changed by the addition of other additives or solvent via the migration of the C3-Pd-X 
bond to the C2-position. Treatment of indole 42 with alkene 43 in the presence of Pd(OAc)2 as 
catalyst at 70 oC yield two different products under the different oxidants and solvents (Scheme 
18). When Cu(OAc)2 was used as the oxidant in a mixture of DMF-DMSO, C3-functionalized 
product 44 was obtained exclusively. However, when tert-butyl benzyl peroxide was employed as 
the reoxidizing agent in the mixture of dioxane and AcOH, the C-H functionalization was 
directed to the C2 position to give 45. If the N-protected indole was used as the substrate, no 
alkenylation product was observed at either C2 or C3 position under the similar condition, 
indicating the crucial role of the free NH moiety.  
 
Scheme 18. Catalyst/solvent controlled alkenylation of indole 
1.4. A short overview of the organogermane chemistry 
Even though germanium is located between silicon and tin in the Group IVA in the periodical 
table, the application of organogermanes to Pd-catalyzed cross couplings has received much less 
attention comparing to Hiyama (organosilicane) and Stille (organotin) reactions.76,78,108 Because 
of the relative high cost and low reactivity of germanium, both the chemistry and biological 
activity of organogermanium are still under developed so far.  
1.4.1. Application of organogermanes to Pd-catalyzed cross-coupling reactions 
Even though the chemistry109 of organogermanium compounds could not compete with 
organosilicon or organotin compounds yet, considerable amount work have been done to the Pd 
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catalyzed cross-coupling area. Kosugi and coworkers110 found that Pd-catalyzed cross-coupling of 
the carbagermatranes 45 with aryl bromides 21 in the presence of ligand yielded corresponding 
products 47 in excellent yields (Scheme 19). Higher reactivity of the carbagermatrane analogues 
have been observed toward Stille-type coupling than the corresponding organotributylgermanes.  
 
Scheme 19. Pd-catalyzed cross-coupling of germatrane derivatives 46 with aryl bromides 
Oshima and coworkers111 reported the Pd-catalyzed cross-coupling of tri(2-furyl)germane 28 
with alkenyl or aryl halides in the presence of base to give aryltri(2-furyl)germane 49 which 
coupled with another aryl halides in the presence TBAF gave various biaryls (Scheme 20). It has 
found that the heteroaryl-Ge bond of 49 could be selective cleaved by the TBFA to form 
ArGe(OH)3 or germanoxanes in situ, which are crucial for the coupling to proceed smoothly. 
Nucleophilic hypervalent organogermanium species, such as [ArGe(OH)3F]-, was formed by the 
attack of the excess fluoride ion, followed by the transmetalation and reductive elimination to 
give biaryls.  
 
Scheme 20. Pd-catalyzed cross-coupling of tri(fur-2-yl)german and tri(fur-2-yl)phenylgerman with aryl halides 
Wnuk and coworkers112,113 noticed that vinyl-Ge(TMS)3 bond of 51 could be selectively 
cleaved upon the treatment of hydrogen peroxide under the basic condition (NaOH/H2O2) or tert-
butyl peroxide (t-BuOOH/KH) by generation of the reactive germanol or germanoxane 
intermediate. Followed by the Pd-catalyzed cross-couplings with alkenyl or aryl halides in the 
presence of Pd(PPh3)4 gave the corresponding coupling product 52 (Scheme 21). It is worthy to 
mention that the E-isomer of vinylgermane 51 gave E-isomer product only, while Z-isomer of 
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vinylgermane 51 gave a mixture of E/Z coupling products. The methodology is also applicable to 
the α-flouro vinylgermane substrates.  
 
Scheme 21. Synthesis of alkenyl arenes via vinyl tris(trimethylsilyl)germanes 
Spivey and coworkers114,115 found that upon irradiation of bis-(2-
naphthylmethyl)arylgermanes 53 with light in the presence of Cu(BF)4 gave difluorogermane 
intermediate 54 by the elimination of 2 equiv. of 2-naphthylmethlene methyl ether. Followed by 
the Pd-catalyzed cross-coupling reaction of 54 with aryl bromide in the presence of TBAF gave 
various biaryls 55 (Scheme 22).  
 
Scheme 22. Photo-induced Pd-catalyzed cross-coupling of bis(2-naphthylmethyl)arylgermens with aryl bromides 
Maleczka and coworkers116 observed that vinyl-Ge(Bu)3 bond of 74 could be cleaved under 
the base condition, followed by the Pd catalyzed cross-coupling with phenyl iodine to give 
corresponding products 75 (Scheme 23). It has been stated that the substituents at the allylic 
position could affect the regio- and stereoselectivity. 
 
Scheme 23. Pd-catalyzed cross-coupling of tri(butyl)vinylgermanes 74 with iodobenzene 
1.4.2. Biological activity of the germanium containing compounds 
Biological activities112,113 of organogermanium compounds have been reviewed and a few 
biologically active germane-modified nucleoside analogues have been developed. Even though 
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germanium is not considered as the essential element for any living organism, but germanium-
containing heterocyclic compounds are usually less toxic than their carbon and silicon 
analogues,117 so more and more biological test have been done on organogermanium 
compounds.118 Since germanium plays an important role in stimulation of iron consumption and 
hemoglobin production, dietary germanium supplements became very popular in the 1970s. Later 
on, the first organogermanium complementary medicine propagermanium (bis(2-
carboxyethylgermanium) sesquioxide) showed up in Japan under the trade name Serocion in 1994. 
Nowadays, there are lots of organogermanium compounds have been synthesized which possess 
antioxidant,119,120 antiviral,121 anti-tumor,117,122-126 anticancer,127-129 antiarthritic,130 antimalarial and 
immunoregulatory130 activity and radio protective property.131 
In 1999, Lukevics and coworkers found that triphenylgermylisoxazoline 58 is a very active 
antitumor germanium-containing compound (Figure 4).117 Spirogermanium 59 is also another 
very important germanium-containing compound which has antitumor,125 antiarthritic, 
antimalarial and immunoregulator activity.128,129,131  
 
Figure 4. Biological activities of germanium containing compounds 
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Germatrane 60 also shows the antitumor activity, and its toxicity is depending on the 
substitution groups which are attached to the germanium atom.131,132 The antitumor activity of 
methylgermanium(IV) porphyrin (MGP) 61 was studied by Miyamoto in 1983.122 The 
germanium containing nucleoside analogues also shows promising biological activities. The 5-
trimethylgermyluracil and 1-(2-tetrahydrofuranyl)-5-trimethylgermyluracil 62 exhibit 
cytotoxicity to melanoma B16 cells.133 The α and β anomer of 2'-deoxy-5-trimethylgermyluridine 
63, which is one of the few known examples of germanium-containing nucleoside analogues, 
display different properties. α-anomer could inhibit the replication of HSV-1 in vitro and block 
incorporation of thymidine and DNA of ovarian cancer cell, while β-anomer does not work as 
well as the other isomer.121 
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2. RESEARCH OBJECTIVES 
The research objectives of this dissertation were to develop novel methods for the preparation 
of 5-modified pyrimidine nucleosides and to explore their possible applications as biochemical 
probes. 
The first objective of this dissertation was to develop a new procedure for the arylation of the 
uracil nucleosides at C5 via Pd catalyzed cross coupling reaction employing organogermanes as 
nucleophilic coupling substrates. On the basis of our finding75,134 that transfer of phenyl groups 
from the phenyl(chloro)germanes to the Pd-activated aryl halides is facilitated by the presence of 
TBAF, I developed the synthesis of 5-aryluracil nucleosides of type 65 by Pd-catalyzed cross-
coupling between arylchlorogermanes and 5-halouracil substrates 64 promoted by TBAF (path A, 
Scheme 24).  
Since the traditional Pd-catalyzed cross-coupling reaction involves the usage of 
organometallic reagents, in the second objective of my dissertation, I developed a novel 
methodology for the synthesis of 5-arylated uracil nucleosides of type 65 via Pd catalyzed direct 
arylation of the 5-halouracil substrates 64 with simple arenes or heteroaromatics, which avoids 
the use of organometallic nucleophiles (path B, Scheme 24). Optimization of direct arylation 
using various fluoride bases (e.g., CsF, KF or TBAF) or regular bases (e.g., Cs2CO3, K2CO3 or 
NaOH) promoters as well as mechanistic considerations would be explored.  
 
Scheme 24. Proposed synthesis of 5-aryl uracil nucleosides by Pd-catalyzed coupling with organogermanes (path 
A) or direct arylation (path B) 
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Since hydrogermylations of alkyl or arylalkynes usually give vinylgermanes in good yields, 
and vinyl tris(trimethylsilyl)germanes are known to be good substrates in the Pd-catalyzed cross-
coupling reactions with alkenyl/aryl halides,112,113 I prepared a series of pyrimidine nucleosides 
modified at the C-5 position with vinylgermane units. Thus radical hydrogermylation of 5-
ethynyluracil nucleosides 66 with alkyl-, aryl- or tris(trimethylsilyl)germane should produce the 
corresponding 5-modified vinylgermanes 67 (Scheme 25). I investigated the application of the 
nucleosides for the synthesis of highly conjugated C5 modified pyrimidine nucleoside analogues 
68 via the Pd catalyzed cross-coupling (path A, Scheme 25). Halodegermylation of 67 with 
electrophilic halogens (e.g., NBS, NIS) was explored to develop an alternative synthesis of the 
important 5-halovinyl pyrimidine nucleosides 69 (path B, Scheme 25).  
 
Scheme 25. Proposed synthesis of 5-vinylgermyl uracil nucleosides by hydrogermylation and application to Pd-
catalyzed coupling with aryl halides (path A) or halodegermylation (path B) 
To further investigate the chemistry of 5-ethynyl pyrimidine nucleosides, I synthesized a 
series of novel 5-(β-halo)vinyl sulfonyl analogues 70. Thus, the synthesis of 5-(β-halo)vinyl 
sulfonyl pyrimidine analogues would be explored via Fe(III) mediated regio- and stereoselective 
hydrosulfonylation of 5-ethynyl analogues 66 with aryl/alkyl sulfonyl chloride in the presence of 
triphenylphosphine (path A, Scheme 26). Alternatively, iron halide catalyzed hydrosulfonylation 
with sulfonylhydrazides in the presence of a catalytic amount of tert-butyl hydroperoxide (TBHP) 
would also be explored (path B, Scheme 26). Since, the 5-(β-halo)vinyl sulfonyl analogues 70 can 
serve as an excellent Michael acceptors, e.g., as electrophiles to form covalent adducts with 
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nucleophile. I studied the addition of typical nucleophiles (e.g., propanethiol, n-butylamine) and 
the corresponding model amino acids (e.g., lysine, cysteine) to these novel 5-modified 
nucleosides. Kinetics and chemical yields of such Michael addition reaction would be “tuned up” 
by incorporation of electron donating group (EDG) or electron withdrawing group (EWG) on the 
aromatic ring of the sulfonyl compounds. I expected that the addition of nucleophiles to such 
Michael acceptors should occur via an addition-elimination reaction with the elimination of 
halides and formation of the vinyl adducts.  
 
Scheme 26. Proposed synthesis of 5-(β-halo)vinyl sulfonyl pyrimidine nucleosides by hydrosulfonylation of 63 
with sulfonyl chloride (path A) or sulfonyl hydrazide (path B) and its application to the nucleophilic substitution 
I expect that direct aerobic difunctionalization of 5-ethynyl nucleoside analogues 66 with 
sulfinic acid in the presence of a catalytic amount of pyridine could serve as an access to the 5-(β-
keto)sulfonyl pyrimidine nucleoside analogues 72 (Scheme 27). Since the methylene protons 
adjacent to ketone and sulfonyl groups are quite acidic with pKa around 12, it was envisioned that 
after deprotonation by base, the corresponding carbon ion could be methylated (e.g., MeI or S-
Adenosyl methionine) or trapped (e.g., proximal protein electrophiles) by electrophiles to give 73. 
 
Scheme 27. Proposed synthesis of 5-(β-keto) sulfonyl pyrimidine nucleosides by hydrogermylation of 63 with 
sulfinic acid and its application to electrophilic substitution 
26 
 
I have also planned to explore the synthesis of 5-(α-azido)vinyl pyrimidine nucleosides 42 via 
silver-catalyzed hydroazidation of 5-ethynyl substrates 66 (Scheme 28). Since 5-azido uracil 
analogues are photo labile, and their application to click chemistry is under development, I am 
planning to utilize these 5-(α-azido)vinyl analogues 74 in copper free click chemistry with the 
ring strained cyclooctyne to synthesize 5-(α-1,2,3-triazol)vinyl pyrimidine nucleosides which 
could be further incorporated into DNA or RNA as fluorescent probes. 
 
Scheme 28. Proposed synthesis of 5-(α-azido)vinyl pyrimidine nucleosides by hydroazidation of 63 with TMSN3 
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3. RESULTS AND DISCUSSION 
3.1. Synthesis of 5-aryluracil nucleosides via Pd-catalyzed cross coupling reactions 
3.1.1. Coupling reactions of 5-halouracil nucleosides with chloro(phenyl)germanes 
3.1.1.1. Developing a general procedure for transfer of phenyl group(s) from 
chloro(phenyl)germanes to aryl halides mediated by TBAF  
Most recently, we have reported the TBAF-promoted synthesis of biaryls via Pd-catalyzed 
cross coupling of trichloro(phenyl)-, dichloro(diphenyl)-, and chloro(triphenyl)germanes 75-77 
with aryl halides in “wet” toluene.75,134-136 It has been stated that the presence of chloride was 
necessary for organogermanes to generate the active fluorophenylgermane intermediate in situ,137 
which are believed to be the active intermediates in transferring of phenyl groups from Ge atom 
to Pd-activated aryl halides. Thus coupling of 75 with 1-iodonaphathalene in the presence of 
Pd2(dba)3 gave 55 in high yield (Scheme 29). Additional amounts of water have been proven to 
be necessary for multiple transfers of the phenyl group from the germane center. It has also been 
shown that the coupling efficiency of arylchlorogermanes is comparable to that of the more 
developed organotin or organosilane substrates.  
 
Scheme 29. Synthesis of 1-phenylnaphthalene via chlorophenylgermanes 
On the basis of these findings and the available knowledge on the susceptibility of 
organogermanes toward coupling, it appears that the reaction is promoted either by: (i) 
intramolecular chelation of a pendant Lewis basic heteroatom which renders the Ge center 
“permanently” pentavalent110 or (ii) coordination of a heteroatom activated Ge center with an 
external Lewis basic ligand (e.g., fluoride, hydroxide, etc.), which is also rendering the Ge center 
pentavalent. 75,110,115,134 Even though the mechanism of fluoride/base activated Pd-catalyzed cross-
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coupling reaction of organogermanes with aryl/alkenyl halides is still unclear, such reactions have 
been achieved. 75,112,113,134,135 
3.1.1.2. Attempted TBAF-promoted coupling of 1-N-benzyl-5-iodouracil with 
chloro(pehnyl)germanes in toluene 
In order to achieve the first objective of my dissertation, which was synthesis of 5-arylated 
pyrimidine nucleosides employing 5-halo substrates to couple with organogermanes as the 
coupling partner, efforts have been taken to develop model coupling between 5-halouracil and 
chloro(phenyl)germanes, which have been used as the substrates for selective transfer of phenyl 
groups from the germyl center.75,112,136,138 Thus, I applied the optimal coupling condition to 5-halo 
pyrimidine nucleosides for the synthesis of 5-aryl analogues. Treatment of 1-N-benzyl-5-
iodouracil 78a with triphenylchlorogermanes 77 in the presence of tetra-N-butylammonium 
fluoride (TBAF, 1 M/THF containing 5% of water) and Pd2(dba)3 catalyst in toluene at 100 oC for 
16 h gave 1-N-benzyl-3-N-butyl-5-phenyluracil 79b as well as the N3-butylated reduction product 
80a (Scheme 30).  
 
Scheme 30. TBAF promoted cross-coupling of 5-iodouracil with chloro(triphenyl)germane 
However, after careful analysis of GC-MS spectra, it was surprising to find that there is a 
mixture of 1-N-benzyl-3-N-butyl-5-(o,m,p-methylphenyl)uracil products 79a which likely derive 
from the coupling of 78a with toluene. In order to clarify and simplify the reaction, 78a was 
heated in toluene alone in the presence of TBAF and Pd2(dba)3 at 100 oC for 18 h. As expected, 
mixture of 5-(o,m,p-methylphenyl)uracil products 79a was obtained in 75 % (combined yield for 
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all three isomers) along with a small amount of N3-butylated reduction product 80a. (See Chapter 
3.1.3 for detail discussion) 
3.1.2. Coupling reactions of 5-halouracil nucleosides with allyl(phenyl)germanes 
Although the chemistry of allylgermanes is well established,139,140 the application of allyl 
(phenyl)germane to the selective transfer of phenyl groups from a germanyl center by Pd-
catalyzed cross-coupling reaction with aryl halides has not been investigated. 
3.1.2.1. Developing a general procedure for transfer of phenyl group(s) from 
allyl(phenyl)germanes to aryl halides mediated by SbF5/TBAF 
3.1.2.1. Optimization for selective transfer of phenyl groups from germane center 
On the basis of our experience and literature research, SbF5 was found to be a suitable reagent 
to selectively cleave Ge-allyl bonds and to generate reactive germanate species for subsequent 
transmetalation. Treatment of allyl(phenyl)germanes 83 or 82 with SbF5 (0.25-0.5 equiv) 
intercalated in graphite141 in toluene (0.5-1h, 50 °C) resulted in disappearance of the germane 
substrates (TLC, 1HNMR). In order to demonstrate that the fluoro(phenyl)germanes are the 
resulting active intermediates, selective deallylation was carried out in benzene-d6 at room 
temperature and 50 oC side by side (Scheme 31).  
 
Scheme 31. Selective cleavage the allyl-Ge bond of allylphenylgermanes with SbF5/C 
The progress of the reaction was monitored by TLC, which showed the disappearance of the 
starting material in 1h. The 19F NMR spectra also indicated the formation of fluorogermane 
intermediates. Reactions with 82 and 83 showed the clean formation of the fluorogermanes 
Ph3GeF (s, δ -202.3 ppm; Figure 5; 1 and 2) and Ph2GeF2 (2 × s, δ -165.2, and -167.4 ppm; Figure 
5; 3 and 4), respectively, with spectroscopic data in agreement with the reported values.75,115,136 
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However, analogous treatment of 81 with SbF5 gave a cluster of peaks at δ -140.2 to -159.7 ppm 
(Figure 5; 5 and 6). It is noteworthy that when 81, 82, or 83 was treated with TBAF only under 
the same condition, no Ge-allyl bond cleavage was observed for any of the substrates.  
 
Figure 5. 19F NMR analysis of the allylgermanes cleavage upon treatment of SbF5/C 
Optimizations were performed to find the best coupling condition. Thus, treatment of the 
fluorogermane generated in situ from 82/SbF5 with 87b in TBAF/toluene resulted in transfer of 
phenyl groups from Ge producing biaryl 88b in addition to the homocoupling byproduct 89b 
(Table 3). Treatment of 82 with SbF5/C alone, as a fluoride source, failed to give coupling 
product 88b. It was found that at least 3 equiv. of TBAF was required to give 88b in maximum 
yield (Entries 1-5). The yield was increased dramatically when couplings were carried out with 
addition of a measured amount of water (~10-30 equiv; Entries 6-8), which was consistent with 
86, Ph3GeF 
86, Ph3GeF 
85, Ph2GeF2 
84, PhGeF3 
84, PhGeF3 
85, Ph2GeF2 
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the previous finding.75,134 As expected, two phenyl groups were transferred upon the treatment 
with the combination of SbF5/TBAF in moist toluene, which has been shown the TBAF promoted 
cross-couplings of Ph2GeCl2 with aryl halides.75,134,136 It is worthy to mentioning that the newly 
developed method here proceeds with the selective cleavage of the allyl-Ge bond of 81-83 with 
SbF5 by generation of fluorogermanes 84-86 in situ, which allows transfer of phenyl groups, 
differs from the previous developed protocol that allow selectively transfer of allyl groups from 
81-83 upon treatment with base.135,136 Thus transfer of phenyl or allyl groups from a Ge center 
could be chemoselective, depending on the activation protocol.  
Table 3. Coupling of diallyl(diphenyl)germane 82 with 1-iodonaphthalene 87b promoted by SbF5 
 
Entry Germanea TBAFb (equiv.) Yield (%)c, d 
Ratio d 
88b:89b 
1 82 1 43 4.4:1 
2 82 2 53 3.9:1 
3 82 3 60 (54) 3.8:1 
4 82 4 47 2.0:1 
5 82 5 44 1.3:1 
6 82 3 e 67 (59) 5.2:1 
7 82 3 f 72 (62) 4.5:1 
8 82 3 g 68 6.1:1 
a Couplings were performed on 0.14mmol scale of germane 82 (0.04 M) with 2 eqiuv of 87b and 0.05 equiv of Pd 
catalyst. b Commercial available 1 M THF solution containing 5% H2O. c The yield was calculated based upon 
transferring of two phenyl groups from 82. Isolated yield in parenthesis. d Based on GC-MS of the crude reaction 
mixture. e With the addition of 25 μL of H2O. f With the addition of 50 μL H2O. g With the addition of 75 μL H2O. 
3.1.2.1.2. Extension of the method to other aryl halides 
Various biaryls have been synthesized with the optimal conditions and the results are 
summarized in table 4. Treatment of 81, 82, or 83 with SbF5/C generated active 
organofluorogermane intermediates in situ, followed by subsequent TBAF-promoted Pd-
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catalyzed cross-coupling reactions with 1, 2, or 3 equiv. of aryl halides respectively afforded 
biaryls 88b-88d in good to excellent yields. Couplings with 1-bromonaphthalene also gave 88b, 
but the yield is lower compared to 1-iodonaphthalene 88b. It is worth mentioning that more than 
one phenyl groups has been transferred during the cross-coupling reaction and aryl halides 
bearing electron donating groups (entries 2, 5, and 8) gave better yields and ratios compared to 
the cases with electron withdrawing groups (entries 3, 6 and 9). 
Table 4. Coupling of allyl(phenyl)germanes 81-83 with aryl halides promoted by SbF5 
 
Entry Germanea Halide Product 
Yield Ratio 
(%)b 88:89 
1 81 1-bromonaphthalene 88e 45 15:1 
2 81 (4)CH3OPhI 88c 91 20:1 
3 81 (4)CF3PhI 88d 49 1.9:1 
4 82 1-bromonaphthalene 88b 73 2.3:1 
5 82 (4)CH3OPhI 88c 95 1.8:1 
6 82 (4)CF3PhI 88d 69 1:1 
7 83 1-bromonaphthalene 88b 46 3.3:1 
8 83 (4)CH3OPhI 88c 104 1.6:1 
9 83 (4)CF3PhI 88d 75 1:1.5 
a Couplings were performed on 0.14mmol scale of 81-83 (0.04 M) with 0.05 equiv of Pd2(dba)3 and 1.0 (for 81), 2.0 
(for 82), or 3.0 (for 83) equiv of aryl halides and TBAF/(1M/THF, 3 equiv)/water (50 μL). b Based upon transferring of 
one, two, or three phenyl groups from 81, 82, or 83, respectively. Isolated yield in parenthesis. c Determined by GC-MS 
of the crude reaction mixture. 
3.1.2.1.3. Proposed mechanism for the selective transfer of phenyl groups from 
allyl(phenyl)germanes 
Contrary to what has been discovered by a previous group member, that allyl could be 
selectively transferred under basic conditions in the presence of Palladium to give the allylation 
product,136 this methodology allows for the selective transfer of the phenyl group from a Ge 
center thereby yielding biaryls upon treatment with SbF5/C and TBAF (Scheme 32). Initially, the 
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allyl-Ge bond of 83 was selectively cleaved upon treatment with SbF5 to give 
fluorophenylgermanes 86 in situ, followed by the treatment of TBAF to yield the active 
pentafluorogermanate intermediates 90, which were readily coupled with Pd-activated aryl 
halides B. After the transmetalation and reductive elimination, various biaryls 88 were obtained 
and organogermane D will go to the next circle until there is no phenyl group available.  
 
Scheme 32. Proposed mechanism for the SbF5 promoted transfer of phenyl group from Ge center 
3.1.2.2. Attempted SbF5/TBAF-promoted coupling of 1-N-benzyl-5-iodouracil with 
allyl(pehnyl)germanes in toluene 
In order to further explore the synthesis of 5-arylated pyrimidine nucleosides employing 5-
halouracil substrates in coupling reactions with organogermanes, TBAF-promoted Pd-catalyzed 
cross-coupling reactions of 5-halouracil have also been applied to allyl(phenyl)germanes 81-83. 
Thus, treatment of allyl(triphenyl)germane 83 with SbF5/C (0.25 equiv) in toluene at 50 °C for    
1 h leads to the formation of active fluoro(phenyl)germane species 86, which was then followed 
by the vacuum filtration to give a clear solution that was used directly for the next step (Scheme 
33). 1-N-benzyl-5-iodouracil 78a, TBAF (1M/THF), and Pd2(dba)3 were added to the crude 
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material from the last step at ambient temperature under nitrogen atmosphere and the resulting 
brownish mixture was stirred at 100 oC for 18 h. However, no coupling product was observed. 
Thus, no further studies were performed.  
 
Scheme 33. SbF5 Mediated Pd-catalyzed cross-coupling of 5-iodouracil 78 with allyl(triphenyl)germane 83 
3.1.3. Direct arylation of 5-halouracils and 5-halouracil nucleosides with arenes and 
heteroarenes  
Intrigued by the unexpected result and after reviewing the literature, it was found that direct 
arylation of the 3-N unprotected uracil analogues has not been reported. The currently available 
methods for direct 5-arylation of the uracil analogues were noted to be either not suitable for the 
natural (3-N-unsubstituted) uracils142 or caused cleavage of the nucleoside glycosidic bond.96 
Because of the importance of the enolization between the 4-oxo group and the hydrogen at the   
3-N position in the biology and chemistry of RNA/DNA, as well as in nucleoside-derived drug 
metabolism, it was deemed of interest to explore the direct arylation of 5-halopyrimidine 
nucleosides with arenes, which would supplement the well-established Suzuki and Stille 
approaches. 
3.1.3.1. TBAF-Promoted Pd-catalyzed direct arylation of 5-halouracil  
To continue with the previous funding (Scheme 30 in Chapter 3.1.1.2), the authentic samples 
of m-79b, o-79b and p-79b were synthesized via Suzuki coupling54 to elucidate the ratio of the 
three isomers. By comparing the retention time of each authetic isomer via GC and spiking the 
reaction mixture with the authentic sample, the ratio of ortho/meta/para was established as 3:2:1. 
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In order to eliminate the N3-butylation during the coupling, the reaction was terminated after 6 h. 
However, besides an isomeric mixture of 79a, both N3-butylated byproducts 80a and the reduced 
substrate 92 were also detected as byproducts in the crude reaction mixture (Table 5, entry 1). 
Table 5. Effect of the reaction parameters in the direct arylation of 1-N-benzyl-5-iodouracil 1a with toluene 
 
Entry Reagent/solventa Pd 
TBAF 
(equiv) 
Base 
(2 equiv) 
Time 
(h) 
91ab 
Yield (%)c,d 
92 
Yield (%)d 
1 Toluene Pd2(dba)3 7 -- 6 45e 3 
2 Toluene Pd2(dba)3 7 -- 0.75 75 (71)f 5 
3 Toluene Pd2(dba)3 6 -- 1 60 15 
4 Toluene Pd2(dba)3 5 -- 1 48 g 17 
5 Toluene Pd2(dba)3 3 -- 1 30 8 
6 Toluene Pd(OAc)2 7 -- 1 70 (68) h 7 
7 Toluene/DMFi Pd2(dba)3 7 -- 1 82 (65) 7 
8 Toluene/DMFj Pd2(dba)3 7k -- 1 65 (50)l 19 
9 Toluene/DMAi Pd2(dba)3 7 -- 1 20 10 
10 Toluene/dioxanei Pd2(dba)3 7 -- 1 40 46 
11 Toluene/DMFj Pd2(dba)3 -- KFm 2 - 11 
12 Toluene/DMFj Pd2(dba)3 -- Cs2CO3n 2 - 25 
13 Toluene/DMFj Pd(OAc)2 -- KOSiMe3 2 - 80 (65) 
14 Toluene/DMFj Pd(OAc)2 - Ag2CO3o 2 - 17 
15 Toluene/DMF/H2O Pd(OAc)2 - K2CO3 2 - 23 
a Couplings were performed on 0.14 mmol scale of 78a [0.05 M (entries 1-10) or 0.07 M (entries 11-18)] with 
0.05 equiv. of Pd catalyst. b Mixture of o/m/p isomers (3:2:1, GC-MS). c Overall yield for o/m/p isomers. d Determined 
by GC-MS of the crude reaction mixture. Isolated yield in parenthesis. e Also 80a (35%) was formed. Longer reaction 
time (18 h) produced 79a in 85% yield (75% isolated yield as mixture of o/m/p isomers; 3.4:2.3:1).  f 70% yield at 90 
oC for 1.5 h. 40% yield at 80 oC for 4 h. g 35% with 4 equiv. of TBAF. h 69% yield at 90 oC for 1.5 h. i 1:1 (v/v). j 1:9 
(v/v). k When neat TBAF·3H2O (7 equiv.) was used 91a (67%) and 92 (20%) were produced. l 25% yield in 1:20 (v/v; 
toluene/DMF). m Reaction with CsF also did not yield 91a. n Attempts with different equivalents of bases (0.5-4.0) or 
prolonged reaction time (4 h)  were also unsuccessful. o Couplings also did not proceed in the presence of Cs2CO3 or 
AgOAc and their combination with pivalic acid. 
After careful investigation of reaction time and temperature, it is found that the direct 
arylation of 78a can be completed in less than one hour (45 min) at 100 oC (entry 2). It is worth 
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noting that no N3-butylation was not observed (GC-MS) until 1.5 h at 100 oC. Experimental data 
also showed that the amount of TBAF is crucial for the coupling to proceed smoothly and at least 
7 equiv. of TBAF was required to give 91a in highest yield and with the best 91a to 92 ratios 
(entries 2-5). Pd2(dba)3 was the best catalyst but Pd(OAc)2 also gave 91a in similar yields 
compared to other tested Pd catalysts (entry 6). In order to increase the coupling efficiency and 
lower the ratio of toluene to 78a, an inert solvent was sought, which is suitable for the direct 
arylation. Thus, the direct arylation was performed in 1:1 and 1:9 (v/v) mixture of toluene/DMF 
to give coupling product 91a in 82 % and 65 % respectively (entries 7 and 8). Replacement of the 
TBAF/THF solution with the same amount of neat TBAF·3H2O also gave 91a with similar yield 
(entry 8, footnote k). It is noteworthy that each of these fluoride reagents introduced 
approximately the same amount of water to the reaction mixture and water is known to play 
multiple roles in enhancing the efficiency of the couplings including the formation of the reactive 
hydroxypalladium intermediates.75,136,143,144Arylation of 78a with toluene in DMA and dioxane 
(1:1, v/v) also gave 91a but in lower yields (entries 9 and 10), whereas, arylation was not 
successful in mixtures of toluene/THF (1:1; v/v) at reflux, which is probably due to the much 
lower reaction temperature. Coupling of 78a with toluene in the presence of either of the fluoride 
sources, e.g., CsF or KF (2 equiv.), or bases, e.g., Cs2CO3, Ag2CO3, K2CO3, or KOSiMe3, instead 
of TBAF, did not yield 91a (entries 11-15). No improvement was observed either by varying the 
amount or combination of bases, Pd catalysts, and reaction times (entry 12) or by addition of 
pivalic acid (entry 14). Even though DMF/H2O (5:1, v/v) was tried as the medium to improve the 
solubility of inorganic salts, the arylation was still not successful (entry 15). 
Determination of the generality of the TBAF-promoted direct arylation in couplings of 5-
halouracils 78a or 78b with various arenes and heteroaromatics is presented in Table 6. Thus, 
treatment of 5-iodouracil 78a with benzene in DMF in the presence of TBAF (7 equiv.) at 100 oC 
for 1 h gave 5-phenyluracil 91b in 71 % as a single product in addition to a small amount of the 
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reduced substrate 92 (Table 6, entry 1). Arylation of 78a with m-xylene gave a mixture of the 
three regioisomers (88%) from which the 2,4-dimethylphenyl isomer 91c was isolated in 55% 
yield (entry 2).  
Table 6. Direct arylation of 5-halouracils 78 with and electron-rich arenes and heteroaromatics  
 
Entry Substratea Product Ar- 91 or 93Yieldb,c (%) 
92 or 94 
Yieldb (%) 
1 78a 91b 71 (59) 13 
2 78a 91c 88d (55)e 5 
3 78a 91d 76f (68) 21 
4 78b 91b 78g (71) 20 
5 78a 91e 95h,i (81) -- 
6 78a 91f 72h,j (66) 22 
7 78a 91g 97h (91) -- 
8 78a 91h 80h (70) 2 
9 78a 91i 61h (54) 28 
10 78b 91e 91 (85) -- 
11 78c 93a - 75 (73) 
12 78c 93g - 59k 
a Couplings were performed on 0.14 mmol scale of 78 (0.07 M) in the presence of 0.05 equiv. of Pd and 7 equiv. 
of TBAF unless otherwise noted. b Determined by GC-MS of the crude reaction mixture. c Isolated yield in parenthesis. 
d Overall yield for three possible isomers (ratio, 14:5:1). e Yield for 2,4-dimethylphenyl isomer of 91c. f  Overall yield 
for mixture of o/m/p (ratio, 4:1:1) isomers. g With 14 equiv. of TBAF. h With 3.5 equiv. of TBAF. i 77% at 90 oC. j 47% 
with benzofuran:78a ratio (1.5:1). k Coupling with furan instead of thiophene also produced 94 (60%).  
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Arylation of 78a with anisole also gave 91d as a mixture of o/m/p regioisomers in 76 % 
(entry 3). As 79b, the ratio for the o/m/p isomers of 91d was established by comparison with 
authentic samples prepared by Suzuki coupling.54 However, coupling of 78a with arenes bearing 
electron withdraw group (EWG) either failed (nitrobenzene) or gave the corresponding 5-arylated 
products in low yields (1,2,3,4,5-pentafluorobenzene, 15%, GC-MS). Analogous treatment of 5-
bromouracil 78b, prepared by bromination of 1-N-benzyluracil with 1,3-dibromo-5,5-
dimethylhydantoin (DBH) in the presence of TMSOTf,145 with benzene also proceeded smoothly 
to give 91b in 78% yield but 14 equiv. of TBAF was required (entry 4). Compared to the regular 
arenes, only 3.5 equiv. of TBAF was required for electron rich heteroaromatics to couple 
efficiently with 78a. Thus, coupling of 78a with furan gave 5-(2-furyl)uracil 91e in 95 % yield as 
the only isomer (entry 5). Arylation of 78a with benzo[b]furan proceeded in good yield even with 
only a slight excess of heteroaromatics (benzo[b]furan/78a, 1.5:1, mol/mol; benzo[b]furan/DMF, 
1:100, v/v; entry 6). Reaction of 78a with thiophene gave 5-(2-thienyl)uracil 91g quantitatively 
(entry 7), while coupling with 2-substituted thiophenes provided single products 91h or 91i in 
good yield as well (entries 8 and 9). The 5-bromouracil 78b also coupled efficiently with furan 
under similar conditions to give 91e but 14 equiv. of TBAF was required (entry 10). It is worthy 
to note that TBAF-promoted direct C-H arylation between 3-N-methyl-5-iodouracil 78c and 
toluene, furan or thiophene only gave the reduced product 94 (entries 11-12). 
3.1.3.2. Base promoted Pd-catalyzed direct arylation of 5-halo uracil  
Contrary to the unsuccessful coupling of 78a with simple arenes under the TBAF condition 
(Table 6, entries 11-18), the π-excessive heteroarenes did couple successfully with 5-iodouracil 
78a in the presence of bases (Table 7). Initially, when 78a was heated with thiophene (15 equiv.) 
in DMF at 100 oC in the presence of Pd(OAc)2 and K2CO3 (2 equiv.) for 2 h, only reduced 
product 92 was obtained (Table 7, entry 1). However, when the reaction was carried out in a 
mixture of DMF/H2O (5:1, v/v), product 91g was obtained in 75% yield (entry 2). Apparently the 
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increased solubility of K2CO3 in the DMF/H2O mixture changed the outcome of the reaction 
dramatically. It also has been noted that the solubility of K2CO3 is very low in pure organic 
solvents146 (e.g., less than 1% of K2CO3 was dissolved in DMA after 30 min heating at 120 oC). 
The yields were only slightly different when 1 or 4 equiv. of K2CO3 was used (entry 3). 
Table 7. Effect of the reaction parameters in the base-promoted direct arylation of 1-N-benzyl-5-iodouracil 78a 
with thiophene  
 
Entry Solventa Base Equiv. 
T 
(oC) 
Yield 
91g (%)b,c 
Yield 
92 (%)b 
1 DMF K2CO3 2 100 - 80 (74) 
2 DMF/H2O d K2CO3 2 100 75 (60)e 20 
3 DMF/H2O K2CO3 1 f 100 73 (61) 17 
4 DMF/H2O NaOH 2 100 16 30 
5 DMF/H2O CsF 2 100 37 35 
6 DMF/H2O Ag2CO3 2 100 20 8 
7 DMF/H2O Cs2CO3 2 100 61 (53) 32 
8 DMF/H2O Cs2CO3 2 80 53 (41) 8 
9 DMF/H2O Cs2CO3 2 60 13 2 
10 DMF Cs2CO3 2 100 76 (65) 11 
11 DMF Cs2CO3 g 2 100 82 (76)h 4 
a Couplings were performed on 0.14 mmol scale of 78a (0.05 M) with 0.05 equiv. of Pd(OAc)2. b Determined by 
GC-MS of the crude reaction mixture. c Isolated yield in parenthesis. d DMF/H2O (5:1, v/v). e Pd2(dba)3 gave 91g in 36% 
isolated yield. f 4 equiv. of K2CO3 gave 91g in 50% isolated yield. g With addition of PivOH (1.25 equiv.). h 80% yield 
with addition of PivOH (1.25 equiv.) and Ag2CO3 (1.0 equiv.). 
Direct arylation in the presence of NaOH or CsF or Ag2CO3 gave 91g in low yields (entries 
4-6) but proceeded efficiently with Cs2CO3 (entry 7). Temperature also plays an important role in 
the direct arylation. Coupling at 80 oC for 2 h gave 91g in 53% but with an increased ratio relative 
to 3 (entry 8), while reaction at 60 oC for 4 h produced 91g in only 15% (entry 9). Arylation of 
78a in the presence of Cs2CO3 in DMF not only increased the yield but also the ratio 91g to 92 
(entry 10), and the result turned out to be even better with the addition of pivalic acid146 (entry 11). 
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Generally, direct arylation of 78a promoted by TBAF gave the best results with Pd2(dba)3 as the 
catalyst while base-promoted coupling proceeded more efficiently with Pd(OAc)2. 
Other electron-rich heteroarenes have also been coupled to the 5-halouracils via the base-
promoted C-H direct arylation (Table 8). Coupling of 78a with furan and thiophene in DMF in 
the presence of Cs2CO3 and PivOH at 100 oC for 2 h gave 91e and 91g in 79% and 82%, 
respectively, in addition to a small amount of reduced product 92 (Table 8, entries 1-2).  
Table 8. Cs2CO3 Promoted direct arylation of 5-halouracils 78 with electron-rich heteroaromatics  
 
Entry Substrate a Product Ar- 91 or 93Yieldb,c (%) 
92 or 94 
Yieldb (%) 
1 78a 91e 79 (73)d 12 
2 78a 91g 82 (76) 4 
3 78a 91j - 11 
4 78b 91e 13 14 
5 78b 91g 16 13 
6 78c 93e 71 (65) 15 
7 78c 93g 70 (62) 15 
8 78a 91a - 65 
9 78c 93a - 74 
a Couplings were performed on 0.14 mmol scale of 78 (0.05 M) with Cs2CO3 (2 equiv.), PivOH (1.25 equiv.), and 
Pd(OAc)2 (0.005 equiv.). b Determined by GC-MS of the crude reaction mixture. c Isolated yield in parenthesis. d 
Coupling without addition of PivOH gave 91e in 65% yield. 
However, coupling was not successful with pyrrole (entry 3). Analogously, 91e and 91g 
could also be obtained in lower yields by the direct arylation of 5-bromouracil 78b with furan and 
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thiophene (entries 4 and 5). Surprisingly, contrary to the unsuccessful arylation of 78c with 
heteroarenes with TBAF (Table 6, entry 12), the base-promoted arylation of 78c with furan or 
thiophene gave coupling products 93e and 93g in good yield (entries 6 and 7). However, 
attempted coupling of the N3-free 78a and N3-protected 78c uracil substrates with simple arenes, 
e.g., benzene or toluene, in the presence of Cs2CO3 failed to give products (entries 8 and 9). 
3.1.3.3. Direct arylation of pyrimidine nucleosides 
Since our TBAF or base promoted direct arylation methodologies not only avoided the use of 
toxic organotin substrates42,43,147 but also worked efficiently with the 3-N unprotected uracil 
substrates,94,96,142 I will apply them to 5-halopyrimidine nucleosides for the synthesis of 5-arylated 
uracil nucleosides. Thus, treatment of 2',3',5'-tri-O-acetyl-1-(-D-arabinofuranosyl)-5-iodouracil 
95 with furan/DMF (1:9, v/v) in the presence of TBAF (3.5 equiv.) and Pd2(dba)3 afforded 5-(2-
furyl)uracil analogue 101 in 61% (Table 9, entry 1). Similarly, the acetyl group protected 2'-
deoxy-5-iodouridine 96 was also converted to 102 by coupling with furan (entry 2). Analogous 
treatment of 97 with furan, thiophene and 2-methylthiophene gave the corresponding products 
103-105 in moderate yield (entries 3-5). It is obvious that our direct arylation conditions are not 
only compatible with natural nucleosides but also compatible with the commonly used acyl 
protection group. Followed by the deacetylation of 101 or 102 with methanolic ammonia at 
ambient temperature, the corresponding unprotected 5-arylated uracil nucleoside derivatives 106 
(92%) and 107 (95%) were obtained. The TBAF-promoted direct arylation has also been applied 
to the unprotected nucleosides to check compatibility. Thus, subjection of 1-(-D-
arabinofuranosyl)-5-iodouracil 98, 2'-deoxy-5-iodouridine 99, and 5-iodouridine 100 with furan 
in the presence of TBAF and Pd-catalyst gave the corresponding 5-(2-furyl)uracil nucleoside 
analogues 106-108 in high yields (entries 6-8).  
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Table 9. Direct arylation of 5-iodouracil nucleosides with electron-rich heteroaromatics  
 
Entry Substrate a Conditions Product Ar- Yieldb 
1 95 a 101 61 
2 96 a 102 72 
3 97 a 103 67 
4 97 a 104 63 
5 97 a 105 55 
6 98 a 106 70 
7 99 a 107 73 
8 100 a 108 80c,d 
9 100 a 109 98 
10 100 a 110 76 
11 100 a 111 45 
12 100 b 108 23 
13 100 b 109 17 
a Couplings were performed on 0.14 mmol scale of nucleosides (0.07 M) in the presence of 3.5 equiv. of TBAF 
and 0.05 equiv. of Pd catalyst. Ratio of Ar-H to substrate nucleosides 15-20:1. b Isolated yields. c 41% yield with 1.75:1 
ratio of furan to 100. d Coupling on 1 mmol scale of 100 gave 105 in 88% yield.  
Coupling of 100 proceeded also with only a small excess of furan (1.75 equiv.) affording 108 
in 41% isolated yield (entry 8, footnote c). The 5-iodouridine 100 coupled efficiently with 
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thiophene and 2-methylthiophene to give products 109 or 110 (entries 9 and 10). It was found that 
pyrrole was also able to couple with 100 to give 5-(2-pyrrolyl)uridine 111 in respectable yield 
(entry 11). This compound can be purified on a silica gel column but is somewhat unstable during 
storage or upon prolonged exposure to air. Base-promoted C-H direct arylation also works 
smoothly with natural nucleosides, but the efficiency is not as good as the TBAF methodology. 
Treatment of 100 with furan or thiophene in the presence of Cs2CO3 and Pd catalyst at 100 oC for 
2 h gave 5-arylated uracil nucleoside derivatives 108 or 109 in 23% and 17% isolated yield 
(entries 12 and 13). The cleavage of the glycosidic bond was observed during the arylation, which 
is consistent with the literature report.96  
In the attempts to expand direct arylation to other pyrimidine systems, the 5-iodocytidine 
analogues were prepared by the modification of the existing procedure (Scheme 34).148,149 Stirring 
of 112 with acetyl chloride in AcOH/CHCl3 (1:1, v/v) at ambient temperature for 40 h gave 
2',3',5'-tri-O-acetylcytidine in 96%, followed by iodination with I2/HIO3 gave 113 in 63%.  
 
Scheme 34. TBAF or base promoted coupling of 5-iodocytidine analogues with furan 
Unfortunately, direct arylation of 113 with furan employing either TBAF or the base protocol 
was not successful. Alternatively, the acetyl protecting groups of 113 were removed by the 
treatment with methanolic ammonia to give unprotected cytidine analogue 114. Acetylation of 
113 was also carried out with acetic anhydride to give fully acetyl protected cytidine analogue 
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115. Both 114 and 115 have been applied to the direct arylation with furan, however, none of 
these substrates worked successfully in the TBAF or base promoted direct arylation. 
3.1.3.4. Scopes and mechanistic consideration 
It is important to establish the generality of the direct arylation methodology. Thus the TBAF 
promoted direct arylation was expanded to other heterocyclic systems, which also have similar 
tautomerization between the oxo group and the hydrogen at the adjacent nitrogen atom. 
Treatment of 3-bromo-2-pyridone 119 with furan or thiophene in the presence TBAF and 
Pd2(dba)3 without other additives added gave products 120 (41%) and 121 (37%) as well as the 
unchanged 119 (Scheme 35). Similarly, treatment of 119 with furan in the presence of 
Cs2CO3/PivOH and Pd(OAc)2 gave 120 in 49%. Interestingly, few examples have been reported 
on the arylation and/or vinylation of the N-alkylated 3-halo-2-pyridones at 3 position using 
Suzuki150,151 or Stille152 or Negishi153 protocols. 
 
Scheme 35. TBAF or base promoted direct arylation of 3-bromo-2-pyridone  
On the basis of literature reports and established mechanisms,80-83,88,146,154 direct arylation of 
5-iodouracils is expected to occur via either electrophilic aromatic substitution (electrophilic 
palladation with nucleophilic arenes) or direct proton abstraction (σ-bond metathesis). There is 
not sufficient data for speculation on the mechanism or the role of TBAF at this moment. 
However, it is clear that 1-N-benzyl-3-N-methyl-5-iodouracil (78c) did not undergo TBAF-
promoted coupling with arenes because of the nonexistence of tautomerization. Thus, it is 
believed that the C4-alkoxide (enol form of uracil) may participate in the intramolecular 
processes of hydrogen abstraction via a six membered ring as depicted in structures A and B 
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(Figure 6). It has also been noted that direct arylation was facilitated by using a Pd-coordinated 
carboxylate group, which assisted in intramolecular proton abstraction.146,154 
 
Figure 6. The plausible intermediates for the Pd-catalyzed direct arylation of 5-halouracils: (A) Electrophilic 
aromatic palladation assisted by C4-alkoxide; (B) Direct proton abstraction assisted by C4-alkoxide. 
The TBAF promoted direct C-H arylation methodology has also been applied to 1-N-
benzyluracil 92 and aryl halides. Thus, treatment of 92 with 4-iodoanisole under the optimal 
conditions did not give uracil products either at the C5 or the C6 position. However, treatment of 
92 with 4-iodoanisole (3 equiv.) in the presence of TBABr/Pd(OAc)2/AgCl94 produced a mixture 
of p-91d (23%) and 122 (33%) in addition to the unchanged 92 (41%, Scheme 36). No further 
efforts have been made to optimize the conditions for direct C-H arylation of uracil analogues, 
since Hocek142,155 and Kim96 have reported the base-promoted direct C-H arylation of 1,3-N-
diprotected uracils at C5 and/or C6 position(s) with aryl halides. They found that higher 
temperature (130-160 oC) and longer reaction time (12-48 h) are required, which led to the 
rampant cleavage of the glycosidic bond.96  
 
Scheme 36. Pd-catalyzed direct C-H arylation of uracil with 4-iodoanisole 
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3.2. Synthesis of highly functionalized 5-vinyluracil nucleosides from 5-acetylene substrates  
3.2.1. Hydrogermylation of 5-ethynyluracil nucleosides 
I also investigated the hydrogermylation of the 5-ethynyluracil and uracil nucleosides with 
germane hydrides with different catalysts. The 5-[2-tris(trimethylsilyl)germanyl]vinyluracil 
nucleoside analogues have been explored in Pd-catalyst cross-coupling reactions with aryl halides 
as well as in halodegermylations.  
3.2.1.1. Synthesis of 5-[2-(germyl)vinyl]uracil and 5-[2-(triphenylgermyl)acetyl]uracil 
nucleosides  
On the basis of screening of all available methods for hydrogermylation of alkynes, such as 
Pd(0)-catalyzed,136,156,157 Lewis acid-promoted,136,158,159 or radical-mediated136,160 processes, I have 
tested for the preparation of 5-[(2-germyl)vinyl]uracil nucleosides 124. The 1-(2,3,5-tri-O-acetyl-
-D-arabinofuranosyl)-5-ethenyluracil161 123 was subjected to Ph3GeH in the presence of 1,1'-
azobis(cyclohexanecarbonitrile) (ACCN) in toluene at 90 oC (Method A) to give the vinyl 
germanes 124a as a mixture of regioisomers with the Z isomer as the major product via anti-
addition of the germyl radical to the triple bond (Table 10). The ratio for E-124a (J = 18.8 Hz) 
and Z-124a (J = 13.5 Hz) diastereomers was established as 5:95 by 1H NMR spectroscopy, which 
was consistent with the literature report.160 Surprisingly, careful purification gave another new 
product, which was assigned (vide infra) as 5-[2-(triphenylgermyl)acetyl]uracil nucleoside 
derivative 126a (12%; Table 10, entry 1).  
Subjection of 123 under the same condition with Ph3GeH in the absence of ACCN gave 124a 
in 60% with a better ratio (E/Z, 3:97) along with the β-keto germyl uracil nucleoside 126a in 15% 
(entry 2). Hydrogermylation of 123 with Ph3GeH in the presence of Et3B162 in THF at -78 oC 
(Method B) gave Z-vinyl germane 124a in 55% as the only product (entry 3), while Z-124a was 
obtained in 28% at 0 °C as well as 126a, which was not observed at -78 oC (entry 4). Analogous 
treatment of 123 with Ph3GeH in the presence of B(C6F5)3159 in CH2Cl2 at ambient temperature 
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gave a trace amount of 124a. Hydrogermylation156 of 123 with Ph3GeH in the presence of 
Pd(PPh3)4 in THF gave a mixture of E-124a and a 5-[1-(triphenylgermyl)ethenyl] regioisomer in 
73% with ratio of 3:2 (Method C). The similar regioisomer, which was formed by the addition of 
a germyl radical to the α-carbon, was also observed.156 It is worthy to note that the β-keto germyl 
uracil nucleoside 126a was only observed with Method A or Method B at 0 oC. Deacetylation of 
Z-124a with NH3/MeOH afforded the 1-(-D-arabinofuranosyl)-5-[2-
(triphenylgermyl)acetyl]uracil Z-125a in 86%. Hydrogermylation of 123 with trimethylgermane 
hydride (Me3GeH)162 by method B at -78 °C did not give 124b, while it could be obtained in 40% 
with low stereoselectivity (E/Z, 13:87) at ambient temperature (entry 6). Surprisingly, 5-2-
(trialkylgermyl)acetyl uracil nucleoside 126b was not observed at either -78 oC or ambient 
temperature. Hydrogermylation of 123 with (Me3Si)3GeH by method A gave 5-2-(TTMS-
germyl)ethenyl uracil analogue Z-124c stereoselectively in 68% in 30 min., but again, β-keto 
germyl uracil nucleoside 126c was not detected (entry 7). Hydrogermylation of 2',3',5'-tri-O-p-
toluoyl-5-ethynyluridine 127 with Ph3GeH by Method B (-78 °C→ 0 oC) gave 129a in 40% along 
with the 5-[2-(triphenylgermyl)acetyl] product 133a in 13% (entry 8). Analogous treatment of 
127 with Me3GeH by Method B (0 °C→ 25 oC) yielded a mixture of stereoisomers 129b in 41% 
(E/Z, 45:55; entry 9). Treatment of 127 with TMS3GeH by Method B (-78 °C→ 0 oC) yielded Z-
129c as the single isomer in 61% (entry 10). Hydrogermylation of 3',5'-di-O-p-toluoyl-5-ethynyl-
2'-deoxyuridine 128 with Ph3GeH by Method B (-78 °C to 0 °C) gave Z-131a in 61% along with 
134a in 12% (entry 11). 
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Table 10. Hydrogermylation of 5-ethynyluracil and related nucleosides with germane hydrides 
 
Entry Substrate Methoda Temp (oC) R3GeH 
Vinyl Germanes Germyl Ketones 
Product 
Yieldb
(%) 
Ratiob 
(E/Z) 
Product 
Yieldb
(%) 
1 123 A 90 Ph3GeH 124ac 47 0:100 126a 12 
2 123 Ad 90 Ph3GeH 124a 60 3:97 126a 15 
3 123 B -78 → -60 Ph3GeH 124a 55 0:100 - - 
4 123 B 0 Ph3GeH 124a 28 0:100 126a 19 
5 123 C 5 Ph3GeH 124ae 45 100:0 - - 
6 123 B 0 → 25 Me3GeH 124b 40 15:85 - - 
7 123 A 0 → 25 (Me3Si)3GeH 124cf 68 0:100 - - 
8 127 B -78 → 0 Ph3GeH 129a 40 0:100 133a 13 
9 127 B 0 →25 Me3GeH 129b 41 45:55 - -- 
10 127 B -78 → 0 (Me3Si)3GeH 129c 61 0:100 - - 
11 128 B -78 → 0 Ph3GeH 131a 61 0:100 134a 12 
12 128 Ag 100h Ph3GeH 131ai 33 0:100 134a 17 
13 128 B 0→25 Me3GeH 131b 35 40:60 - - 
a Method A: R3GeH/ACCN/toluene/90 or 100 oC; Method B: R3GeH/Et3B/THF/-78 or 0 oC; Method C: 
Pd(PPh3)4/THF/rt. b Isolated yield. c Crude reaction mixture (E/Z-124a, 5:95). d Without the presence of ACCN. e In 
addition to E-124a the α-addition product was formed as well (~3:2, 73% overall). f Crude reaction mixture (E/Z-124c, 
4:96). g Toluene/THF (20:1, v/v) was used as solvent. h Oil-bath. i With toluene/DMF/H2O (20:1:0.1, v/v/v) as solvents 
E-131a, Z-131a and 134a (~2:2:1, 40% overall) were obtained.  
Analogous treatment of 128 with Ph3GeH by Method A in toluene/THF (20:1, v/v) gave Z-
131a and 134a (entry 12). Interestingly, analogous hydrogermylation of 128 in toluene/DMF with 
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addition of a "measured" amount of water (14 equiv.) produced E/Z-131a (~1:1) and 134a (entry 
12, footnote i). Treatment of 128 with Me3GeH by Method B (0 °C→ 25 oC) gave only E/Z-131b 
(entry 13) but once again no germyl ketone product was observed. Deprotection of E/Z-129b with 
MeONa/MeOH gave uridine analogue E/Z-130b in 71%, while deprotection of Z-131a with 
NH3/MeOH yielded 2'-deoxyuridine analogue Z-132a (65%), confirming the stability163 of the 
C(sp2)-Ge(alkyl)3 and C(sp2)-Ge(aryl)3 bonds. 
It has been stated that hydrogermylation of the alkyl or aryl alkynes gives vinyl germanes in 
high yields; however, the detection of β-germylketones has not been reported yet.112,160,162,164 Thus, 
the hydrogermylation of phenylacetylene with Ph3GeH under the optimal conditions described in 
Method A and B has been reexamined. No β-germylketones were neither observed under such 
conditions, which is consistent with the literature report. I have also checked the 
hydrostannylation and hydrosilylation of 5-alkyne nucleoside 127 with Ph3SnH and Ph3SiH under 
the same reaction conditions, but again either 5-[2-(triphenylstannyl,- or silyl)acyl] products of 
type 129a were not observed, which suggest the formation of 129a were exclusive for Ph3GeH. 
Intrigued by this interesting finding, 1-N-benzyl-5-ethynyluracil 135 was employed as the 
model substrate for hydrogermylation to examine the chemistry and mechanism involving the 
formation of 5-keto pyrimidine nucleosides 126a, 133a or 134a. The 18O-labeled alkyne 136 was 
also synthesized to elucidate the origin of the acetyl oxygen. The synthesis of 135 and [18O]-136 
was depicted in Scheme 37. Treatment of 1-N-benzyluracil 92 with Lawesson’s reagent in THF at 
56 °C for 1 h gave the 1-N-benzyl-4-thiouracil 137 in 65%. S-Methylation165 of the purified 137 
by treatment with MeI in the presence Et3N in CH2Cl2 led to the formation of thioether 138 in 
93%. The acid-catalyzed hydrolysis166 of 138 with H2[18O] (99.2% 18O) in anhydrous EtOH 
produced desired 18O-labeled 1-N-benzyluracil analogue 139 in 90% with 85% of isotopic 
incorporation, which was calculated on the basis of the corresponding peak intensities in the mass 
spectra. Iodination of 92, as well as 139, with a solution of iodine monochloride30 (1 M in CH2Cl2) 
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in dry CH2Cl2 afforded 5-iodouracils 140 and 141 in excellent yields (93%). Sonogashira 
couplings of the 5-iodouracils 140 or 141 with trimethylsilylacetylene in Et3N resulted in the 
formation of 142 (80%) and 143 (62%) respectively. The fluoride-promoted desilylation with 
TBAF furnished 5-ethynyluracil 135 and its 18O-labeled 136 in good yields (60% and 58%, 
respectively). It is noteworthy that desilylation with NH4F/MeOH167 offered similar results but 
substantially eased the purification from TBAF-derived residues. 
 
Scheme 37. Synthetic route for the preparation of 5-ethynyluracil and 18O-labeled 5-ethynyluracil 
Hydrogermylation of 135168,169 with Ph3GeH in the presence of ACCN in toluene at 90 o C for 
2 h gave Z-vinyl germane 144 in 27% along with 5-[2-(triphenylgermyl)acetyl]uracil 146 in 13% 
(Table 11, entry 1). Analogously, 135 was subjected to Ph3GeH in toluene at 100 oC for 10 h in 
the absence of ACCN to yield Z-144 and 146 in 34% and 20% yields (entry 2). However, 
analogous treatment of 135 with Ph3GeH in "moist" toluene gave syn-addition product E-144 in 
86% exclusively (entry 3). Hydrogermylation of 135 with Ph3GeH in the presence of Et3B/THF at 
0 °C produced Z-144 in 52% as the only product (entry 4). Similar treatment of the 18O-labeled 
alkyne 136 with Ph3GeH in toluene at 100 oC for 10 h without ACCN afforded Z-145 as 
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crystalline product in 31% as well as 1147 in 18% (entry 5). On the basis of the mass 
spectroscopy, the incorporation [18O]-isotopic for both 145 and 147 are the same as the 136. 
Table 11. Hydrogermylation of 1-N-benzyl-5-ethynyluracil with triphenylgermane 
 
Entry Substrate Methoda Temp (oC) R3GeH 
Vinyl Germanes Germyl Ketones 
Product 
Yieldb
(%) 
Ratiob 
(E/Z) 
Product 
Yieldb
(%) 
1 135 A 90 Ph3GeH 144 27 0:100 146 13 
2 135 Ac 100 Ph3GeH 144 34 0:100 146 20 
3 135 Ac,d 100 Ph3GeH 144 86 100:0 - - 
4 135 B 0 Ph3GeH 144 52 0:100 - - 
5 136 A 100 Ph3GeH 145 31 0:100 147 18 
a Method A: R3GeH/ACCN/toluene/90 or 100 oC. b Isolated yield. c Without the presence of ACCN.  j With 
addition of 25 µL H2O (14 equiv.).  
3.2.2.2. Mechanistic consideration and the origin of 5-acetyl oxygen 
The structures of the 5-[(2-triphenylgermyl)acetyl]uracil derivatives were established using 
NMR spectroscopic data and HRMS analysis. The absence of the vinyl unit for 133a at the 
expected downfield region and appearance of two doublets at 3.76 and 3.87 ppm (J = 9.0 Hz) in 
the 1H NMR spectrum supported the presence of the methylene adjacent to carbonyl and the Ge 
moiety. The peak at 193.3 ppm in the 13C NMR spectrum of 133a confirmed the presence of the 
ketone.  
The (+)ESI-MS analyses of 146 and the 18O-labeled 147 samples produced predominantly the 
[M + Na]+ ions of 146 and 147. The collision-induced dissociation (CID) of the [M - H]- ions did 
produce ions indicative of the 18O-containing portion of the molecules (Figure 7). Thus, (-)ESI-
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MS/MS of the [M - H]- ion of 146 (m/z  547 [74Ge]) showed the most abundant ion cluster 
containing Ge at m/z 504 [74Ge] because of the loss of 43 u (CONH) in addition to m/z 158, 200 
and 241 fragmentation ions which do not contain Ge. On the other hand (-)ESI-MS/MS of the [M 
- H]- ion of [18O]-147 (m/z  549 [74Ge]) showed a cluster at m/z 506 [74Ge] in addition to m/z 160, 
202, and 243 product ions (M + 2 ions relative to 146). These results indicated that during 
hydrogermylation the 18O-isotope remained at C4 of the uracil ring and that the 4-carbonyl group 
did not participate in the reaction pathway leading to the formation of -(triphenylgermyl)methyl 
ketones.  
 
Figure 7. Proposed decomposition route for 5-[2-(triphenylgermyl)acetyl]uracils 146 and 147 
On the basis of the experimental results, it is believed that the formation of the 5-[2-
(triphenylgermyl)acetyl]uracil products (e.g., 146) should involve an initial attack of the 
triphenylgermyl radical at the triple bond of 135 to give a vinylic radical 148 (Scheme 38). 
Abstraction of hydrogen from triphenylgermane in an anti fashion would produce Z-vinyl 
germane 144 as a major product while the syn addition could produce the E isomer of 144 (path 
a). Reaction of 148 with residual oxygen present in the reaction mixture might lead to the 
formation of peroxyl radical 149,170 followed by the abstract of hydrogen from Ph3GeH171 to give 
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hydroperoxide. The latter can be converted to enol 150, probably by a radical mechanism, and 
undergo tautomerization to yield the β-germylketone 146 (path b). 
 
Scheme 38. A plausible pathway for the formation of 5-[(2-triphenylgermyl)acetyl]uracil 147 during radical 
addition of Ph3GeH to 5-acetylenic substrate 135 
Efforts have been made to optimize conditions for the preparation 146 in higher yield from 
the reaction of 135 with Ph3GeH. Thus, hydrogermylations have been performed varying several 
experimental parameters. Hydrogermylation of 135 under various condition, such as, Ar vs N2 vs 
aerobic conditions with dry vs reagent-grade toluene vs "moist" toluene (with the added measured 
amount of H2O or D2O), did not improve the yield of 146. It is important to note that 
hydrogermylation of 135 with Ph3GeH in oxygenated toluene resulted in the recovery of 
unchanged 135, which is probably because of the oxygen induced radical termination. I have also 
attempted the hydrogermylation employing slow addition of Ph3GeH via syringe-pump over 24 
hours, but the yield of 146 is not improved. Thus, the optimal conditions for the formation of β-
germylketones would require very low rate of initiation with very low and nearly constant 
concentration of Ph3GeH and oxygen, and then for the germyl radical to react with the terminus 
of the acetylene group rather than oxygen to give the vinylic radical 148, which should react with 
oxygen rather than germane to give 146.  
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During recrystallization of 146 from MeOH, the formation of a new product was observed by 
TLC, which was characterized as 5-acetyl-1-N-benzyluracil 152 both spectroscopically and by 
comparison with an authentic sample of 152 that was independently synthesized by acid-
catalyzed hydration172 of 135. It has been noticed that (triphenylgermyl)methyl ketone 146 could 
be converted to the 5-acetyl product 152 quantitatively in MeOH at 65 oC, which should involve 
intramolecular thermal isomerization via a four-membered ring rearrangement (Scheme 39). 
Hydrolysis of the resulting O-germyl substituted enol 151 led to the formation of the ketone 152. 
Analogous thermal rearrangements of the β-silylketones into O-silyl substituted enols have been 
noted as well.173 Heating 146 in either MeOD or MeOH-d4 gave 1-deuteriomethyl ketone 153 in 
quantitative yield, which supports the proposed degradation pathway. 
 
Scheme 39. Proposed route for the thermal degradation of 5-[(2-triphenylgermyl)acetyl]uracil 146 into the 5-
acetyl product 152 
3.2.1.3. Application of the 5-[2-(germyl)vinyl]uracil to organic synthesis 
3.2.1.3.1. Towards Pd-catalyzed cross coupling reaction 
The vinyl tris(trimethylsilyl)germanes are known to be good substrates in the Pd-catalyzed 
cross-coupling reactions with alkenyl/aryl halides.112,113 Thus, various TTMSGe have been 
prepared under optimal conditions. Hydrogermylation of 123 with reactive (Me3Si)3GeH by 
Method A gave 5-[2-(tris(trimethylsilyl)germyl)ethenyl]arabino-uridine analogue 124c in 68 % 
(Scheme 40). Treatment of 2',3',5'-tri-O-p-toluoyl protected 127 with (Me3Si)3GeH by Method B 
afforded TTMS-germyl vinyl uracil nucleoside product Z-129c in 61% as a single isomer. 
Analogously, 1-N-benzyl-5-ethynyluracil 135 was converted to Z-154. The couplings of 
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synthesized 5-[2-(TTMS-germyl)vinyl]uracil nucleoside derivatives with the aryl halides via Pd-
catalyzed cross-coupling were performed. However, the attempted Pd-catalyzed [Pd(PPh3)4] 
coupling of 124c, 129c, or 154 with β-bromostyrene as well as aryl iodides or bromides under 
oxidative aqueous (H2O2/NaOH/H2O) or anhydrous (t-BuOOH/KH) conditions in THF112 gave a 
complex mixture with the desired coupling products 155 only in 0-15% (GC-MS). Thus, no 
additional studies were performed.  
 
Scheme 40. Hydrogermylation of 5-ethynyluracil and uracil nucleosides 123, 127 and135 with (Me3Si)3GeH and 
attempted Pd-catalyzed cross-coupling of the resulting vinyl germanes with alkenyl or aryl halides 
3.2.1.3.2. Radical halodegermylation 
It is known that the 5(E)-[2-(tributylstannyl)vinyl]uracil nucleosides174-176 are good substrates 
for mild and rapid radiohalogenation via halodestannylation reactions.174-177 However, the 
tendency of 5(E)-[2-(tributylstannyl)vinyl]arabinosyl uridine176 and 5-trimethylstannyl 
arabinouridine177 to undergo protiodestannylation was noted. Lindlar hydrogenation of 5-[2-
(trimethylsilyl)ethynyl]uracil nucleoside substrates12,178 gave 5(Z)-[2-(trimethylsilyl)vinyl]uracil 
analogues in good yield, but underwent the solvent-dependent isomerization to give the 5-E-
isomer analogue as the major component.179 Halogenative desilylation of 5-E-vinyl silane 
substrates180 with XeF2 and metal halides gave 5-(2-halovinyl)uracil products in good yield and 
short time,179 and such reactions have been utilized for radioiodination via iododesilylations 
reactions178,180 Germyldesulfonylation protocols have also been developed for the synthesis of 
vinyl and (-fluoro)vinyl germanes.113 Thus, I carried out the radical halodegermylation of β-
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TMSGe vinyl uracil substrates with electrophilic halogen as an alternative practical route for the 
preparation of β-halovinyl pyrimidine nucleoside derivatives.  
Treatment of 5-[2-(trimethylgermyl)vinyl]uracil nucleoside 131c (E/Z, 40:60) with N-
bromosuccinimide (NBS) at ambient temperature gave 156 via a radical mechanism in high yield, 
followed by the deprotection with NH3/MeOH to afford a mixture of 5-(2-bromovinyl)-2'-
deoxyuridine 3 in 70% (E/Z, ~2:3) with retention of the stereochemistry159,163,181 (Scheme 41). It 
indicated the potential application of 5-[2-(trimethylgermyl)vinyl]uracil nucleosides towards the 
synthesis 5-(2-halovinyl)uracil analogues as well as potential applications to radiolabeling. It is 
important to note that substitution of the trialkylgermyl group adjacent to an sp182,183 or sp2 
carbon181,182 with a halogen proceeded more easily than that of trialkylsilyl substrates and with 
better stereochemical outcome. 
 
Scheme 41. Radical halodegermylation and deprotection of vinyl trimethylgermane uracil nucleoside with NBS 
and methanolic ammonia 
3.2.2. Iron-mediated regio- and stereoselective hydrosulfonylation of 5-ethynyluracil 
nucleosides 
Vinyl sulfones, which are also known as α, β-unsaturated sulfones, could be synthesized by a 
broad variety of traditional synthetic methods, such as the ionic and radical addition to 
unsaturated alkenes, alkynes and allenes, the addition of sulfonyl-stabilized carbanions to 
carbonyl substrates, the manipulation of acetylenic sulfones or the use of organometallic 
reagents.184,185 As a result of the electron withdrawing property of the sulfonyl group and electron 
poor nature of their double bond, vinyl sulfones can be treated as excellent Michael acceptors, 
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which could be attacked by nucleophiles via 1,4-addition. Since thiol and amine groups, which 
are good nucleophiles, naturally present or routinely introduced in most biomolecules, such units 
could be efficiently installed to the β-position of the vinyl sulfones. Thus, on this basis, the 1,4 
addition of vinyl sulfones could be employed to synthesize β-heterosubstituted vinyl sulfones. 
Moreover, the sulfonyl moiety can either undergo subsequent functional group transformations or 
can be easily removed by treatment with Mg or Hg/Na.186  
Vinyl sulfones also play an important role in the biosciences. These molecules can act as 
irreversible inhibitors of many types of cysteine proteases through conjugate addition of the thiol 
group of the active site in the cysteine residue, which is the basis of some modern applications of 
this chemical function in Proteomics. There are two prominent features for vinyl sulfones: first, it 
is easy to introduce the vinyl sulfones functional group to proteins or nucleosides and the 
resulting functionalized reagents or intermediates are stable. Secondly, it is the possibility to carry 
out the Michael additions in physiological conditions (aqueous media, slightly alkaline pH and 
room temperature) that preserve the biological function of the proteins in the absence of catalysts 
and by-products. 
Even though there are several reports about the chemical reactivity of vinyl sulfones which 
allow the functionalization of many organic substrates, the full potential applications of vinyl 
sulfones are only partially realized. In 2013, Hocek187 and coworkers reported the interaction 
between the vinylsulfone modified oligonucleotides/DNA and cysteine or glutathione from 
protein via the Michael addition (Figure 8). The research indicated that the Michael addition 
modified oligonucleotides/DNA are readily able to couple with cysteine or cysteine-containing 
peptides/proteins via the Michael addition under physiological conditions. The Michael addition 
modified nucleotides did not interfere with DNA polymerase, and the vinyl sulfone-modified 
nucleoside triphosphates are still suitable for the primer extension synthesis of modified 
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oligonucleotides. Thus, vinyl sulfone-modified DNA could communicate with different 
constructs of p53 protein to form the covalent bond via Michael addition.  
 
Figure 8. Synthesis of vinylsulfone modified DNA and cross coupling with p53 protein 
3.2.2.1. Synthesis of 5-(1-chloro-2-tosyl)vinyl uracil nucleosides 
My strategy for the synthesis of reactive vinylsulfone modified nucleosides exploit the iron 
catalyzed regio- and stereoselective radical halosulfonylation188,189 of 5-ethynyluracil nucleosides 
with sulfonylhydrazides. Compared to the vinylsulfones, there is an additional halogen atom 
attached to the β-carbon of the vinylsulfones, which makes the β-carbon even more prone to be 
attacked by nucleophiles. Treatment of 1-N-benzyl-5-ethynyluracil 135 with sulfonyl chloride 
157 in the presence of Fe(acac)3 and triphenylphosphine at 100 oC for 10 h gave 5-(1-chloro-2-
tosyl)vinyl uracil 158 with complete region- and stereoselectivity (Scheme 42), and this process 
could also tolerate the acetyl protection group. However, the usage of phosphine ligand and 
relatively harsh reaction conditions limited the application with temperature sensitive substrates. 
Moreover, only chlorine substituted vinyl sulfones could be obtained by this method. In order to 
explore other halogenated vinylsulfones and to compare the reactivity of the different 5-(1-
chloro-2-tosyl)vinyl uracil analogues, other reaction conditions will be explored.  
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Scheme 42. Synthesis of 5-(1-chloro-2-tosyl)vinyl uracil via hydrosulfonylation of 1-N-benzyl-5-ethynyluracil 
with tosyl chloride 
It is known that FeCl3 could act as a chlorine source in some radical sulfonylation 
reaction.188,190 Thus, efforts have been made to improve the methodology for hydrosulfonylation 
of 5-ethynyluracil and uracil nucleosides as well as to achieve the synthesis of bromine 
substituted β-halovinyl sulfones. Thus, treatment of 1-N-benzyl-5-ethynyluracil 135 with 
sulfonylhydrozides 159 in the presence of FeCl3 and TBHP in acetonitrile at 80 oC for 4 h gave 5-
(1-chloro-2-tosyl)vinyl uracil 158 in 90% with absolute regio and stereoselectivity (Scheme 43).  
 
Scheme 43. Synthesis of 5-[(E)-(β-chloro)vinyl]sulfonyl uracil via hydrosulfonylation of 5-ethynyluracil with 
tosyl hydrazide in the presence of FeCl3 
Similarly, the Fe(III) catalyzed hydrosulfonylation could be also extended to the synthesis of 
β-bromovinyl sulfones via addition of FeBr3 as the bromine source. Treatment of 1-N-benzyl-5-
ethynyluracil 135 with sulfonylhydrozides 159 in the presence of FeBr3 and TBHP in acetonitrile 
at 80 oC for 4 h gave 5-(1-bromo-2-tosyl)vinyl uracil 160 as well as the dibromo substituted uracil 
analogue 161 as the byproduct (Scheme 44). It is worth mentioning that the formation of dihalo 
uracil analogues 161 is specific for FeBr3-promoted hydrosulfonylation and could be inhibited by 
the increase of the loading of 159.  
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Scheme 44. Synthesis of 5-[(E)-(β-bromo)vinyl]sulfonyl uracil via hydrosulfonylation of 5-ethynyluracil with 
tosyl hydrazide in the presence of FeBr3 
In order to check the generality of the hydrosulfonylation, the methodology was extended to 
5-ethynyluracil nucleoside substrates, which share the same nucleobase. Thus, treatment of 
2',3',5'-tri-O-acetyl-5-ethynyluridine 162, or 2,3,5-tri-O-acetyl-1-(-D-arabinofuranosyl)-5-
ethynyluracil 123 with tosyl hydrazide 159 under the optimal conditions gave 5-(1-chloro-2-
tosyl)vinyluracil nucleosides 165 and 166 in 68% and 66% respectively (Scheme 45). Analogous 
treatment of 3',5'-di-O-acetyl-5-ethynyl-2'-deoxyuridine 163 with 159 gave the corresponding 
product 167 in 76%. The hydrosulfonylation is also compatible with the unprotected 5-
ethynyluracil nucleosides. Thus, heating of 2'-deoxy-5-ethynyluridine 157 with 159 in the 
presence of FeCl3 and TBHP gave 168 in 69 %. 
 
Scheme 45. Synthesis of 5-[(E)-(β-chloro)vinyl]sulfonyl uracil nucleosides via hydrosulfonylation 
On the basis of the experimental results and literature reports,188,189 the proposed mechanism 
is summarized in Figure 9.  
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Figure 9.Proposed mechanism for the Fe(III) mediated hydrosulfonylation of 5-ethynyluracil nucleosides 
Initially, hydrogen abstraction of sulfonylhydrazides 159 by the tert-butoxyl or tert-
butylperoxy radicals, which were generated in situ from an iron-TBHP catalytic circle, gave 
sulfonylhydrazide radical intermediate I, followed by another two hydrogen abstractions to give 
active sulfonyl radical IV with release of N2. Meanwhile, the 5-ethynyluracil nucleoside V is also 
activated by the iron halides to form the Fe-coordinated alkynes VI. Regio- and stereoselective 
addition of the sulfonyl radical IV to the terminal carbon of the Fe-coordinated acetylene 
intermediate VI leads to Fe(IV) intermediate VII. Subsequent reductive elimination afforded the 
(E)-β-halovinylsulfones VIII with the generation of the Fe(II) catalyst.  
3.2.2.2. Application of 5-(1-chloro-2-tosyl)vinyl uracil nucleosides to organic synthesis 
As it is known that vinyl sulfones are good acceptors for Michael addition reactions, 
treatment of vinylsulfones with nucleophiles should provide highly functionalized β-substituted 
vinylsulfones. Thus, it is interesting to contemplate what will ensure in such system when the β-
position is occupied by halogen. Treatment of (E)-1-N-benzyl-5-(1-chloro-2-tosyl)vinyl uracil 
158 with methanolic ammonia in MeOH at room temperature for 2 h led to the formation of a 
white suspension. Subsequent vacuum filtration gave a white precipitate which was characterized 
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by NMR and HRMS as the (E)-1-N-benzyl-5-(1-amino-2-tosyl)vinyl uracil 169a (Scheme 46). It 
is worthy to note that only one isomer was isolated after the reaction, as the nucleophilic 
substitution maintained the stereochemical configuration of the starting vinyl sulfonyl substrates.  
In order to check the generality of the reaction, 158 was subjected to n-butylamine under 
similar conditions to yield the corresponding product 169b in quantitative yield in 2 h. However, 
analogous treatment of 158 with 1-propanethiol only gave unchanged starting substrate after 
stirring at room temperature for 24 h. Considering the nucleophilicity of the thiol group vs the 
thio anion, a catalytic amount of triethylamine was added as the external base to abstract the 
hydrogen from the thiol group; surprisingly, the reaction proceeded to completion in 1 h to give 
169c as a single isomer in 99 % yield.  
 
Scheme 46. Nucleophilic substitution of (E)-1-N-benzyl-5-(1-chloro-2-tosyl)vinyluracil with methanolic ammonia 
The stability of the glycosidic bond as well as the protecting group of uracil nucleoside have 
also been tested. Thus, acetyl protected vinyl sulfonyl uridine 165 was subjected to methanolic 
ammonia for 48 h and gave 5-(1-amino-2-tosyl)vinyl uridine 170a as well as small amount of the 
partial deprotected 5'-O-acetyl-5-(1-amino-2-tosylvinyl)uridine (Scheme 47). It is obvious that 
both deacetylation and nucleophilic substitution took place even in the presence of n-butylamine. 
Similarly, the nucleophilic substitution of 165 with n-butylamine and propanethiol (with catalytic 
amount of Et3N) gave 170b and 170c in respectable yield. The nucleophilic substitution has also 
been applied to the 5-(1-chloro)vinyl-2'-deoxyuridine derivatives 167 and 168, which are relative 
more labile comparing to the ribosyl nucleoside.  
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Scheme 47. Synthesis of nucleophile substituted vinyl sulfonyl uracil nucleoside analogues via addition-
elimination mechanism 
On the basis of the experimental evidence, the nucleophilic substitution is believed to proceed 
through the addition-elimination mechanism. The proposed mechanism is depicted in Scheme 48. 
Initially, the nucleophile attacks the β-carbon of vinylsulfone 171, which is partially positive 
because of the electron withdrawing property of the sulfonyl group as well as the electro-
negativity of the halogen, followed by a rearrangement to give intermediate 172, which 
tautomerizes to 173, and ends up as β-substituted vinyl sulfone 166 by the elimination of halogen 
ion.  
 
Scheme 48. Proposed mechanism for the nucleophilic substitution of 5-[(1-halo-2-tosyl)vinyl]uracil and uracil 
nucleosides 
Since the 5-(1-halo-2-tosyl)vinyl uracil nucleosides are excellent substrates for substitution, 
they could be potentially incorporated into DNA or RNA and employed as a reactive site to study 
the interaction between oligonucleotide and peptide or protein in biological model systems. With 
the synthetic method in hand,191-193 my plan was to convert the 2'-deoxy-5-(1-halo-2-tosyl)vinyl 
uridine 168 to 5'-triphosphate product 175 by a modified Yoshikawa method, followed by 
exposure to polymerase to give functionalized nucleotide 176 (Scheme 49).  
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Scheme 49. Phosphorylation of 2'-deoxy-5-[(1-halo)-2-tosyl]vinyluridine 168 and the synthesis of functionalized 
nucleotide 
3.2.2 Aerobic difunctionalization of 5-ethynyluracil nucleosides 
β-Keto sulfones 177 are important synthetic intermediates and some of them have shown 
biological activity.194 The summary of the synthetic methods for β-keto sulfones is depicted in 
Scheme 50, which includes i) alkylation of sulfinates with either α-halo ketones195 or α-tosyloxy 
ketones 178,196 (ii) oxidation of β-thioether ketones 179,197 (iii) reactions of diazo sulfones 180 
with aldehydes in the presence of SnCl2,198(iv) ruthenium(II) catalyzed reaction of sulfonyl 
chlorides with silylenol ethers 181,199 and (v) acylation of alkyl sulfones 180, which could be 
converted into β-keto sulfones by N-Acylbenzotriazoles200 
 
Scheme 50. Reported synthetic route for the preparation of β-keto sulfones 
3.2.2.1. Synthesis of 5-(β-keto)sulfonyluracil nucleosides 
Contrary to the 5-[(1-halo)-2-tosyl]vinyluracil nucleoside derivatives 171, which are 
excellent Michael acceptors, 5-(β-keto)sulfonyl pyrimidine nucleoside analogues 177 would be 
good electrophiles after abstraction of a methylene proton with base. They could be synthesized 
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by direct aerobic difunctionalization of 5-ethynyl uracil nucleoside analogues with sulfinic acid in 
the presence of a catalytic amount of pyridine. Thus, these two types of 5-modified pyrimidine 
nucleosides will be excellent substrates for the study of both nucleophilic and electrophilic 
substitution. Treatment of 1-N-benzyl-5-ethynyluracil 135 with p-toluyl sufinic acid 183 in the 
presence of air (oxygen) with a catalytic amount of pyridine at 45 oC for 4h gave the 5-(β-
keto)sulfonyl uracil derivative 184 in 50% (Scheme 51). Since the sulfinic acid is very easily to 
be oxidized in air, it is better to synthesize the sulfinic acid just before the hydrosulfonylation. 
 
Scheme 51. Synthesis of 5-[(β-keto)sulfonyl]uracil via aerobic difunctionalization of 5-ethynyluracil 135 
On the basis of the experimental result and literature reports,170 a proposed reaction pathway 
for the synthesis of 5-(β-keto)sulfonyl uracil derivatives is depicted in Figure 10. First, pyridine 
abstract the active hydrogen from sulfinic acid to give sulfinyl anion I, followed by the 
autoxidation with oxygen via a single electron transfer (SET) process to afford an oxygencentered 
radical II, which could tautomerize to the more stabilized sulfonyl radical III. Subsequently, the 
terminal carbon of such alkynes is attacked by the sulfonyl radical III to produce the reactive 
vinyl radical IV, which could be trapped by dioxygen to give peroxide radical intermediate V. 
Then, peroxide VII, which was obtained via another single electron transfer and proton transfer 
successively with sulfinyl anion I and pyridinium, undergoes reduction by sulfinic acid to give 
the β-hydroxyvinyl sulfonyl intermediate VII. Finally, subsequent tautomerization gave 5-(β-
keto)sulfonyl uracil derivative 184. 
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Figure 10. Proposed mechanism for the synthesis of 5-(β-keto)sulfonyluracil via aerobic difunctionalization 
3.2.2.2. Application of 5-(β-keto)sulfonyluracil nucleosides to organic synthesis 
The pKa of a methylene proton adjacent to a ketone and sulfonyl group is around 12, which is 
quite acidic. Deprotonation with base should give a stabilized anion 185, which could act as the 
nucleophile (Scheme 52). Subsequent addition of an electrophile should provide the highly 
substituted 5-(β-keto)sulfones 187.  
 
Scheme 52. Proposed mechanism for the electrophilic substitution of 5-[(2-sulfonyl)acetyl]uracil and uracil 
nucleosides 
Thus, treatment of 1-N-benzyl-5-[(2-sulfonyl)acetyl]uracil 184 with NaOH at room 
temperature followed by the addition of benzylbromide gave 188 in 41 % (Scheme 53). In the 
future, the protocol will be extended to nucleoside substrates as well to functionalized nucleotides. 
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Scheme 53. Synthesis of 5-[(2-benzyl-2-sulfonyl)acetyl]uracil via the electrophilic substitution 
3.2.4 Silver catalyzed hydroazidation of 5-ethynyluracil nucleosides 
The size of the azido group is extremely small which is favorable for cell permeability, and 
this feature avoids perturbations. The azide is particularly bioorthogonal, because it is also 
metabolically stable, and does not naturally exist in cells, so, there are no competing biological 
side reactions. The incorporation of azido modified nucleoside analogues into living cells can 
enable sensitive detection of DNA replication through copper(I)-catalyzed azide–alkyne 
cycloaddition (CuAAC, first generation of click reaction) and strain-promoted azide–alkyne 
cycloaddition (SPAAC, second generation of click reaction). Since the cyclooctynes are the 
smallest stable cyclic alkynes which could increases reactivity through ring strain, this high 
reactivity resulted in the fact that there is no copper catalyst required and that the reaction is 
quantitative. Thus, cyclooctynes are the best candidate for the click reaction of the azido 
nucleoside analogues.  
The photo-labile 5-azido-2'-deoxyuridine 192 has been synthesized201-203 via preparation and 
reduction of 5-nitro pyrimidine nucleosides 190201,202 (path A, Scheme 54). Due to the 
inefficiency and tedious preparation of 5-nitrouridine 190, Clivio and coworkers203 developed a 
new approach to synthesize the 5-azido-2'-deoxyuridine 192 in three steps and quantitative yield 
from the commercially available 5-bromo-2'-deoxyuridine nucleoside 193 via a benzylamination 
reduction sequence (path B, Scheme 54). Since 5-Azido-2'-deoxyuridine 192 is photo-sensitive 
and has the tendency to decompose when exposed to light (4 h half-life in water204,205). It is not 
surprising that up to seven products were detected, when 5-azido-2'-deoxyuridine 192 was 
irritated with UV light in water.205  
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Scheme 54. Synthesis of 5-azido-2'-deoxyuridine via two different pathways 
In order to overcome the poor chemical stability of 5-azido pyrimidine nucleoside analogues, 
Luedtke and coworker204 synthesized 5-(azidomethyl)-2'-deoxyuridine 197, which is stable in 
solution at 37 oC, and it gives robust labeling of cellular DNA upon addition of fluorescent alkyne 
derivatives (Scheme 55). However, the azido group and the pyrimidine ring are isolated by the 
methylene carbon which is sp3 hybridized. In other words, the pyrimidine is not conjugated with 
the 1,2,3-triazole ring that is the formed by the click reaction. As a result, the fluorescent intensity 
of 5-(azidomethyl)-2'-deoxyuridine 197 might be lower than a derivative whose two aromatic 
rings are connected by sp2 hybridized carbons.  
 
Scheme 55. Synthesis of 5-(azidomethyl)-2'-deoxyuridine from thymidine 
3.2.4.1.Synthesis of 5-(α-azidovinyl)uracil nucleosides 
Keeping this goal in mind along with careful screening of the literature,206 I have synthesized 
the 5-(α-azido)vinyl pyrimidine nucleoside analogues as the substrates for the click reaction. 
Since the pyrimidine and 1,2,3-triazole ring are conjugated (two aromatics rings are connected by 
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the sp2 hybridized carbon), it is expected that higher fluorescent intensity will be observed. 
Treatment of 123 with TMS-N3 in the presence of silver carbonate with 2 equiv. of H2O in 
DMSO at 80 oC for 4 h gave 5-(α-azidovinyl)uridine analogue 198, which is stable at room 
temperature in MeOH solution (Scheme 56).  
 
Scheme 56. Silver catalyzed hydroazidation of 5-ethynyluridine and click reaction 
3.2.4.1. Application of 5-(α-azidovinyl)uracil nucleosides to organic synthesis 
The copper free Click reaction has been performed with acetyl protected 5-(α-
azido)vinyluridine 198 to check the stability of the azido group. Thus, stirring of 198 with 
cyclooctyne 199 in MeOH at ambient temperature for 1 h gave the corresponding trizole 200 in 
80 % as a mixture of two regio-isomers with ratio of 1:1. Deprotection of 200 with NH3/MeOH 
gave 201 in quantitative yield (Scheme 57). 
 
Scheme 57. Strain promoted copper free Click reaction of 5-[(α-azido)vinyl]uridine 198 with cyclooctyne 199 
It has been noted that clickable oligonucleotides with acetylene residues in the 5-position of 
pyrimidines (uridine and cytidine) have the tendency to hydrolyze to the acetyl substrates during 
solid-phase oligonucleotide synthesis and workup conditions.207 The 5-azido pyrimidine 
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nucleoside 192 is photo-labile.204,205 Thus, they are not good substrates for the preparation of base 
modified oligonucleotides. Even though the 5-methylazido uridine is fairly stable, the azido group 
and nucleic base are isolated by the methylene group, which will interfere with the conjugation of 
the system. Thus, it is not the perfect choice as well. Accordingly, it is desirable to synthesize the 
oligonucleotides with α-azidovinyl in the 5-position of pyrimidines. Treatment of 5-ethynyl-2'-
deoxyuridine 164 with TMSN3 under the optimal conditions should provide 5-(α-
azidovinyl)uridine analogues, and subsequent phosphorylation and proton exchange should give 
202 (Scheme 58). The 5-(α-azido)vinyl functionalized oligonucleotide 203 should be obtained by 
exposure of 202 to polymerase. 
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4. EXPERIMENTAL SECTION 
4.1 General Procedures 
1H (Me4Si) NMR spectra at 400 MHz, 13C (Me4Si) at 100.6 MHz and 19F (CCl3F) at 376.4 
MHz were determined with solutions in CDCl3. TLC was performed on Merck kieselgel 60-F254 
and products were detected with 254 nm light or by development of color with I2. Merck 
kieselgel 60 (230-400 mesh) was used for column chromatography. Purity, yields and ratio of the 
products (crude and/or purified) were established using a GC-MS (EI) system with a mass 
selective detector [capillary column (30 m × 0.25 mm × 25 μm)] using calibrated standards for 
products or 2-ethylnaphthalene as internal standard. Mass spectra (MS) was obtained with 
atmospheric pressure chemical ionization (APCI) technique and HRMS in ESI-TOF mode unless 
otherwise noted. Tris(dibenzylidene-acetone)dipalladium(0) [Pd2(dba)3] was purchased from 
Aldrich-Sigma Co (catalog number: 328774). Germane chlorides are commercially available 
from Gelest Co., Morrisville, PA, USA. 
4.2 Synthesis 
1-(Phenyl)naphthalene (55). TBAF (1M/THF, 0.98 mL, 0.98 mmol) was added to a stirred 
solution of dichlorodiphenylgermane (76; 30.0 µL, 42 mg, 0.14 mmol), 1-iodonaphthalene (45 
µL, 78 mg, 0.31 mmol), water (100 µL, 5.7 mmol) and Pd2(dba)3 (6.5 mg, 0.007 mmol) in 
toluene (3.0 mL) at ambient temperature under nitrogen atmosphere. The resulting brownish 
mixture was heated at 100 oC (oil bath) for 15 h. The volatiles were evaporated and the residue 
was partitioned (H2O/CH2Cl2). The organic layer was dried (MgSO4), evaporated and purified by 
column chromatography (hexane) to give 55 (51 mg, 89%) followed by homocoupling product 
binaphthlene (6.3 mg, 8%; 16% consumption of 1-iodonaphthalene). 
Analogous treatment of trichlorophenylgermane (75; 24.0 µL, 35.9 mg, 0.14 mmol) with 1-
iodonaphthalene (22.5 µL, 39.1 mg, 0.155 mmol), TBAF (1M/THF, 0.98 mL, 0.98 mmol), water 
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(100 µL, 5.7 mmol), and Pd2(dba)3 (6.5 mg, 0.007 mmol) in toluene (3.0 mL) at 100 oC (oil bath) 
for 15 h. gave 55 (27.4 mg, 96%). 
Analogous treatment of chlorotriphenylgermane (77; 47.5 mg, 0.14 mmol) with 1-
iodonaphthalene (67.5 µL, 117 mg, 0.46 mmol), TBAF (1M/THF, 0.98 mL, 0.98 mmol), water 
(100 µL, 5.7 mmol), and Pd2(dba)3 (6.5 mg, 0.007 mmol) in toluene (3.0 mL) at 100 oC (oil bath) 
for 15 h. gave 55 (75 mg, 88%). 
Triallyl(phenyl)germane (81). In a flame-dried round-bottom flask a solution of 
trichloro(phenyl)germane (250 mg, 160 μL, 0.976 mmol) in Et2O (2 mL) was treated with 
allylmagnesium bromide (3.1 mL, 3.12 mmol, 1 M solution in Et2O) added dropwise for 20 min 
at 0 oC. After 1 h stirring at 0 oC the reaction mixture was refluxed (38 oC) overnight. The 
reaction was allowed to cool to room temperature and quenched with NH4Cl at 0 oC. The organic 
layer was separated and the aqueous layer extracted with Et2O (2 x 5 mL). The combined extracts 
was washed (water and brine), dried (MgSO4) and was concentrated in vacuo. The residue was 
chromatographed (hexanes) to give 81 (227 mg, 85%) as clear oil: 1H NMR  2.04 (d, J = 8.3 Hz, 
6H), 4.89 (d, J = 10.0 Hz, 3H), 4.95 (d, J = 16.9 Hz, 3H), 5.88 (m, 3H), 7.38 (m, 3H), 7.47 (m, 
2H); 13C NMR  19.54, 113.67, 127.99, 128.74, 133.87, 134.84, 137.95; GC-MS (tR 19.1 min) 
m/z 274 (33, M+ [74Ge]), 151 (100) and (tR 16.2 min) m/z 233 (89, M+[74Ge]-41), 151 (100). Anal. 
Calcd for C15H20Ge (272.96): C, 66.00; H, 7.39. Found: C, 65.78; H, 7.44. 
Diallyl(diphenyl)germane (82). Treatment of a solution of dichloro(diphenyl)germane (1.0 g, 
0.707 μL, 3.359 mmol) in Et2O (2 mL), as reported for 81, afforded 82 (980 mg, 94%) as clear oil: 
1H NMR  2.27 (dt, J = 8.3, 1.0 Hz, 4H), 4.90 (dq, J = 9.2 Hz, 1.7 Hz, 2H), 4.95 (d, J = 16.9 Hz, 
2H), 5.90 (m, 2H), 7.39 (m, 6H), 7.49 (m, 4H); 13C NMR  20.08, 114.12, 128.08, 128.90, 134.48, 
134.62, 137.12; GC-MS (tR 22.3 min) m/z 269 (100, M+[74Ge]-41), 227 (29), 151 (80). 
Allyl(triphenyl)germane (83). Treatment of a solution of chloro(triphenyl)germane (260.0 
mg, 0.77 mmol) in Et2O (2 mL) with allylmagnesium bromide as reported for 81, (mixing at 
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room temperature instead of 0 oC) afforded 83 (245 mg, 92%) as white solid: 1H NMR  2.52 (d, 
J = 8.1 Hz, 2H), 4.90 (dq, J = 10.0 Hz, 1.0 Hz, 1H), 5.00 (dq, J = 16.9 Hz, 1.6 Hz, 1H), 5.95 (m, 
1H), 7.40 (m, 9H), 7.51 (m, 6H); 13C NMR  21.24, 114.50, 128.18, 129.02, 134.53, 135.02, 
136.55; GC-MS (tR 24.5 min) m/z 305 (100, M+[74Ge]-41), 227 (14), 151 (23). 
Treatment of a solution of allyltrichlorogermane (855 mg, 560 μL, 3.89 mmol) in Et2O (2 mL) 
with phenylmagnesium bromide (4.0 mL, 12 mmol, 3 M solution in Et2O), following the 
procedure as described for 81, gave compound 83 (590 mg, 44%). 
1-Phenylnaphthalene (88b). Method A: The antimony (V) fluoride (50 wt % on graphite, 
45 mg, 0.105 mmol) was added to a stirring solution of triallyl(phenyl)germane (81; 38 mg, 0.14 
mmol) in toluene (3.0 mL) at ambient temperature under nitrogen atmosphere in a plastic tube. 
The resulting mixture was heated at 50 oC (oil bath) for 1.5 h. After cooled down the solution to 
ambient temperature, the graphite was filtered off and the mother solution was apply to the 
second step directly. TBAF (1M/THF, 0.42 mL, 0.42 mmol), 1-iodonaphthalene (87b; 35 mg, 20 
μL, 0.14 mmol), water 25 μL, and Pd2(dba)3 (6.5 mg, 0.007 mmol) was added to the elute at 
ambient temperature under nitrogen atmosphere. The resulting brownish mixture was heated at 
100Ԩ (oil bath) for 15 h. The volatiles were evaporated and the residue was partitioned 
(H2O/CH2Cl2). The organic layer was dried (Na2SO4), evaporated and purified by column 
chromatography (hexane) to give 88b (13 mg, 45%) followed by 89b [1.7 mg, 5%, 10% 
consumption of the iodonaphthalene; GC-MS (tR 25.02 min) m/z 254 (100, M+)]. Compound 88b 
had: 1H NMR δ 7.41-7.58 (m, 9H), 7.89 (d, J=8.2Hz, 1H), 7.91-7.96 (m, 2H) ; 13C NMR δ 125.5, 
125.9, 126.15, 126.18, 127.1, 127.4, 127.8, 128.4, 130.2, 131.8, 134.0, 140.4, 140.9; GC-MS (tR 
19.87 min) m/z 204 (100, M+). 
Analogous treatment of 82 (43 mg, 0.14 mmol) and 1-iodonaphthalene (87b; 71 mg, 41 μL, 
0.28 mmol) with antimony (V) fluoride (50 wt % on graphite, 30 mg, 0.07 mmol) by general 
method A gave 88b (35 mg, 62%) and 89b (8 mg, 11%). 
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Analogous treatment of 83 (48 mg, 0.14 mmol) and 1-iodonaphthalene (87b; 106 mg, 61 μL, 
0.42 mmol) antimony (V) fluoride (50 wt % on graphite, 15 mg, 0.035 mmol) by general method 
A gave 88b (54 mg, 63%) and 89b (16.5 mg, 15%). 
Analogous treatment 81 (38 mg, 0.14 mmol) with 1-bromonaphthalene (87e; 29 mg, 19 μL, 
0.14 mmol) by general method A gave 88b (42%) and 89b (3%) based on the GC-MS analysis of 
the crude reaction mixture. 
Analogous treatment of 82 (43 mg, 0.14 mmol) and 1-bromonaphthalene (87e; 58 mg, 39 μL, 
0.28 mmol) with antimony (V) fluoride (50 wt % on graphite, 30 mg, 0.07 mmol) by general 
method A gave 88b (34%) and 89b (15%) based on the GC-MS analysis of the crude reaction 
mixture. 
Analogous treatment of 83 (48 mg, 0.14 mmol) and 1-bromonaphthalene (87e; 87 mg, 58 μL, 
0.42 mmol) with antimony (V) fluoride (50 wt % on graphite, 15 mg, 0.035 mmol) by general 
method A gave 87b (14%) and 88b (4%) based on the GC-MS analysis of the crude reaction 
mixture. 
1-Phenyl-4-methyloxybenzene (88c). Analogous treatment of 81 (38 mg, 0.14 mmol) with 
4-iodoanisole (87c; 33mg, 0.14 mmol) by general method A give 88c (18 mg, 71%) followed by 
89c [1 mg, 3.5%, 7% consumption of the 4-iodoanisole; GC-MS (tR 20.81 min) m/z 214 (100, 
M+)]. Compound 88c had: 1H NMR δ 3.86 (s, 3H), 7.98 (d, J = 7.8 Hz, 2H), 7.31 (t, J = 7.8 Hz, 
1H), 7.42 (t, J = 8.6 Hz, 2H), 7.50-7.58 (m, 4H); 13C NMR δ 55.5, 114.4, 126.8, 126.9, 128.3, 
128.9, 134.0, 141.0, 159.3; GC-MS (tR 17.41 min) m/z 184 (100, M+). 
Analogous treatment of 82 (43 mg, 0.14 mmol) and 4-iodoanisole (87c; 66 mg, 0.28 mmol) 
with antimony (V) fluoride (50 wt % on graphite, 30 mg, 0.07 mmol) by general method A gave 
88c (45%) and 89c (16%) based on the GC-MS analysis of the crude reaction mixture. 
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Analogous treatment of 83 (48 mg, 0.14 mmol) and 4-iodoanisole (87c; 98 mg, 0.42 mmol) 
with antimony (V) fluoride (50 wt % on graphite, 15 mg, 0.035 mmol) by general method A gave 
88c (32%) and 89c (20%) based on the GC-MS analysis of the crude reaction mixture. 
1-Phenyl-4-trifluoromethylbenzene (7d). Analogous treatment of 81 (38 mg, 0.14 mmol) 
with 4-iodobenzotrifluoride (87d; 38 mg, 21 μL, 0.14 mmol) by general method A gave 88d (13 
mg, 41%) followed by 89d [8.7 mg, 21.5%, 43% consumption of the 4-iodobenzotrifluoride; GC-
MS (tR 13.08 min) m/z 290 (100, M+)]. Compound 88d had: 1H NMR δ 7.39-7.45 (m, 1H), 7.49 (t, 
J = 7.6 Hz, 2H), 7.61 (d, J = 7.3 Hz, 2H), 7.71 (s, 4H); 13C NMR δ 124.5 (q, 1J C-F = 271.5 Hz), 
125.9 (q, 3J C-F = 3.6 Hz), 127.4, 127.6, 128.3, 129.1, 129.5 (q, 2J C-F = 32.7 Hz), 144.9 (q, 5J C-F = 
1.1 Hz); GC-MS (tR 12.96 min) m/z 222 (100, M+). 
Analogous treatment of 82 (43 mg, 0.14 mmol) with 4-iodobenzotrifluoride (87d; 76 mg, 41 
μL, 0.28 mmol) by general method A gave 88d (33%) and 89d (33%) based on the GC-MS 
analysis of the crude reaction mixture. 
Analogous treatment of 83 (35 mg, 0.14 mmol) and 4-iodobenzotrifluoride (87d; 114 mg, 61 
μL, 0.42 mmol) by general method A gave 88d (22%) and 89d (33%) based on the GC-MS 
analysis of the crude reaction mixture. 
1-N-Benzyl-3-N-methyl-5-iodouracil (78c). Freshly distilled diazomethane solution in ether 
(10 mL), generated from Diazald (3.0 g, 14.0 mmol), was added dropwise to a stirred solution of 
78a168 (357 mg, 1.09 mmol) in CH2Cl2 (20 mL) at 0 oC. After 18 h, the volatiles were evaporated 
to give 78c (354 mg, 95%) as white powder: 1H NMR δ 3.34 (s, 3H), 4.86 (s, 2H), 7.21-7.30 (m, 
5H), 7.57 (s, 1H); 13C NMR δ 29.7, 52.7, 68.0, 128.2, 128.8, 129.3, 135.0, 146.4, 151.5, 160.2; 
GC-MS (tR 21.70min.) m/z 342 (85, M+), 91 (100); HRMS calcd for C12H12IN2O2 [M + H]+ 
342.9938, found 342.9935. 
1-N-Benzyl-5-(2-, 3-, and 4-methylphenyl)uracil (o/m/p-91a). Procedure A. Toluene (0.2 
mL, 173 mg, 1.89 mmol), TBAF (1M/THF solution containing ca 5% wt of water; 980 µL, 0.98 
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mmol) and Pd2(dba)3 (6.4 mg, 0.007 mmol) were added to a stirring solution of 1-N-benzyl-5-
iodouracil168 (78a, 46 mg, 0.14 mmol) in DMF (1.8 mL) under the N2 atmosphere at ambient 
temperature. The resulting suspension was stirred for 1 h at 100 oC (oil bath). Volatiles were 
evaporated, and the oily residue was dissolved in EtOAc or MeOH and filtrated through Celite or 
Whatman GF/A filter paper. The filtrate was partitioned (EtOAc/H2O). The organic layer was 
then washed (brine), dried (Na2SO4) and evaporated. GC-MS of this material showed peaks at tR 
31.46, 32.38 and 32.70 min. (m/z 292, M+) for the three isomers of 91a (ortho/meta/para with 
relative intensities of ~3:2:1, respectively). Column chromatography (hexane/EtOAc, 8:2 → 6:4) 
gave a mixture of o/m/p-91a (o/m/p, 3:2:1; 29 mg, 71% overall yield) followed by 92 (1 mg, 4%). 
Mixture of o/m/p-91a had: GC-MS tR 31.46 (o-91a), 32.38 (m-91a) and 32.70 (p-91a) min. (m/z 
292, M+); 1H NMR δ 2.21 (s, 1.5H, o-91a), 2.35 (s, 0.5H, p-91a), 2.36 (s, 1H, m-91a), 4.97 (s, 1H, 
o-91a), 4.985 (s, 0.33H, p-91a), 4.990 (s, 0.67H, m-91a), 7.07-7.41 (m, 10H), 8.91 (s, 1H); 
HRMS calcd for C18H17N2O2 [M + H]+ 293.1285, found 293.1294.  
Attempted purification of the o/m/p-91a mixture on a long silica gel column (hexane/EtOAc, 
8:2 → 7:3) gave partial separation of the o/m/p isomers of 91a but failed to yield single isomers. 
Note: Treatment of 78a (46 mg, 0.14 mmol) with toluene/TBAF/Pd2(dba)3 in DMF for 18 h 
at 100 oC, as described above (column chromatography; hexane/EtOAc, 98:2 → 95:5) gave 
mixture of 1-N-benzyl-3-N-butyl-5-(2-methylphenyl)uracil (o-79a), 1-N-benzyl-3-N-butyl-5-(3-
methylphenyl)uracil (m-79a) and 1-N-benzyl-3-N-butyl-5-(4-methylphenyl)uracil (p-79a) (36.6 
mg, 75% overall yield; o-79a/m-79a/p-79a, 3:2:1): GC-MS tR 27.29 (o-79a), 28.27 (m-79a) and 
28.74 (p-79a) min. (m/z 348, M+); 1H NMR δ 0.92 (t, J = 7.3 Hz, 3H), 1.36 ("sextet", J = 7.4 Hz, 
2H), 1.67 ("quint", J = 7.6, Hz, 2H), 2.18 (s, 1.5H, o-79a), 2.30 (s, 0.5H, p-79a), 2.32 (s, 1H, m-
79a), 4.00 ("t", J = 7.6 Hz, 2H), 4.94 (s, 1H, o-79a), 4.95 (s, 0.33H, p-79a), 4.96 (s, 0.67H, m-
79a), 7.02-7.37 (m, 10H); HRMS calcd for C22H25N2O2 [M + H]+ 349.1911, found 349.1920. 
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1-N-Benzyl-5-(3-methylphenyl)uracil (m-91a). Suzuki Coupling:54 3-Tolylboronic acid (29 
mg, 0.21 mmol) and PPh3 (9 mg, 0.034 mmol) were added to a stirring solution of 1-N-benzyl-5-
iodouracil (78a, 46 mg, 0.14 mmol) in CH3CN/H2O (3 mL; v/v, 2:1) under the N2 atmosphere at 
ambient temperature, followed by the addition of Na2CO3 (22 mg, 0.21 mmol) and Pd(OAc)2 (3 
mg, 0.013 mmol). The resulting suspension was stirred for 4 h at 80 oC (oil bath). Volatiles were 
evaporated, and the residue was partitioned between EtOAc and H2O. The organic layer was then 
washed (brine), dried (Na2SO4) and evaporated. Column chromatography (hexane/EtOAc, 6:4 → 
5:5) gave m-91a (21.7 mg, 53%): 1H NMR δ 2.38 (s, 3H), 5.01 (s, 2H), 7.16 (dt, J = 6.8, 2.0 Hz, 
1H), 7.23-7.29 (m, 2H), 7.30 (t, J = 1.7 Hz, 1H), 7.32 (s, 1H), 7.34-7.46 (m, 5H), 9.35 (s, 1H); 
13C NMR δ 21.6, 51.5, 116.1, 125.3, 128.2, 128.5, 128.7, 128.97, 129.01, 129.3, 132.1, 135.4, 
138.3, 141.2, 150.9, 162.5; GC-MS (tR 32.38 min.) m/z 292 (85, M+), 91 (100); HRMS calcd for 
C18H17N2O2 [M + H]+ 293.1285, found 293.1293. 
1-N-Benzyl-5-(4-methylphenyl)uracil (p-91a). Suzuki Coupling:54 Treatment of 78a (46 mg, 
0.14 mmol) with 4-tolylboronic acid (29 mg, 0.21 mmol), as described above for m-91a, gave p-
91a (20.0 mg, 49%): 1H NMR δ 2.34 (s, 3H), 4.98 (s, 2H), 7.17 (d, J = 7.9 Hz, 2H), 7.28 (s, 1H), 
7.32-7.41 (m, 7H), 9.03 (s, 1H); 13C NMR δ 21.3, 51.5, 115.9, 128.1, 128.2, 128.7, 129.2, 129.3, 
129.4, 135.4, 138.2, 140.8, 150.8, 162.4; GC-MS (tR 32.70 min.) m/z 292 (85, M+), 91 (100); 
HRMS calcd for C18H17N2O2 [M + H]+ 293.1285, found 293.1291. 
1-N-Benzyl-5-phenyluracil (91b). Treatment of 78a (46 mg, 0.14 mmol) with benzene (0.2 
mL, 175 mg, 2.24 mmol) by procedure A gave 91b (25.3 mg, 59%): 1H NMR δ 4.99 (s, 2H), 7.32 
(s, 1H), 7.33-7.49 (m, 10H), 9.02 (s, 1H); 13C NMR δ 51.6, 115.9, 128.2, 128.3, 128.7, 128.8, 
129.4, 132.2, 135.3, 141.2, 150.7, 162.3; GC-MS (tR 24.52 min.) m/z 278 (80, M+), 91 (100); 
HRMS calcd for C17H14N2NaO2 [M + Na]+ 301.0947, found 301.0945.  
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Analogues treatment of 1-N-benzyl-5-bromouracil208 (78b, 39 mg, 0.14 mmol) with benzene 
(0.2 mL, 175 mg, 2.24 mmol) by procedure A (14 equiv. of TBAF) gave 91b (27.6 mg, 71%) 
with spectroscopic data as described above.  
1-N-Benzyl-5-(2,4-dimethylphenyl)uracil (91c). Treatment of 78a (46 mg, 0.14 mmol) with 
m-xylene (0.2 mL, 172 mg 1.62 mmol) by procedure A gave the desired product which was 
recrystallized from hexane/EtOAc to give a single isomer 91c (23.6 mg, 55%): 1H NMR δ 2.16 (s, 
3H), 2.31 (s, 3H), 4.95 (s, 2H), 6.95 (d, J = 8.0 Hz, 1H), 6.99 (br d, J = 8.1 Hz, 1H), 7.05 (s, 1H), 
7.11 (s, 1H), 7.30-7.41 (m, 5H), 8.30 (s, 1H); 13C NMR δ 20.1, 21.2, 51.4, 116.5, 126.8, 128.3, 
128.7, 128.8, 129.4, 130.5, 131.4, 135.3, 137.6, 138.8, 142.2, 150.8, 161.9; GC-MS (tR 27.34 
min.) m/z 306 (70, M+), 91 (100); HRMS calcd for C19H19N2O2 [M + H]+ 307.1441, found 
307.1442.  
GC-MS of the crude reaction mixture showed peaks for three isomers with tR at 27.34, 27.90 
and 28.33 min. with relative intensities of 14:5:1 (m/z 306, M+). 
1-N-Benzyl-5-(2-,3-,and 4-methoxyphenyl)uracil (o/m/p-91d). Treatment of 78a (46 mg, 
0.14 mmol) with anisole (0.2 mL, 199 mg, 1.84 mmol) by procedure A gave 91d (o/m/p, 4:1:1; 
29.3 mg, 68%): GC-MS tR 25.52 (o-91d), 26.68 (m-91d) and 27.31 (p-91d) min. (m/z 308, M+); 
1H NMR δ 3.73 (s, 2H, o-91d), 3.80 (s, 0.5H, p-91d), 3.81 (s, 0.5H, m-91d), 4.96 (s, 1.3H, o-91d), 
4.98 (s, 0.7H, m,p-91d), 6.86-7.34 (m, 10H), 9.01(s, 0.67H, o-91d) 9.14(s, 0.33H, m,p-91d); 
HRMS calcd for C18H17N2O3 [M + H]+ 309.1234, found 309.1247. 
1-N-Benzyl-5-(3-methoxyphenyl)uracil (m-91d). Suzuki Coupling:54 Treatment of 78a (46 
mg, 0.14 mmol) with 3-methoxyphenylboronic acid (32 mg, 0.21 mmol), as described above for 
m-91a, gave m-91d (22 mg, 51%): 1H NMR δ 3.80 (s, 3H), 4.98 (s, 2H), 6.88 (dd, J = 8.8, 2.5 Hz, 
1H), 7.03 ("dt", J = 7.6, 2.0 Hz, 1H), 7.10 ("t", J = 2.0 Hz, 1H), 7.26 (t, J = 8.0 Hz, 1H), 7.33-
7.40 (m, 6H), 9.33 (s, 1H); 13C NMR δ 51.4, 55.3, 113.6, 114.0, 115.5, 121.4, 128.1, 128.6, 129.2, 
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129.5, 133.4, 135.2, 141.3, 150.7, 159.6, 162.2; GC-MS (tR 26.68 min.) m/z 308 (75, M+), 91 
(100); HRMS calcd for C18H17N2O3 [M + H]+ 309.1234, found 309.1238. 
1-N-Benzyl-5-(4-methoxyphenyl)uracil (p-91d). Suzuki Coupling:54 Treatment of 78a (46 
mg, 0.14 mmol) with 4-methoxyphenylboronic acid (32 mg, 0.21 mmol), as described above for 
m-91a, gave p-91d (23.7 mg, 55%): 1H NMR δ 3.80 (s, 3H), 4.98 (s, 2H), 6.90 (d, J = 8.8 Hz, 
2H), 7.25 (s, 1H), 7.32-7.39 (m, 7H), 8.64 (s, 1H); 13C NMR δ 51.5, 55.5, 114.2, 115.7, 124.5, 
128.2, 128.7, 129.3, 129.5, 135.4, 140.3, 150.8, 159.7, 162.5; GC-MS (tR 27.31 min.) m/z 308 (80, 
M+), 91 (100); HRMS calcd for C18H17N2O3 [M + H]+ 309.1234, found 309.1241. 
1-N-Benzyl-5-(fur-2-yl)uracil (91e). Method A. Treatment of 78a (46 mg, 0.14 mmol) with 
furan (0.2 mL, 187 mg, 2.75 mmol) by procedure A (3.5 equiv. of TBAF) gave 91e (29.3 mg, 
78%): 1H NMR δ 5.01 (s, 2H), 6.43 (dd, J = 3.0, 1.9 Hz, 1H), 7.05 (d, J = 3.0 Hz, 1H), 7.28-7.43 
(m, 6H), 7.69 (s, 1H), 9.19 (s, 1H); 13C NMR δ 51.9, 107.6, 109.7, 112.1, 128.2, 128.8, 129.3, 
135.3, 137.7, 141.3, 145.7, 150.2, 160.4; GC-MS (tR 27.41 min.) m/z 268 (60, M+), 91 (100); 
HRMS calcd for C15H13N2O3 [M + H]+ 269.0921, found 269.0934.  
Analogues treatment of 78b (39 mg, 0.14 mmol) with furan (0.2 mL, 187 mg, 2.75 mmol) by 
procedure A (14 equiv. of TBAF) gave 91e (31.9 mg, 85%) with spectroscopic data as described 
above.  
Method B. Procedure B. Furan (0.2 mL, 187 mg, 2.75 mmol), Cs2CO3 (91.2 mg, 0.28 mmol) 
and Pd(OAc)2 (1.6 mg, 0.007 mmol) were added to a stirring solution of 78a (46 mg, 0.14 mmol) 
in DMF (1.8 mL) under the N2 atmosphere at ambient temperature. The resulting suspension was 
stirred for 2 h at 100 oC (oil bath) and after cooling down to ambient temperature was diluted with 
EtOAc (3 mL). The resulting mixture was vacuum filtered using Whatman GF/A filter paper and 
the filtrates were evaporated. The oily residue was dissolved in EtOAc and partitioned 
(EtOAc/H2O). The organic layer was then washed (brine), dried (Na2SO4) and evaporated. 
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Column chromatography (hexane/EtOAc, 8:2 → 6:4) gave 91e (24.5 mg, 65% yield) with the 
spectroscopic data as above and 94 (5 mg, 17%). 
Procedure C. Analogous treatment of 78a (46 mg, 0.14 mmol) with furan (0.2 mL, 187 mg, 
2.75 mmol) and Cs2CO3 (91.2 mg, 0.28 mmol) in the presence of PivOH (17.9 mg, 0.175 mmol) 
and Pd(OAc)2 (1.6 mg, 0.007 mmol) by Procedure B gave 91e (27 mg, 73% yield). 
Analogues treatment of 78b (39 mg, 0.14 mmol) with furan (0.2 mL, 187 mg, 2.75 mmol) by 
procedure B gave 91e (5 mg, 13% yield) with the spectroscopic data as above. 
1-N-Benzyl-5-(benzo[b]fur-2-yl)uracil (91f). Treatment of 78a (46 mg, 0.14 mmol) with 
benzo[b]furan (23.1 µL, 24.8 mg, 0.21 mmol) by procedure A (3.5 equiv. of TBAF) gave 91f 
(29.4 mg, 66%): 1H NMR δ 5.06 (s, 2H), 7.2 (td, J = 7.3, 1.2 Hz, 1H), 7.26 (dt, J = 7.3, 1.4 Hz, 
1H), 7.37-7.42 (m, 6H), 7.47 (d, J = 0.6 Hz, 1H), 7.56 (ddd, J = 7.3, 1.5, 0.8 Hz, 1H), 7.95 (s, 1H), 
8.67 (s, 1H); 13C NMR δ 52.2, 106.1, 107.0, 110.7, 121.6, 123.3, 124.8, 128.2, 128.9, 129.3, 
129.4, 135.1, 139.5, 147.6, 149.9, 153.9, 160.1; HRMS calcd for C19H15N2O3 [M + H]+ 319.1077, 
found 319.1081. 
1-N-Benzyl-5-(thiophen-2-yl)uracil (91g). Method A. Treatment of 78a (46 mg, 0.14 mmol) 
with thiophene (0.2 mL, 210 mg, 2.5 mmol) by procedure A (3.5 equiv. of TBAF) gave 91g209 
(36.2 mg, 91%): 1H NMR (DMSO-d6) δ 4.98 (s, 2H), 7.06 (dd, J = 5.1, 3.7 Hz, 1H), 7.29-7.32 (m, 
1H), 7.34-7.37 (m, 4H), 7.44-7.47 (m, 2H), 8.45 (s, 1H), 11.72 (s, 1H); 13C NMR (DMSO-d6) δ 
50.8, 108.1, 122.7, 125.6, 126.4, 127.4, 127.6, 128.6, 133.7, 136.7, 140.9, 149.9, 161.7; HRMS 
calcd for C15H13N2O2S [M + H]+ 285.0692, found 285.0691. 
Method B. Analogues treatment of 78a (46 mg, 0.14 mmol) with thiophene (0.2 mL, 210 mg, 
2.5 mmol) by procedure B gave 91g (30.2 mg, 76% yield) with the spectroscopic data as above. 
Analogues treatment of 78b (39 mg, 0.14 mmol) with thiophene (0.2 mL, 210 mg, 2.5 mmol) 
by procedure B gave 91g (6 mg, 16% yield) with the spectroscopic data as above. 
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1-N-Benzyl-5-(5-methylthiophen-2-yl)uracil (91h). Treatment of 78a (46 mg, 0.14 mmol) 
with 2-methylthiophene (0.2 mL, 203 mg, 2.1 mmol) by procedure A (3.5 equiv. of TBAF) gave 
91h (29.2 mg, 70%): 1H NMR δ 2.46 (d, J = 0.8 Hz, 3H), 4.98 (s, 2H), 6.66 (dd, J = 3.6, 1.1 Hz, 
1H), 7.15 (d, J = 3.6 Hz, 1H), 7.30-7.40 (m, 5H), 7.42 (s, 1H), 9.06 (s, 1H); 13C NMR δ 15.3, 51.7, 
110.9, 125.0, 125.5, 128.2, 128.8, 129.4, 130.8, 135.2, 138.2, 140.4, 152.2, 161.4; HRMS calcd 
for C16H14N2O2SNa [M + Na]+ 321.0668, found 321.0674.  
1-N-Benzyl-5-(5-acetylthiophen-2-yl)uracil (91i). Treatment of 78a (46 mg, 0.14 mmol) 
with 2-acetylthiophene (0.2 mL, 234 mg, 2.1 mmol) by procedure A (3.5 equiv. of TBAF) gave 
91i (25 mg, 54%): 1H NMR (DMSO-d6) δ 2.50 (s, 3H), 4.99 (s, 2H), 7.29-7.34 (m, 1H), 7.37 (d, J 
= 4.3 Hz, 4H), 7.59 (d, J = 4.1 Hz, 1H), 7.87 (d, J = 4.1 Hz, 1H), 8.76 (s, 1H), 11.89 (s, 1H); 13C 
NMR (DMSO-d6) δ 26.4, 51.2, 107.1, 123.0, 127.4, 127.7, 128.6, 133.1, 136.5, 141.9, 142.5, 
143.2, 149.7, 161.5, 190.6; GC-MS (tR 31.00 min.) m/z 326 (20, M+), 91 (100); HRMS calcd for 
C17H15N2O3S [M + H]+ 327.0798, found 327.0801. 
1-N-Benzyluracil (92). Treatment of 78a (46 mg, 0.14 mmol) with toluene (0.2 mL, 173 mg, 
1.89 mmol) by procedure A [using KOSiMe3 (53.8 mg, 0.42 mmol) instead of TBAF] gave 92210 
(18.4 mg, 65%): 1H NMR δ 4.92 (s, 1H), 5.70 (dd, J = 7.9, 1.5 Hz, 1H), 7.16 (d, J = 7.9 Hz, 1H), 
7.25-7.44 (m, 3H), 9.46 (s, 1H); 13C NMR δ 51.4, 102.8, 128.2, 128.7, 129.3, 135.2, 144.0, 151.3, 
163.7; GC-MS (tR 24.38 min.) m/z 202 (35, M+), 91 (100); HRMS calcd for C11H11N2O2 [M + H]+ 
203.0815, found 203.0817. 
1-N-Benzyl-3-N-methyl-5-(fur-2-yl)uracil (93e). Treatment of 78c (48 mg, 0.14 mmol) with 
furan (0.2 mL, 187 mg, 2.75 mmol) by procedure B (column chromatography; hexane/EtOAc, 8:2 
→ 7:3) gave 93e (19 mg, 48% yield): GC-MS (tR 17.67 min.) m/z 282 (75, M+), 91 (100); 1H 
NMR δ 3.45 (s, 3H), 5.03 (s, 2H), 6.45 (dd, J = 3.4, 1.8 Hz, 1H), 7.06 (d, J = 3.3 Hz, 1H), 7.35 (d, 
J = 5.9 Hz, 1H), 7.33-7.39 (m, 3H), 7.36 (d, J = 8.1 Hz, 2H), 7.72 (s, 1H); 13C NMR δ 28.5, 53.0, 
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106.6, 109.3, 112.0, 128.1, 128.7, 129.3, 135.4, 136.0, 141.2, 146.3, 151.0, 160.2; HRMS calcd 
for C16H15N2O3 [M + H]+ 283.1077, found 283.1065. 
1-N-Benzyl-3-N-methyl-5-(thiophen-2-yl)uracil (93g). Treatment of 78c (48 mg, 0.14 
mmol) with thiophene (0.2 mL, 210 mg, 2.5 mmol) by procedure B (column chromatography; 
hexane/EtOAc, 8:2 → 7:3) gave 93g (17 mg, 41% yield): GC-MS (tR 23.66 min.) m/z 298 (75, 
M+), 91 (100); 1H NMR δ 3.46 (s, 3H), 5.03 (s, 2H), 7.02 (dd, J = 5.1, 3.7 Hz, 1H), 7.28 – 7.39 
(m, 7H), 7.55 (s, 1H). 13C NMR δ 28.7, 52.8, 109.6, 124.0, 125.8, 126.9, 128.2, 128.8, 129.3, 
134.9, 135.3, 137.0, 151.1, 161.4; HRMS calcd for C16H15N2O2S [M + H]+ 299.0849, found 
299.0852. 
1-N-benzyl-3-N-methyluracil (94). Treatment of 78c (48 mg, 0.14 mmol) with toluene (0.2 
mL, 173 mg, 1.89 mmol) by procedure A (column chromatography; hexane/EtOAc, 6:4 → 4:6) 
gave 94211 (29 mg, 73%): 1H NMR δ 3.36 (s, 3H), 4.94 (s, 2H), 5.75 (d, J = 7.9 Hz, 1H), 7.17 (d, 
J = 7.9 Hz, 1H), 7.2-7.48 (m, 5H); 13C NMR δ 28.0, 52.4, 102.0, 128.1, 128.6, 129.2, 135.4, 
141.7, 152.0, 163.2; GC-MS (tR 20.49 min.) m/z 216 (50, M+), 91 (100); HRMS calcd for 
C12H13N2O2 [M + H]+ 217.0972, found 217.0976. 
Analogous treatment (TBAF 3.5 equiv.) of 78c (48 mg, 0.14 mmol) with furan (0.2 mL, 187 
mg, 2.75 mmol) by procedure A gave 94211 (24 mg, 60%). 
1-(2,3,5-Tri-O-acetyl-β-D-arabinofuranosyl)-5-(fur-2-yl)uracil (101). Treatment (TBAF 
3.5 equiv.) of 1-(2,3,5-tri-O-acetyl-β-D-arabinofuranosyl)-5-iodouracil (95, 69.5 mg, 0.14 mmol) 
with furan (0.2 mL, 187 mg, 2.75 mmol) by procedure A (column chromatography; 
hexane/EtOAc, 6:4 → 5:5) gave 101 (37.3 mg, 61%) as a slightly yellow solid: 1H NMR δ 2.01 (s, 
3H), 2.18 (s 3H), 2.19 (s, 3H), 4.24 (dt, J = 5.2, 3.9 Hz, 1H), 4.44 (dd, J = 12.0, 5.2 Hz, 1H), 4.53 
(dd, J = 12.0, 4.2 Hz, 1H), 5.22 (dd, J = 3.6, 1.7 Hz, 1H), 5.48 (dd, J = 4.1, 1.7 Hz, 1H), 6.43 (d, J 
= 4.1 Hz, 1H), 6.49 (dd, J = 3.4, 1.8 Hz, 1H), 7.09 (d, J = 3.2 Hz, 1H), 7.39 (dd, J = 1.8, 0.6 Hz, 
1H), 7.97 (s, 1H), 9.39 (s, 1H); 13C NMR δ 20.4, 20.65, 20.68, 62.7, 74.7, 76.5, 80.5, 84.2, 106.6, 
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109.7, 112.0, 134.1, 141.3, 145.5, 149.0, 159.6, 168.6, 169.6, 170.5; HRMS calcd for 
C19H21N2O10 [M + H]+ 437.1191, found 437.1176. 
3',5'-Di-O-acetyl-5-(fur-2-yl)-2'-deoxyuridine (102). Treatment of 3',5'-di-O-acetyl-2'-
deoxy-5-iodouridine212 (96, 61.3 mg, 0.14 mmol) with furan (0.2 mL, 187 mg, 2.75 mmol) by 
procedure A (column chromatography; hexane/EtOAc, 6:4 → 5:5) gave 102 (38.1 mg, 72%): 1H 
NMR δ 2.12 (s, 3H), 2.15 (s, 3H), 2.54 (ddd, J = 14.4, 6.5, 2.1 Hz, 1H), 2.54 (ddd, J = 14.2, 5.6, 
1.6 Hz, 1H), 4.31 ("q", J = 2.7 Hz, 1H), 4.38-4.39 (m, 2H), 5.28 (dt, J = 6.6, 1.7 Hz, 1H), 6.44 (dd, 
J = 6.5, 5.6 Hz, 1H), 6.45 (dd, J = 3.4, 1.8 Hz, 1H), 7.08 (d, J = 3.2 Hz, 1H), 7.32 (dd, J = 1.8, 0.6 
Hz, 1H), 7.99 (s, 1H), 9.63 (s, 1H); 13C NMR δ 20.8, 21.0, 38.1, 64.2, 74.6, 82.7, 85.4, 107.9, 
109.9, 112.2, 132.5, 141.2, 145.8, 149.6, 160.0, 170.4, 170.5; HRMS calcd for C17H19N2O8 [M + 
H]+ 379.1136, found 379.1136. 
2',3',5'-Tri-O-acetyl-5-(fur-2-yl)uridine (103). Ttreatment of 2',3',5'-tri-O-acetyl-5-
iodouridine (97, 69.5 mg, 0.14 mmol) with furan (0.2 mL, 187 mg, 2.75 mmol) by procedure A 
(column chromatography; hexane/EtOAc, 6:4 → 5:5) gave 103 (40.8 mg, 67%): 1H NMR δ 2.07 
(s, 3H), 2.10 (s, 3H), 2.14 (s, 3H), 4.33-4.36 (m, 3H), 5.33-5.44 (m, 2H), 6.16 (d, J = 5.6 Hz, 1H), 
7.04 (dd, J = 5.1, 3.7 Hz, 1H), 7.30 (dd, J = 5.1, 1.1 Hz, 1H), 7.42 (dd, J = 3.6, 1.1 Hz, 1H), 7.75 
(s, 1H), 9.39 (s, 1H); 13C NMR δ 20.5, 20.7, 20.8, 64.6, 70.9, 73.0, 80.6, 86.8, 108.4, 110.2, 112.3, 
132.5, 141.3, 145.6, 149.6, 157.8, 169.77, 169.83, 170.4; HRMS calcd for C19H21N2O10 [M + H]+ 
437.1191, found 437.1178. 
2',3',5'-Tri-O-acetyl-5-(thiophen -2-yl)uridine (104). Ttreatment of 2',3',5'-tri-O-acetyl-5-
iodouridine (97, 69.5 mg, 0.14 mmol) with thiophene (0.2 mL, 210 mg, 2.5 mmol) by procedure 
A (column chromatography; hexane/EtOAc, 6:4 → 5:5) gave 104 (40 mg, 63%): 1H NMR δ 2.07 
(s, 3H), 2.10 (s, 3H), 2.14 (s, 3H), 4.33-4.46 (m, 3H), 5.33-5.44 (m, 2H), 6.16 (d, J = 5.6 Hz, 1H), 
7.04 (dd, J = 5.1, 3.7 Hz, 1H), 7.30 (dd, J = 5.1, 1.1 Hz, 1H), 7.42 (dd, J = 3.6, 1.1 Hz, 1H), 7.75 
(s, 1H), 9.39 (s, 1H); 13C NMR δ 20.5, 50.6, 20.8, 63.4, 70.5, 73.0, 80.5, 87.3, 111.3, 125.4, 125.9, 
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127.3, 133.1, 134.2, 149.6, 160.9, 169.8, 170.3; HRMS calcd for C19H21N2O9S [M + H]+ 
453.0962, found 453.0966. 
2',3',5'-Tri-O-acetyl-5-(methylthiophen-2-yl)uridine (105). Ttreatment of 2',3',5'-tri-O-
acetyl-5-iodouridine (97, 69.5 mg, 0.14 mmol) with 2-methylthiophene (0.2 mL, 203 mg, 2.1 
mmol) by procedure A (column chromatography; hexane/EtOAc, 6:4 → 5:5) gave 105 (35.9 mg, 
55%): 1H NMR δ 2.09 (s, 3H), 2.10 (s, 3H), 2.14 (s, 3H), 2.47 (d, J = 0.7 Hz, 3H), 4.33-4.45 (m, 
3H), 5.34-5.40 (m, 2H), 6.16 (d, J = 5.4 Hz, 1H), 6.68 (dd, J = 3.6, 1.1 Hz, 1H), 7.21 (d, J = 3.6 
Hz, 1H), 7.65 (s, 1H), 9.18 (s, 1H); 13C NMR δ 15.3, 20.5, 20.7, 20.9, 63.4, 70.5, 72.9, 80.5, 87.2, 
111.6, 125.56, 125.57, 130.7, 133.5, 140.6, 149.6, 160.9, 169.76, 169.78, 170.4; HRMS calcd for 
C20H23N2O9S [M + H]+ 467.1119, found 467.1108. 
1-(β-D-Arabinofuranosyl)-5-(fur-2-yl)uracil (106). Method A. Treatment of 1-(β-D-
arabinofuranosyl)-5-iodouracil213 (98, 52 mg, 0.14 mmol) with furan (0.2 mL, 187 mg, 2.75 
mmol) by procedure A (column chromatography; CH2Cl2/MeOH, 15:1 → 10:1) gave 106 (30.5 
mg, 70%) as off-white solid. The analytical sample was obtained by precipitation from minimum 
amount of MeOH:CH2Cl2 (1:1, v/v) with hexane: 1H NMR (DMSO-d6) δ 3.60 (dt, J = 10.3, 5.0 
Hz, 1H), 3.68 (dt, J = 10.3, 5.1 Hz, 1H), 3.78 ("q", J = 4.6 Hz, 1H), 3.97 (dd, J = 7.3, 3.8 Hz, 1H), 
4.04 (dt, J = 7.8, 3.9 Hz, 1H), 5.09 (t, J = 5.2 Hz, 1H), 5.51 (d, J = 4.4 Hz, 1H), 5.64 (d, J = 5.0 
Hz, 1H), 6.07 (d, J = 4.3 Hz, 1H), 6.52 (dd, J = 3.3, 1.9 Hz, 1H), 6.85 (dd, J = 3.3, 0.5 Hz, 1H), 
7.63 (dd, J = 1.8, 0.7 Hz, 1H), 8.07 (s, 1H), 11.65 (s, 1H); 13C NMR (DMSO-d6) δ 60.7, 75.3, 
75.6, 84.8, 85.3, 104.0, 107.6, 111.5, 136.5, 141.4, 146.5, 149.4, 160.2. HRMS calcd for 
C13H15N2O7 [M + H]+ 311.0784, found 311.0811. 
Method B. Compound 101 (43.6 mg, 0.10 mmol) was dissolved in NH3/MeOH (3 mL) at 0 
oC (ice bath), and the resulting solution was stirred overnight. Volatiles were removed under the 
reduced pressure and the residue was column chromatographed (CH2Cl2/MeOH, 15:1 → 10:1) to 
give 106 (27.9 mg, 90%) with the spectroscopic data as above.  
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5-(Fur-2-yl)-2'-deoxyuridine (107). Method A. Treatment of 2'-deoxy-5-iodourdine212 (99, 
49.6 mg, 0.14 mmol) with furan (0.2 mL, 187 mg, 2.75 mmol) by procedure A (column 
chromatography; CH2Cl2/MeOH, 15:1 → 10:1) gave 107 (30.1 mg, 73%) as yellow solid: 1H 
NMR (DMSO-d6) δ 2.18 (dd, J = 6.6, 4.8 Hz, 2H), 3.61 (dd, J = 8.8, 5.0 Hz, 2H), 3.84 (q, J = 3.3 
Hz, 1H), 4.28 ("quint", J = 4.0 Hz, 1H), 5.08 (t, J = 4.8 Hz, 1H), 5.27 (d, J = 4.2 Hz, 1H), 6.22 (t, 
J = 6.7 Hz, 1H), 6.52 (dd, J = 3.3, 1.8 Hz, 1H), 6.85 (dd, J = 3.3, 0.5 Hz, 1H), 7.61 (dd, J = 1.8, 
0.7 Hz, 1H), 8.33 (s, 1H), 11.62 (s, 1H); 13C NMR (DMSO-d6) δ 40.1, 61.1, 70.4, 84.7, 87.6, 
105.6, 107.8, 111.5, 134.6, 141.5, 146.4, 149.4, 160.1. HRMS calcd for C13H13N2O6 [M - H]- 
293.0779, found 293.0788. 
Method B. Treatment of 102 (38 mg, 0.10 mmol) with NH3/MeOH, as described for 106 
(Method B), gave 107 (26 mg, 90%) with the spectroscopic data as above.  
5-(Fur-2-yl)uridine (108). Method A. Treatment of 5-iodouridine212 (100, 52 mg, 0.14 
mmol) with furan (0.2 mL, 187 mg, 2.75 mmol) by procedure A (column chromatography; 
CH2Cl2/MeOH, 15:1 → 10:1) gave 108 (34.7 mg, 80%) as off-white solid. Precipitation of 108 
from MeOH:CH2Cl2 (1:1, v/v) solution with hexane gave analytical sample of 108: UV (MeOH) 
λmax = 314 nm; 1H NMR (DMSO-d6) δ 3.60 (ddd, J = 11.9, 4.6, 2.9 Hz, 1 H), 3.68 (ddd, J = 11.9, 
4.7, 2.9 Hz, 1H), 3.90 ("q", J = 3.2 Hz, 1H), 4.02 ("q", J = 4.5 Hz, 1H), 4.12 ("q", J = 5.1 Hz, 1H), 
5.11 (d, J = 5.0 Hz, 1H), 5.21 (t, J = 4.7 Hz, 1H), 5.43 (d, J = 5.5 Hz, 1H), 5.87 (d, J = 5.1 Hz, 
1H), 6.52 (dd, J = 3.3, 1.8 Hz, 1H), 6.86 (dd, J = 3.3, 0.6 Hz, 1H), 7.60 (dd, J = 1.8, 0.7 Hz, 1H), 
8.42 (s, 1H), 11.64 (s, 1H); 13C NMR (DMSO-d6) δ 60.6, 69.9, 74.0, 85.0, 88.2, 105.7, 108.0, 
111.6, 134.9, 141.6, 146.4, 149.7, 160.1; HRMS calcd for C13H13N2O7 [M - H]- 309.0728, found 
309.0734. 
Analogous treatment of 100 (310 mg, 1.0 mmol) with furan (1.1 mL, 1.03 g, 15 mmol) by 
procedure A gave 108 (273 mg, 88%). 
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Method B. Treatment of 100 (52 mg, 0.14 mmol) with furan (0.2 mL, 187 mg, 2.75 mmol) 
by procedure B (column chromatography; CH2Cl2/MeOH, 15:1 → 10:1) gave 108 (10 mg, 23% 
yield) with the spectroscopic data as above. 
5-(Thiophen-2-yl)uridine (109). Method A. Treatment of 5-iodouridine (100, 52 mg, 0.14 
mmol) with thiophene (0.2 mL, 210 mg, 2.5 mmol) by procedure A (column chromatography; 
CH2Cl2/MeOH, 15:1 → 10:1) gave 109 (44.7 mg, 98%) as off-white solid. Precipitation of 109 
from MeOH:CH2Cl2 (1:1, v/v) solution with hexane gave analytical sample of 109: UV (MeOH) 
λmax = 318 nm; 1H NMR (DMSO-d6) δ 3.64 (ddd, J = 12.0, 4.4, 2.3 Hz, 1H), 3.76 (ddd, J = 12.0, 
4.7, 2.8 Hz, 1H), 3.92 (dt, J = 4.8, 2.7 Hz, 1H), 4.06 ("q", J = 5.1 Hz, 1H), 4.13 ("q", J = 4.8 Hz, 
1H), 5.09 (d, J = 5.5 Hz, 1H), 5.42 (t, J = 4.6 Hz, 1H), 5.46 (d, J = 5.3 Hz, 1H), 5.84 (d, J = 4.2 
Hz, 1H), 7.05 (dd, J = 5.1, 3.7 Hz, 1H), 7.40 (dd, J = 3.7, 1.1 Hz, 1H), 7.46 (dd, J = 5.1, 1.1 Hz, 
1H), 8.65 (s, 1H), 11.69 (s, 1H); 13C NMR (DMSO-d6) δ 60.2, 69.4, 74.3, 84.7, 88.7, 108.3, 122.5, 
125.7, 126.4, 133.9, 135.7, 149.6, 161.3; HRMS calcd for C13H14N2NaO6S [M + Na]+ 349.0465, 
found 349.0465. 
Method B. Treatment of 100 (52 mg, 0.14 mmol) with thiophene (0.2 mL, 210 mg, 2.5 mmol) 
by procedure B (column chromatography; CH2Cl2/MeOH, 15:1 → 10:1) gave 109 (8 mg, 17% 
yield) with the spectroscopic data as above. 
5-(5-Methylthiophen-2-yl)uridine (110). Treatment of 5-iodouridine (100, 52 mg, 0.14 
mmol) with 2-methylthiophene (0.2 mL, 203 mg, 2.1 mmol) by procedure A (column 
chromatography; CH2Cl2/MeOH, 15:1 → 10:1) gave 110 (36.5 mg, 76%) as off-white solid. 
Precipitation of 110 from MeOH:CH2Cl2 (1:1, v/v) solution with hexane gave analytical sample 
of 110: 1H NMR (DMSO-d6) δ 2.42 (s, 3H), 3.63 (ddd, J = 12.0, 4.4, 2.3 Hz, 1H), 3.74 (ddd, J = 
12.0, 4.6, 2.8 Hz, 1H), 3.91 ("dt", J = 4.8, 2.4 Hz, 1H), 4.05 ("q", J = 5.0 Hz, 1H), 4.11 ("q", J = 
4.8 Hz, 1H), 5.08 (d, J = 5.4 Hz, 1H), 5.38 (t, J = 4.6 Hz, 1H), 5.44 (d, J = 5.4 Hz, 1H), 5.83 (d, J 
= 4.4 Hz, 1H), 6.72 (dd, J = 3.6, 1.1 Hz, 1H), 7.19 (d, J = 3.6 Hz, 1H), 8.53 (s, 1H), 11.63 (s, 1H); 
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13C NMR (DMSO-d6) δ 14.7, 60.2, 69.4, 74.2, 84.7, 88.6, 108.6, 122.6, 124.7, 131.5, 134.9, 138.8, 
149.5, 161.3; HRMS calcd for C14H17N2O6S [M + H]+ 341.0802, found 341.0803. 
5-(Pyrrol-2-yl)uridine (111). Treatment of 5-iodouridine (100, 52 mg, 0.14 mmol) with 
pyrrole (0.2 mL, 193 mg, 2.88 mmol) by procedure A [reaction was carried out in a flask covered 
in aluminum foil under N2 atmosphere; column chromatography (CH2Cl2/MeOH, 15:1 → 10:1)] 
gave 111 (19.4 mg, 45%) as brownish amorphous powder. This material is stable when stored in 
refrigerator under the inert condition for at least 1 month: 1H NMR (DMSO-d6) δ 3.60 (ddd, J = 
12.0, 4.4, 3.3 Hz, 1H ), 3.70 (ddd, J = 11.8, 4.6, 3.5 Hz, 1H), 3.87 ("q", J = 3.5 Hz, 1H), 4.03 ("q", 
J = 4.7 Hz, 1H), 4.14 ("q", J = 5.2 Hz, 1H), 5.10 (d, J = 5.2 Hz, 1H), 5.27 (t, J = 4.8 Hz, 1H), 5.42 
(d, J = 5.6 Hz, 1H), 5.83 (d, J = 5.1 Hz, 1H), 6.03 (dd, J = 5.8, 2.6 Hz, 1H), 6.39 (dd, J = 4.5, 2.7 
Hz, 1H), 6.76 (dd, J = 4.1, 2.5 Hz, 1H), 8.22 (s, 1H), 10.85 (s, 1H), 11.54 (bs, 1H); 13C NMR 
(DMSO-d6) δ 60.6, 69.6, 73.6, 84.7, 88.2, 105.5, 107.2, 108.0, 118.2, 123.8, 133.6, 149.7, 162.0; 
HRMS calcd for C13H16N3O6 [M + H]+ 310.1034, found 310.1034. 
2',3',5'-Tri-O-acetylcytidine hydrochloride. Cytidine (112, 486 mg, 2 mmol) was dissolved 
in the mixture of CH3COOH/CHCl3 (9 mL, 1:2, v/v), followed by the addition of acetyl chloride 
(0.6 mL). The resulting clear solution was stirred at ambient temperature for 40h. Volatiles was 
removed under the reduced pressure and the oily residue was column chromatographed 
(CHCl3:MeOH = 9:1) to give product 112 as white precipitate (776 mg, 96%). 1H NMR (400 
MHz, DMSO-d6) δ 2.05 (s, 3H), 2.06 (s, 3H), 2.07 (s, 3H), 4.18-4.37 (m, 3H), 5.32 (t, J = 6.0 Hz, 
1H), 5.48 (dd, J = 6.1, 4.4 Hz, 1H), 5.90 (d, J = 4.3 Hz, 1H), 6.20 (d, J = 7.8 Hz, 1H), 7.97 (d, J = 
7.8 Hz, 1H), 8.70 (s, 1H), 9.70 (s, 1H); 13C NMR (101 MHz, DMSO-d6) δ 20.27, 20.31, 20.6, 
62.8, 69.4, 72.4, 79.3, 89.2, 94.8, 144.7, 148.1, 160.6, 169.3, 170.1. 
2',3',5'-Tri-O-acetyl-5-iodocytidine (113). 2',3',5'-Tri-O-acetylcytidine hydrochloride (405 
mg, 1 mmol) was dissolved in the mixture of CCl4/CH3COOH (8 mL, 1:1, v/v), followed by the 
addition of I2 (152 mg, 0.6 mmol) and HIO3 (153 mg, 0.87 mmol). The resulting red solution was 
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stirred at 40 oC for 12 h. After cool down to ambient temperature, reaction mixture was washed 
with water and saturated NaHCO3. The color of iodine was reduced with 5% of NaHSO3, and the 
organic was dried over the Na2SO4. Volatiles was removed under the reduced pressure and the 
residue was column chromatographed (CHCl3:MeOH = 95:5) to give product 113 as white 
precipitate (361 mg, 73%). 1H NMR (400 MHz, DMSO-d6) δ 2.05 (s, 3H), 2.06 (s, 3H), 2.07 (s, 
3H), 4.13-4.27 (m, 2H), 4.27-4.37 (m, 1H), 5.30-5.39 (m, 1H), 5.45 (dd, J = 6.4, 4.4 Hz, 1H), 
5.80 (d, J = 4.3 Hz, 1H), 6.83 (s, 1H), 8.04 (s, 1H), 8.07 (s, 1H); 13C NMR (101 MHz, DMSO-d6) 
δ 20.3, 20.7, 48.6, 57.8, 63.0, 69.7, 72.5, 78.9, 98.8, 148.6, 153.6, 164.1, 169.4, 170.0. 
3-(Fur-2-yl)pyridin-2(1H)-one (120). Method A. Treatment of 119 (24.36 mg, 0.14 mmol) 
with furan (0.2 mL, 187 mg, 2.75 mmol) by procedure A (14 equiv. of TBAF) gave 120 (7 mg, 
31%) followed by 119 (11 mg, 45%). Compound 120 had: UV (MeOH) λmax = 332 nm;  1H NMR 
(CD3CN) δ 6.33 (t, J = 6.9 Hz, 1H), 6.53 (dd, J = 3.3, 1.8 Hz, 1H), 7.27-7.29 (m, 2H), 7.54 (dd, J 
= 1.8, 0.7 Hz, 1H), 7.89 (dd, J = 7.1, 2.0 Hz, 1H), 10.33 (s, 1H); 13C NMR (CD3CN) δ 106.5, 
111.1, 112.7, 122.2, 133.7, 134.6, 143.0, 150.4, 160.2; HRMS calcd for C9H8NO2 [M + H]+ 
162.0550, found 162.0553. 
Method B. Treatment of 119 (24.36 mg, 0.14 mmol) with furan (0.2 mL, 187 mg, 2.75 mmol) 
by procedure B gave 120 (15.3 mg, 68% yield) with the spectroscopic data as above. 
3-(Thiophen-2-yl)pyridin-2(1H)-one (121). Treatment of 119 (24.36 mg, 0.14 mmol) with 
thiophene (0.2 mL, 210 mg, 2.5 mmol) by procedure A (14 equiv. of TBAF) gave 121 (7 mg, 
27%) followed by 119 (12 mg, 49%). Compound 22 had: UV (MeOH) λmax = 346 nm; 1H NMR 
(CD3CN) δ 6.32 (dd, J = 7.0, 6.6 Hz, 1H), 7.09 (dd, J = 5.1, 3.8 Hz, 1H), 7.28 (dd, J = 6.5, 1.9 Hz, 
1H), 7.40 (dd, J = 5.1, 1.1 Hz, 1H), 7.67 (dd, J = 3.8, 1.1 Hz, 1H), 7.97 (dd, J = 7.1, 1.9 Hz, 1H), 
9.98 (s, 1H); 13C NMR (CD3CN) δ 105.4, 123.6, 126.2, 126.4, 128.2, 129.2, 132.4, 134.5, 159.6; 
HRMS calcd for C9H8NOS [M + H]+ 178.0321, found 178.0320. 
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1-N-Benzyl-6-(4-methoxyphenyl)uracil (122). AgCl (60 mg, 0.42 mmol), Pd(OAc)2 (3.2 
mg, 0.014 mmol) and tetrabutylammonium bromide (TBABr, 67.7 mg, 0.21 mmol) were added to 
a stirred solution of 1-N-benzyluracil210 (92, 28.3 mg, 0.14 mmol) and 4-iodoanisole (98.3 mg, 
0.42 mmol) in DMSO (1 mL) under the N2 atmosphere at ambient temperature. The resulting 
suspension was stirred for 16 h at 100 oC (oil bath). Volatiles were evaporated, and the oily 
residue was dissolved in EtOAc and filtrated through Whatman GF/A filter paper. The filtrate 
was column chromatographed (hexane/EtOAc, 5:5 → 4:6) to give p-91d (10 mg, 23%) and 122 
(14 mg, 33%) followed by 92 (12 mg, 41%). Compound 23 had: 1H NMR δ 3.84 (s, 1H), 4.96 (s, 
1H), 5.65 (s, 1H), 6.87 (d, J = 8.6 Hz, 1H), 6.90-6.95 (m, 1H), 7.08 (d, J = 8.5 Hz, 1H), 7.19-7.26 
(m, 1H), 9.73 (s, 1H); 13C NMR δ 48.6, 55.5, 104.1, 114.2, 125.3, 127.0, 127.7, 128.7, 129.5, 
136.5, 152.3, 157.3, 161.0, 163.1; GC-MS (tR 24.77 min.) m/z 308 (70, M+), 91 (100); HRMS 
calcd for C18H17N2O3 [M + H]+ 309.1234, found 309.1229. 
1-(2,3,5-Tri-O-acetyl--D-arabinofuranosyl)-5-(E/Z)-[2-(triphenylgermyl)ethenyl]uracil 
(124a) and 1-(2,3,5-tri-O-acetyl--D-arabinofuranosyl)-5-[2-(triphenylgermyl)acetyl]uracil 
(126a). Method A. ACCN-induced hydrogermylation. Nucleoside 123161 (50 mg, 0.13 mmol) 
was added to freshly distilled toluene (6 mL) and the suspension was stirred and degassed with N2 
for 30 min. The mixture was then pre-heated at 80 °C and Ph3GeH (50 mg, 0.16 mmol) was 
added followed by ACCN (4 mg, 0.02 mmol). The temperature was increased to 90 °C and the 
solution was stirred until 123 was completely consumed (TLC; 14 h). The volatiles were removed 
in vacuo and the oily residue was chromatographed (hexane/EtOAc, 2:3) to give a separable 
mixture of Z-124a (43 mg, 47%) and 126a (10.5 mg, 12%). Compound Z-124a had: 1H NMR  
1.99 (s, 3H), 2.09 (s, 3H), 2.11 (s, 3H), 3.70 (dd, J = 13.7, 7.7 Hz, 1H), 3.91-3.98 (m, 2H), 4.97 
(dd, J = 3.2, 2.0 Hz, 1H), 5.27 (dd, J = 4.1, 1.9 Hz, 1H), 5.71 (d, J = 4.1 Hz, 1H), 6.56 (d, J = 13.5 
Hz, 1H), 7.08 (d, J = 1.0 Hz, 1H), 7.36 (m, 10H), 7.52 (m, 6H), 8.30 (br. s, 1H); 13C NMR  20.4, 
20.6, 20.7, 62.3, 74.6, 76.1, 79.8, 84.4, 113.4, 128.4, 129.1, 131.7, 134.8, 136.38, 136.41, 138.2, 
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148.6, 161.3, 168.5, 169.4, 170.2; MS m/z 701 (100, MH+, 74Ge), 699 (71, MH+, 72Ge) 698 (51, 
MH+, 70Ge); Anal. Calcd for C35H34GeN2O9 (699.29): C, 60.11; H, 4.90; N, 4.01. Found: C, 59.63; 
H, 4.92; N, 4.00. 
1H NMR of the crude reaction mixture showed also a presence (~5%) of the E-124a with the 
characteristic peaks at  6.31 (d, J = 4.0 Hz, H1'), 6.69 (d, J = 18.8 Hz, CH).  
Compound 126a had: 1H NMR  1.90 (s, 3H), 2.14 (s, 3H), 2.15 (s, 3H), 3.48 (d, J = 9.3 Hz, 
1H), 4.16-4.19 (m, 1H), 4.17 (d, J = 9.3 Hz, 1H), 4.33 (dd, J = 12.1, 4.5 Hz, 1H), 4.44 (dd, J = 
12.1, 4.9 Hz, 1H), 5.12 (dd, J = 3.3, 1.6 Hz, 1H), 5.33 (dd, J = 4.1, 1.6 Hz, 1H), 6.23 (d, J = 4.1 
Hz, 1H), 7.21-7.37 (m, 9H), 7.50-7.55 (m, 6H), 8.08 (s, 1H), 8.49 (br. s, 1H); 13C NMR  20.4, 
20.7, 20.8, 33.0, 62.4, 74.6, 76.6, 80.8, 83.9, 113.3, 128.4, 129.5, 135.1, 135.3, 146.6, 148.8, 
160.4, 168.8, 169.6, 170.8, 194.2; HRMS calcd for C35H3474GeN2NaO10 [M + Na]+ 739.1323, 
found 739.1311. 
Treatment of 123 (100 mg, 0.26 mmol) and Ph3GeH (94 mg, 0.30 mmol) in toluene without 
ACCN (85 °C, 14 h; column chromatography (50 → 60% EtOAc/hexane) gave E/Z-124a (110 
mg, 60%; E/Z, 3:97) and 126a (26 mg, 15%). 
Method B. Et3B-induced hydrogermylation. A solution of Et3B in THF (1M; 140 L, 0.14 
mmol) was added to a stirred solution of 123 (50 mg, 0.127 mmol) and Ph3GeH (43 mg, 0.14 
mmol) in dry THF (5 mL) at -78 °C placed in a screw-capped glass tube. The resulting mixture 
was stirred for 3 hours at -78 °C until TLC showed appearance of a less polar spot. The reaction 
mixture was slowly warmed up to -60 °C and was stirred for another 1.5 h. The volatiles were 
evaporated and the resulting oil was column chromatographed (hexane/EtOAc, 2:3) to give Z-
124a (49 mg, 55%). 
Treatment of 123 (49 mg, 0.12 mmol) with Ph3GeH (42 mg, 0.14 mmol) by Method B 
(0 °C/6 h) gave a mixture of Z-124a and 126a (39 mg, ~46%; 124a/126a, 59:41, 1H NMR). 
Recrystallization (hexane/Et2O) gave Z-124a as a white powder (22 mg, 25% from 123). 
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Method C. Pd-catalyzed hydrogermylation. Ph3GeH (59 mg, 0.2 mmol) and Pd(PPh3)4 (8 mg, 
0.08) was added to stirred suspension of 123 (70 mg, 0.18 mmol) in THF (3 mL) in a flamed 
dried round bottle flask at ambient temperature under N2. After 5 h, the volatiles were evaporated 
in vacuo and the resulting oil was column chromatographed (hexane/EtOAc, 1:1) to give 
inseparable mixture of the E-isomer of 124 and the corresponding regioisomer resulting from the 
addition to α-carbon (90 mg, 73%; E-124/α-addition product, 3:2; 1H NMR;): MS (ESI) m/z 701 
(100, MH+, 74Ge), 699 (70, MH+, 72Ge), 697 (50, MH+, 70Ge). Compound E-124a had: 1H NMR  
1.88 (s, 3H), 1.98 (s, 3H), 2.14 (s, 3H), 4.23 (m, 2H), 4.35-4.39 (m, 1H), 5.09 (dd, J = 3.4, 1.5 Hz, 
1H), 5.43 (dd, J = 3.9, 1.5 Hz, 1H), 6.31 (d, J = 4.0 Hz, 1H), 6.69 (d, J = 18.8 Hz, 1H), 7.60 (s, 
1H), 7.33-7.40 (m, 10H), 7.51-7.55 (m, 6H), 9.29 (br. s, 1H). The α-addition product 1-(2,3,5-tri-
O-acetyl--D-arabinofuranosyl)-5-[1-(triphenylgermyl)ethenyl] uracil had: 1H NMR  1.80 (s, 
3H), 2.07 (s, 3H), 2.11 (s, 3H), 4.00-4.23 (m, 2H), 4.45-4.49 (m, 1H), 4.98 (dd, J = 3.5, 1.9 Hz, 
1H), 5.35 (dd, J = 4.1, 1.5 Hz, 1H), 5.72 (d, J = 2.0 Hz, 1H), 6.17 (d, J = 4.1 Hz, 1H), 6.41 (d, J = 
2.0 Hz, 1H), 7.33-7.40 (m, 9H), 7.42 (s, 1H), 7.51-7.55 (m, 6H), 8.98 (br. s, 1H). 
1-(2,3,5-Tri-O-acetyl--D-arabinofuranosyl)-5-(E/Z)-[2-(trimethylgermyl)ethenyl]uracil 
(124b). Nucleoside 123 (50 mg, 0.13 mmol) was treated with Me3GeH (30 mg, 29.6 L, 0.25 
mmol) in dry THF (5 mL) as described in Method B (with injection of Me3GeH into the reaction 
mixture via syringe and progressive warming from 0 °C to ambient temperature) for 14 h. The 
volatiles were removed under reduced pressure and the residue was column chromatographed 
(hexane/EtOAc, 2:3) to give E/Z-124b (27 mg, 40%; E/Z, 13:87). 1H NMR  0.26 (s, 7.83H), 
0.28 (s, 1.17H), 2.02 (s, 3H), 2.12 (s, 2.61H), 2.15 (s, 0.39H), 2.16 (s, 2.61H), 2.17 (s, 0.39H), 
4.19-4.25 (m, 1H), 4.34 (dd, J = 11.9, 6.2 Hz, 0.87H), 4.37-4.45 (m, 0.13H), 4.44 (dd, J = 11.9, 
4.2 Hz, 0.87H), 4.52 (dd, J = 11.9, 6.2 Hz, 0.13H), 5.11 (dd, J = 3.8, 1.4 Hz, 0.87H), 5.15 (dd, J = 
3.4, 1.6 Hz, 0.13H), 5.44-5.48 (m, 1H), 6.10 (d, J = 13.8 Hz, 0.87H), 6.24 (d, J = 3.8 Hz, 0.87H), 
6.33 (d, J = 4.0 Hz, 0.13H), 6.60 (d, J = 18.9 Hz, 0.13H), 6.80 (d, J = 19.0 Hz, 0.13H), 6.98 (dd, J 
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= 13.8, 1.0 Hz, 0.87H), 7.45 (d, J = 1.0 Hz, 0.87, 1H), 7.59 (s, 0.13H), 8.97 (br. s, 0.13H), 9.09 
(br. s, 0.87H); 13C NMR  -1.7, -0.2, 20.5, 20.6, 20.8, 20.87, 20.92, 62.7, 63.2, 74.7, 74.8, 76.4, 
76.5, 80.4, 80.8, 84.6, 112.9, 114.2, 132.1, 133.6, 134.3, 136.1, 136.4, 137.6, 149.2, 149.6, 161.8, 
162.2, 168.6, 168.7, 169.7, 169.8, 170.5; HRMS calcd for C20H2874GeNaN2O9 [M + Na]+ 
537.0899, found 537.0888. 
1-(2,3,5-Tri-O-acetyl--D-arabinofuranosyl)-5-(Z)-[2-(tris(trimethylsilyl)germyl)ethenyl] 
uracil (124c). Nitrogen gas was bubbled through a heterogeneous mixture of 123 (127 mg, 0.32 
mmol) in dry toluene (10 mL) for 30 min. The suspension was pre-heated up to 90 °C (~5 min) 
and (Me3Si)3GeH (115 mg, 123 L, 0.39 mmol) was added via syringe in one portion followed 
by ACCN (8 mg, 0.04 mmol) dissolved in degassed toluene (1 mL). The solution was heated at 
95 oC over 30 min as TLC revealed total consumption of 123. The mixture was cooled down to 
ambient temperature. Volatiles were evaporated and the residue was column chromatographed 
(hexane/EtOAc, 3:2) to give Z-124c (152 mg, 68%): 1H NMR  0.20 (s, 27H), 2.01 (s, 3H), 2.10 
(s, 3H), 2.14 (s, 3H), 4.17-4.24 (m, 1H), 4.34 (dd, J = 12.0, 5.5 Hz, 1H), 4.38 (dd, J = 12.0, 5.2 Hz, 
1H), 5.14 (dd, J = 3.8, 1.6 Hz, 1H), 5.47 (dd, J = 3.8, 1.7 Hz, 1H), 6.16 (d, J = 3.9 Hz, 1H), 6.28 
(d, J = 13.5 Hz, 1H), 6.90 (dd, J = 13.5, 1.4 Hz, 1H), 7.29 (d, J = 1.4 Hz,1H), 8.27 (br. s, 1H); 13C 
NMR  1.95, 20.7, 20.9, 21.0, 63.1, 75.0, 76.5, 80.7, 85.4, 116.1, 133.9, 134.1, 136.2, 149.6, 
162.0, 168.9, 169.7, 170.6; HRMS calcd for C26H4774GeN2O9Si3 [M + H]+ 689.1801, found 
689.1798. 
1H NMR of the crude reaction mixture showed 4:96 mixture of E/Z isomers of 124c. The E-
124c had the characteristic peaks on the 1H NMR spectrum at:  6.36 (d, J = 3.5 Hz, H1'), 6.63 (d, 
J = 18.7 Hz, CH), 6.86 (d, J = 18.5 Hz, CH). 
1-(-D-Arabinofuranosyl)-5-(Z)-[2-(triphenylgermyl)ethenyl]uracil (125a). A saturated 
solution of MeOH/NH3 (2 mL) was added to a suspension of Z-124a (40.0 mg, 0.057 mmol) in 
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MeOH (2 mL) and the reaction mixture stirred for 6 h at 0 °C. An additional portion of 
MeOH/NH3 solution (1 mL) was then added and the solution was stirred overnight at ambient 
temperature. Volatiles were evaporated under vacuum and the residue was column 
chromatographed (EtOAc/MeOH, 98:2) to give Z-125a (28.2 mg, 86%). 1H NMR (MeOH-d4)  
3.28 (dd, J = 11.3, 4.0 Hz, 1H), 3.37 (dd, J = 11.3, 5.6 Hz, 1H), 3.76 (ddd, J = 5.8, 4.1, 2.1 Hz, 
1H), 3.98-4.02 (m, 2H), 5.59 (d, J = 3.3 Hz, 1H), 6.50 (d, J = 13.2 Hz, 1H), 7.30 (d, J = 13.3 Hz, 
1H), 7.35 (m, 10H), 7.51 (m, 6H); 13C NMR (MeOH-d4)  62.6, 76.6, 78.4, 87.0, 88.3, 113.8, 
129.3, 130.0, 131.5, 136.0, 138.2, 139.9, 140.7, 151.3, 165.0; HRMS calcd for 
C29H2874GeNaN2O6 [M + Na]+ 597.1051, found 597.1076. Anal. Calcd for C29H28GeN2O6• 
CH3OH•H2O (623.24): C, 57.81; H, 5.50; N, 4.49. Found: C, 57.84; H, 5.41; N, 4.69. 
5-Ethynyl-2',3',5'-tri-O-p-toluoyluridine (127). The p-toluoyl chloride (86 µL, 101 mg, 
0.65 mmol) was added to a stirred solution of 5-ethynyluridine214 (50 mg, 0.19 mmol) in the dry 
pyridine (5 mL). After 24 h, the volatiles were evaporated and the residue was partitioned 
between NaHCO3/H2O//CHCl3. The organic layer was washed with diluted HCl/H2O, 
NaHCO3/H2O, brine, and was dried (MgSO4), and evaporated. The residue was column 
chromatographed (hexane/EtOAc, 7:3 → 6:4) to give 127 (85 mg, 73%): 1H NMR  2.40 (s, 3H), 
2.44 (s, 6H, 2 x Me), 2.94 (s, 1H), 4.69-4.76 (m, 2H), 4.78-4.84 (m, 1H), 5.70 ("t", J = 6.0 Hz, 
1H), 5.84 (dd, J = 5.9, 3.6 Hz, 1H, H3), 6.37 (d, J = 6.1 Hz, 1H), 7.18 (d, J = 8.0 Hz, 2H), 7.24 (d, 
J = 8.0 Hz, 2H), 7.31 (d, J = 8.0 Hz, 2H), 7.81 (s, 1H), 7.84 (d, J = 8.2 Hz, 2H), 7.91 (d, J = 8.2 
Hz, 2H), 8.02 (d, J = 8.2 Hz, 2H), 8.18 (s, 1H); 13C NMR  21.8, 21.9, 63.8, 71.5, 73.76, 73.77, 
81.4, 82.5, 87.9, 100.6, 125.7, 126.1, 126.5, 129.4, 129.5, 129.7, 129.9, 130.1, 130.2, 143.2, 144.6, 
144.8, 144.9, 148.8, 160.6, 165.4, 165.5, 166.3; HRMS calcd for C35H31N2O9 [M + H]+ 623.2024, 
found 623.2033. 
5-(Z)-[2-(Triphenylgermyl)ethenyl]-2',3',5'-tri-O-p-toluoyluridine (129a) and 5-[2-
(triphenylgermyl)acetyl]-2',3',5'-tri-O-p-toluoyluridine (133a). Nucleoside 127 (49 mg, 0.08 
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mmol; prepared by treatment of 5-ethynyluridine214 with para-toluoyl chloride in pyridine as 
described in SI) was treated with Ph3GeH (26 mg, 0.085 mmol) in dry THF (5 mL) as described 
in Method B. After 6 h at -78 °C, TLC revealed slow progression towards product. The reaction 
mixture was slowly warmed to 0 °C until TLC showed approximately 95% consumption of the 
substrate 127 (~24 h). The volatiles were removed under vacuum and the residue was column 
chromatographed (hexane/EtOAc, 1:1) to give a separable mixture of Z-129a (29 mg, 40%) and 
133a (10 mg, 13%). Compound Z-129a had: 1H NMR  2.40 (s, 6H), 2.42 (s, 3H), 4.34 (dd, J = 
12.2, 5.4 Hz, 1H), 4.40 (dd, J = 12.2, 3.4 Hz, 1H), 4.47 (ddd, J = 5.8, 5.4, 3.5 Hz, 1H), 5.38 (dd, J 
= 6.2, 4.5 Hz, 1H), 5.51 (“t”, J = 6.0 Hz, 1H), 5.52 (d, J = 4.4 Hz, 1H), 6.50 (d, J = 13.6 Hz, 1H), 
7.11 (d, J = 0.9 Hz, 1H), 7.16 (d, J = 8.1 Hz, 2H), 7.19 (d, J = 8.0 Hz, 2H), 7.22 (dd, J = 13.5, 0.9 
Hz, 1H), 7.24 (d, J = 8.0 Hz, 2H), 7.31-7.36 (m, 9H), 7.50-7.55 (m, 6H), 7.80 (d, J = 8.2 Hz, 4H), 
7.96 (d, J = 8.2 Hz, 2H), 8.09 (br. s, 1H); 13C NMR  21.67, 21.69, 21.72, 63.5, 70.5, 73.6, 79.9, 
89.8, 115.0, 125.9, 126.0, 126.7, 128.5, 129.1, 129.2, 129.3, 129.7, 129.8, 129.9, 131.4, 134.7, 
136.6, 137.0, 138.2, 144.2, 144.4, 144.5, 148.8, 161.4, 165.0, 165.1, 166.1; HRMS calcd for 
C53H4674GeN2NaO9 [M + Na]+ 951.2307, found 951.2315.  
Compound 133a had: UV (MeOH) max = 282 nm; 1H NMR  2.35 (s, 3H), 2.40 (s, 3H), 2.42 
(s, 3H), 3.76 (d, J = 9.0 Hz, 1H), 3.87 (d, J = 9.0 Hz, 1H), 4.67-4.75 (m, 3H), 5.66 (dd, J = 5.9, 5.1 
Hz, 1H), 5.83 (“t”, J = 5.7 Hz, 1H), 6.01 (d, J = 5.0 Hz, 1H), 7.16-7.22 (m, 6H), 7.31-7.36 (m, 
9H), 7.50-7.55 (m, 6H), 7.83 (d, J = 8.2 Hz, 2H), 7.87 (d, J = 8.2 Hz, 2H), 8.02 (d, J = 8.2 Hz, 
2H), 8.05 (s, 1H); 13C NMR  21.7, 33.0, 63.5, 71.0, 73.9, 80.9, 90.4, 113.7, 125.7, 126.0, 126.6, 
128.2, 129.21, 129.24, 129.3, 129.4, 129.8, 129.9, 135.0, 135.1, 144.1, 144.5, 144.7, 146.6, 148.5, 
160.2, 165.19, 165.21, 166.3, 193.3; HRMS calcd for C53H4774GeN2O10 [M + H]+ 945.2437, 
found 945.2456. 
5-(E/Z)-[2-(Trimethylgermyl)ethenyl]-2',3',5'-tri-O-p-toluoyluridine (129b). Nucleoside 
127 (50.0 mg, 0.08 mmol) was treated with Me3GeH (19.0 mg, 18.8 L 0.16 mmol) in dry THF 
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(5 mL) as described in Method B (with injection of Me3GeH into the reaction mixture via syringe 
and progressive warming from 0 °C to 25 °C) for 10 h. The volatiles were evaporated and the oily 
residue was column chromatographed (hexane/EtOAc, 3:2) to give E/Z-129b (24.5 mg, 41%; E/Z, 
45:55). 1H NMR  0.12 (s, 4.05H), 0.20 (s, 4.95H), 2.40, 2.43, 2.44 (singlets, 9H), 4.68-4.82 (m, 
3H), 5.72 (“t”, J = 6.0 Hz, 0.55H), 5.78 (“t”, J = 6.3 Hz, 0.45H), 5.82 (dd, J = 6.1, 3.9 Hz, 0.55H), 
5.88 (dd, J = 5.8, 2.8 Hz, 0.45H), 5.98 (d, J = 13.7 Hz, 0.55H), 6.34 (d, J = 5.9 Hz, 0.55H), 6.37 
(d, J = 19.0 Hz, 0.45H), 6.50 (d, J = 6.8 Hz, 0.45H), 6.69 (d, J = 19.0 Hz, 0.45H), 6.72 (dd, J = 
13.7, 1.0 Hz, 0.55H), 7.16-7.32 (m, 6H), 7.34 (d, J = 1.0 Hz, 0.55H), 7.54 (s, 0.45H), 7.83-8.04 
(m, 6H), 8.24 (br. s, 0.45H), 8.27 (br. s, 0.55H); 13C NMR  -2.0, -0.2, 21.7, 63.7, 64.2, 71.1, 71.5, 
73.45, 73.53, 80.7, 81.0, 86.9, 88.0, 114.4, 116.0, 125.65, 125.70, 125.96, 125.97, 126.3, 126.5, 
129.24, 129.25, 129.29, 129.4, 129.6, 129.71, 129.73, 129.88, 129.9, 129.95, 130.0, 131.8, 134.1, 
134.4, 135.1, 135.8, 138.7, 144.3, 144.5, 144.57, 144.63, 144.64, 144.7, 149.3, 149.7, 161.3, 
161.7, 165.3, 165.35, 165.38, 165.5, 166.1; MS (ESI+) m/z 765 (100, MNa+, 74Ge), 763 (71, MNa+, 
72Ge), 762 (52 MNa+, 70Ge); Anal. Calcd for C38H40GeN2O9 • H2O (759.39): C, 60.10; H, 5.57; N, 
3.69. Found: C, 60.39; H, 5.38; N, 3.87.   
5-(E/Z)-[2-(Trimethylgermyl)ethenyl]uridine (130b). A 0.1 N solution of MeONa in 
anhydrous MeOH (2 mL) was added to 129b (18.8 mg, 0.025 mmol; E/Z, 45:55) and the 
resulting mixture stirred for 6 h. An additional portion of 0.1N MeONa/MeOH was added (0.75 
mL) and stirring was continued until the substrate 129b was consumed (TLC). The reaction 
mixture was carefully neutralized by addition of Dowex 50WX2-200(H+) to pH 6.2. The 
mixture was filtered, and the resin washed with MeOH. The combined filtrate was evaporated 
under reduced pressure and the residue partitioned between Et2O/H2O. The organic layer was 
extensively washed with water. The combined aqueous layer was evaporated to yield E/Z-130b (7 
mg, 71%; E/Z, 40:60): 1H NMR (D2O)  0.27 (s, 5.4H), 0.32 (s, 3.6H), 3.84-3.91 (m, 1H), 3.95 
(dd, J = 12.7, 2.7 Hz, 0.6H), 4.05 (dd, J = 12.9, 2.4 Hz, 0.4H), 4.18-4.24 (m, 1H), 4.29 (“t”, J = 
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5.0 Hz, 0.6H), 4.34 (“t”, J = 5.7 Hz, 0.4H), 4.39-4.44 (m, 1H), 6.00 (d, J = 3.8 Hz, 0.4H), 6.05 (d, 
J = 5.3 Hz, 0.6H), 6.36 (d, J = 13.6 Hz, 0.6H), 6.70 (d, J = 19.0 Hz, 0.4H), 6.83 (d, J =19.0 Hz, 
0.4H), 6.93 (d, J =13.6 Hz, 0.6H), 7.77 (s, 0.6H), 8.20 (s, 0.4H); 13C NMR (MeOH-d4)  -2.9, -
1.2, 60.1, 61.0, 68.9, 69.8, 73.7, 74.1, 84.0, 84.7, 88.8, 89.7, 113.8, 115.7, 132.1, 134.1, 134.7, 
137.6, 137.8, 140.8, 151.1, 151.6, 164.6, 165.3; HRMS calcd for C14H2374GeN2O6 [M + H]+ 
389.0762, found 389.0775.  
1-(2-Deoxy-3,5-di-O-p-toluoyl--D-erythro-pentofuranosyl)-5-(Z)-[2-(triphenylgermyl) 
ethenyl]uracil (131a) and 1-(2-deoxy-3,5-di-O-p-toluoyl--D-erythro-pentofuranosyl)-5-[2-
(triphenylgermyl)acetyl]uracil (134a). Nucleoside 128178 (44 mg, 0.09 mmol) was treated with 
Ph3GeH (30 mg, 0.1 mmol) in dry THF (5 mL) as described in Method B. After 6 h at -78 oC 
TLC revealed slow progression towards product. Thus, the reaction mixture was slowly warmed 
to 0 oC until TLC showed approximately 95% consumption of the starting 128. The volatiles were 
evaporated under vacuum and the residue was column chromatographed (hexane/EtOAc, 3:2) to 
give a separable mixture of Z-131a (43 mg, 61%) and 134a (9 mg, 12%). Compound Z-131a had: 
1H NMR  1.68 (ddd, J = 14.9, 8.1, 7.0 Hz, 1H), 2.31 (ddd, J = 14.5, 5.7, 1.8 Hz, 1H), 2.41 (s, 
3H), 2.45 (s, 3H), 4.16 (dd, J = 11.1, 3.5 Hz, 1H), 4.26-4.30 (m, 1H), 4.32 (dd, J = 11.1, 5.0 Hz, 
1H), 5.15 (“dt”, J = 6.8, 1.8 Hz, 1H), 5.84 (dd, J = 8.1, 5.7 Hz, 1H), 6.51 (d, J = 13.5 Hz, 1H), 
7.11 (d, J = 1.0 Hz, 1H), 7.21-7.27 (m, 5H), 7.36-7.40 (m, 9H), 7.52-7.56 (m, 6H), 7.88 (d, J = 8.2 
Hz, 2H), 7.91 (d, J = 8.2 Hz, 2H); 13C NMR  21.68, 21.72, 37.3, 63.9, 74.5, 82.3, 85.5, 114.8, 
126.4, 126.7, 128.5, 129.2, 129.25, 129.28, 129.6, 129.8, 131.0, 134.8, 135.6, 136.6, 138.8, 144.2, 
144.5, 149.3, 161.7, 165.8, 166.0; HRMS calcd for C45H4174GeN2O7 [M + H]+ 795.2120, found 
795.2131.  
Compound 134a had: 1H NMR  2.18-2.27 (m, 1H), 2.36 (s, 3H), 2.45 (s, 3H), 2.64 (ddd, J = 
14.3, 5.7, 1.8 Hz, 1H), 3.81 (d, J = 9.1 Hz, 1H), 3.85 (d, J = 9.1 Hz, 1H), 4.53-4.60 (m, 2H), 4.74-
4.80 (m, 1H), 5.54 (“d”, J = 6.6 Hz, 1H), 6.16 (dd, J = 8.3, 5.7 Hz, 1H), 7.16 (d, J = 8.0 Hz, 2H), 
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7.28 (d, J = 8.1 Hz, 2H), 7.32-7.39 (m, 9H), 7.53-7.57 (m, 6H), 7.94 (d, J = 8.2 Hz, 2H), 7.95 (d, J 
= 8.2 Hz, 2H), 8.15 (s, 1H); 13C NMR  21.70, 21.73, 32.8, 38.4, 63.8, 74.5, 83.2, 86.2, 113.6, 
126.3, 126.6, 128.2, 129.25, 129.28, 129.3, 129.8, 135.1, 135.2, 144.1, 144.5, 145.2, 148.8, 160.3, 
165.8, 166.2, 193.5; HRMS calcd for C45H4174GeN2O8 [M + H]+ 811.2075, found 811.2063. 
Note: Treatment of 128 (50 mg, 0.10 mmol) with Ph3GeH (36 mg, 0.12 mmol) in toluene (4 
mL) as described in Method A  [DMF (0.2 mL) and water (25 µL, 25 mg, 1.4 mmol) were added 
to the pre-heated reaction mixture] gave partially separated E-131a (13 mg, 16%), 134a (6.5 mg, 
8%) and Z-131a (13 mg, 16%). Compound E-131a had characteristic peaks for trans vinylic 
protons at  6.63 (d, J = 18.8 Hz, 1H) and within the envelope of aromatic protons at  7.20-7.50 
(Cosy). 
1-(2-Deoxy-3,5-di-O-p-toluoyl--D-erythro-pentofuranosyl)-5-(E/Z)-[2-(trimethylgermyl) 
ethenyl]uracil (131b). Nucleoside 128178 (45.0 mg, 0.092 mmol) was treated with Me3GeH (21.8 
mg, 21.6 L, 0.18 mmol) in dry THF (5 mL) as described in Method B (with injection of 
Me3GeH into the reaction mixture via syringe and progressive warming from 0 °C to 25 °C) for 
10 h. The volatiles were evaporated under vacuum and the residue was column chromatographed 
(hexane/EtOAc, 1:1) to give E/Z-131b (16.5 mg, 35%; E/Z, 40:60): 1H NMR  0.14 (s, 3.6H), 
0.21 (s, 5.4H), 2.25-2.34 (m, 1H), 2.42, 2.43, 2.45 (singlets, 6H), 2.78 (ddd, J = 14.2, 5.5, 1.6 Hz, 
0.6H), 2.80 (ddd, J = 14.3, 5.1, 1.2 Hz, 0.4H), 4.56-4.61 (m, 1H), 4.65 (dd, J = 12.2, 3.2 Hz, 0.6H), 
4.73-4.77 (m, 0.8H), 4.75 (dd, J = 12.2, 3.8 Hz, 0.6H), 4.59 (“dt”, J = 4.9, 1.9 Hz, 0.6H), 4.63 
(“d”, J = 6.4 Hz, 0.4H), 6.00 (d, J = 13.7 Hz, 0.6H), 6.40 (dd, J = 8.7, 5.4 Hz, 0.6H), 6.41 (d, J = 
19.2 Hz, 0.4H), 6.46 (d, J = 8.9, 5.2 Hz, 0.4H), 6.72 (d, J = 19.0 Hz, 0.4H), 6.78 (dd, J = 13.7, 1.0 
Hz, 0.6H), 7.22-7.32 (m, 4H), 7.48 (d, J = 1.0 Hz, 0.6H), 7.67 (s, 0.4H), 7.85-7.99 (m, 4H), 8.51 
(br. s, 0.4H), 8.57 (br. s, 0.6H); 13C NMR  -2.0, -0.2, 21.70, 21.73, 38.5, 64.1, 64.4, 74.7, 75.0, 
82.9, 83.1, 85.6, 113.9, 115.4, 126.3, 126.4, 126.5, 129.30, 129.34, 129.50, 129.54 129.6, 129.8, 
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131.9, 133.9, 134.2, 134.9, 135.1, 138.3, 144.4, 144.5, 144.6, 149.2, 149.7, 161.5, 161.9, 166.0, 
166.1; HRMS calcd for C30H3474GeN2NaO7 [M + Na]+ 631.1470, found 631.1482. 
Note. Treatment of 131b (E/Z, 40:60; 12 mg; 0.02 mmol;) with NBS (5 mg, 0.028 mmol) in 
CHCl3/CH2Cl2 (1:1.5, v/v; 2.5 mL) for 6 h at 0 oC (ice-bath) followed by deprotections with 
NH3/MeOH  (0 oC to ambient temperature, 12 h) gave give E and Z 5-(2-bromovinyl)-2'-
deoxyuridine (2:3, 70% overall from 131b) with data as reported.64,215 
1-(-D-Erythro-pentofuranosyl)-5-(Z)-[2-(triphenylgermyl)ethenyl]uracil (132a). A 
saturated solution of MeOH/NH3 (2 mL) was added to a suspension of Z-131a (33 mg, 0.042 
mmol) in MeOH (2 mL) and the resulting mixture was stirred for 20 h at ambient temperature. An 
additional portion of MeOH/NH3 solution (1 mL) was added and the solution was stirred for 48 h 
at ambient temperature. The volatiles were evaporated and the residue was column 
chromatographed (dry method, EtOAc) to give Z-132a (15 mg, 65%): 1H NMR (MeOH-d4)  
1.44 (ddd, J = 14.2, 7.9, 6.6 Hz, 1H), 1.87 (ddd, J = 13.6, 5.9, 2.7 Hz, 1H), 3.38 (“d”, J = 4.4 Hz, 
2H), 3.70 (“q”, J = 3.8 Hz, 1H), 3.97 (ddd, J = 6.0, 3.3, 2.8 Hz, 1H), 5.81 (dd, J = 8.0, 6.0 Hz, 1H), 
6.52 (d, J = 13.3 Hz, 1H), 7.28 (d, J = 1.1Hz, 1H), 7.31 (dd, J = 13.3, 1.1 Hz, 1H), 7.36-7.41 (m, 
9H), 7.49-7.54 (m, 6H); 13C NMR (MeOH-d4)  40.3, 63.0, 72.3, 86.3, 88.6, 115.8, 129.5, 130.2, 
131.8, 135.9, 138.1, 138.2, 140.8, 151.6, 164.7; MS (ESI+) m/z 581 (100, MNa+, 74Ge), 579 (70, 
MNa+, 70Ge), 577 (49, MNa+, 70Ge); Anal. Calcd for C29H28GeN2O5 (557.18): C, 62.51; H, 5.07; 
N, 5.03. Found: C, 62.14; H, 5.28; N, 4.86.  
1-N-Benzyluracil (92). In a flame-dried 100 mL round-bottomed flask uracil (1.8 g, 16.0 
mmol) was suspended in 1,1,1,3,3,3-hexamethyldisilazane (HMDS; 20 mL) and stirred for 10 
min under nitrogen. Trimethylsilyl chloride (687 mg, 800 L, 6.33 mmol) was added via syringe 
and the resulting mixture was refluxed (125 °C, oil bath) for 2 h until it became a clear solution. 
Volatiles were evaporated in vacuum and the resulting white solid was dissolved in 1,2-
dichloroethane (70 mL). Benzyl bromide (3.29 g, 2.29 mL, 19.25 mmol) followed by I2 (100 mg, 
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0.39 mmol) were added and the resulting orange solution was refluxed for 5 h. Volatiles were 
evaporated and the brownish solidified residue was washed with small amount of cold MeOH (2 
× 2 mL). The resulting orange solid was recrystallized from EtOH to give 92 (2.75 g, 75%; two 
crops) as a white solid with data identical as reported:210 1H NMR  4.92 (s, 2 H, CH2), 5.70 (dd, 
3J5-6 = 7.9 Hz, 1 H, H5), 7.15 (d, 3J6-5 = 7.9 Hz, 1 H, H6), 7.27-7.41 (m, 5 H, Ph). GC-MS (tR 
21.90 min) m/z 202 (27, M+), 200 (<1), 91 (100). 
1-N-Benzyl-4-thiouracil (137). Compound 92 (501 mg, 2.48 mmol) was placed in a flamed-
dry round-bottomed flask under a N2 atmosphere and dissolved in dry THF (40 mL). Dried 
Lawesson’s reagent (1.02 g, 2.52 mmol) was added and the resulting suspension was heated at 
56 °C for about 1 h until TLC showed 95% consumption of the substrate 92. Volatiles were 
evaporated and the residue was partitioned between NaHCO3 and EtOAc. The organic phase was 
washed with brine and was dried over anhydrous Na2SO4. Column chromatography 
(hexanes/EtOAc, 3:2) gave 137216 (315 mg, 65%) as a yellowish solid: 1H NMR  4.92 (s, 2 H, 
CH2), 6.36 (d, 3J5-6 = 7.5 Hz, 1 H, H5), 6.98 (d, 3J6-5 = 7.5 Hz, 1 H, H6), 7.28-7.33 (m, 2 H, Ph), 
7.34-7.43 (m, 3 H, Ph), 9.86 (br. s, 1 H, NH). 13C NMR  51.9, 113.5, 128.3, 128.9, 129.3, 134.4, 
138.6, 148.4, 189.8. GC-MS (tR 27.26 min.) m/z 218 (39, M+), 91 (100). 
1-Benzyl-4-(methylthio)-2(1H)-pyrimidinone (138). Freshly distilled Et3N (146 mg, 203 
L, 1.44 mmol) was added to a stirred solution of 137 (314.8 mg, 1.44 mmol) in dry CH2Cl2 (42 
mL) at ambient temperature under N2. After 10 min, methyl iodide (410 mg, 180 L, 2.89 mmol) 
was added via syringe and the reaction vessel was covered with aluminum foil. After 1.5 h, the 
volatiles were evaporated and the residue was dissolved in CH2Cl2 and was washed with H2O 
(2×). The organic layer was dried (Na2SO4) and was evaporated to give 138217 (320 mg, 93%): 1H 
NMR  2.57 (s, 3 H, Me), 5.04 (s, 2 H, CH2), 6.16 (d, 3J5-6 = 6.8 Hz, 1 H, H5), 7.22 (d, 3J6-5 = 6.8 
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Hz, 1 H, H6), 7.29-7.40 (m, 5 H, Ph); 13C NMR  12.9, 52.9, 103.8, 128.5, 128.5, 129.1, 135.4, 
143.1, 154.9, 177.7. GC-MS (tR 24.39 min.) m/z 232 (44, M+), 91 (100). 
4-[18O]-1-N-benzyluracil (139). Compound 137 (248 mg, 1.07 mmol) was suspended in 
anhydrous absolute EtOH (6 mL) and stirred at room temperature for 5 min in a screw-capped 
glass tube. Isotope enriched H2[18O] (277 mg, 250 L, 12.5 mmol, 99.2% 18O) was added via 
syringe followed by three drops of concentrated HCl and the mixture was refluxed until TLC 
showed consumption of the all substrate 138. The volatiles were evaporated and the residue was 
partitioned between CHCl3 and NaHCO3 solution. The organic layer was washed with brine, 
dried (MgSO4), evaporated and the residue was column chromatographed (hexanes/EtOAc, 2:3) 
to give 139 (197 mg, 90%) as a puffy white powder with data identical to the reported above for 
92; except for GC-MS (tR 21.91 min) m/z 204 (22, M+), 202 (3.3, M-2), 91 (100). The 18O/16O 
ratio in 6 (85:15) was calculated from the peak intensities at m/z 204 and 202. 
1-N-Benzyl-5-iodouracil (140). Iodine monochloride (ICl; 361 mg, 2.22 mmol) was added to 
a stirred solution of 92 (297.6 mg, 1.47 mmol) in dry CH2Cl2 (30 mL) at ambient temperature 
under N2. The resulting red-wine solution was refluxed until TLC showed complete consumption 
of 92. The reaction mixture was diluted with CH2Cl2 (30 mL) and decolorized with the minimum 
amount of 2% NaHSO3 aqueous solution. The organic phase was washed with H2O (20 mL), 
dried (Na2SO4) and was evaporated to give crude 140 as a slightly yellow solid. Washing of this 
material with small amount of cold MeOH (3 × 2 mL) yielded 140168 (446 mg, 93%) as white 
powder: 1H NMR  4.92 (s, 2 H, CH2), 7.28-7.32 (m, 2 H, Ph), 7.35-7.44 (m, 3 H, Ph), 7.59 (s, 1 
H, H6), 8.42 (br. s, 1 H, NH); 13C NMR  51.6, 68.2, 128.1, 128.9, 129.3, 134.6, 148.3, 150.4, 
159.9. GC-MS (tR 25.90 min.) m/z 328 (30, M+), 91 (100), with no peak at m/z 326 (M-2)+. 
4-[18O]-1-N-benzyl-5-iodouracil (141). Treatment of 139 (257 mg, 1.26 mmol) with ICl 
(310 mg, 1.9 mmol), as described for 140, afforded 141 (394 mg, 95%) as a white powder with 
data identical to that reported above for 140, except for GC-MS (tR 25.90 min.) m/z 330 (24, M+), 
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328 (5, M-2), 91 (100). The 18O/16O ratio in 141 (83:17) was calculated from peak intensities at 
m/z 330 and 328. 
1-N-Benzyl-5-[(trimethylsilyl)ethynyl]uracil (142). Compound 140 (602 mg, 1.83 mmol) 
was suspended in freshly distilled Et3N (56 mL) and the mixture degassed for 1 h. 
Trimethylsilylacetylene (723 mg, 1.04 mL, 7.36 mmol) was added followed by (PPh3)2PdCl2 (30 
mg, 0.043 mmol) and CuI (22 mg, 0.12 mmol). The resulting mixture was then heated at 50 °C 
until TLC showed consumption of the substrate 140. Volatiles were evaporated and the brownish 
residue was chromatographed (CH2Cl2/EtOAc, 10:1) to give 142169 (438 mg, 80%) as a off white 
powder: 1H NMR  0.21 (s, 9 H, Me3), 4.92 (s, 2 H, CH2), 7.28-7.32 (m, 2 H, Ph), 7.35-7.43 (m, 3 
H, Ph), 7.47 (s, 1 H, H6), 8.35 (br. s, 1 H, NH); 13C NMR  -0.2 (Me), 51.7 (CH2), 94.8, 100.1, 
100.6, 128.1, 128.9, 129.3, 134.6, 147.1, 149.7, 161.0. GC-MS (tR 26.68 min.) m/z 298 (29, M+), 
283 (29, M-15), 91 (100), with no peak at m/z 296 (M-2)+. 
4-[18O]-1-N-Benzyl-5-[(trimethylsilyl)ethynyl]uracil (143). Treatment of 141 (388 mg, 1.18 
mmol), as described for 142, gave 143 (218 mg, 62%) as a off white powder with data identical to 
that reported above for 142, except for GC-MS (tR 26.67 min.) m/z 300 (23, M+), 298 (4, M-2), 
285 (23, M-15), 91 (100). The 18O/16O ratio in 143 (14:86) was calculated from the peak 
intensities at m/z 300 and 298. 
1-N-Benzyl-5-ethynyluracil (135). Procedure A. TBAF (1 M/THF; 1.88 mL, 1.88 mmol,) 
was added via syringe to a stirred solution of 142 (560 mg, 1.88 mmol) in dry THF (32 mL) at 0 
oC (ice-bath). After 1 h, the volatiles were evaporated and the oily yellowish residue was 
dissolved in CHCl3 (30 mL) and successively washed with saturated NaHCO3 and brine. The 
organic layer was dried (Na2SO4) and was column chromatographed (CH2Cl2/EtOAc, 5:1) to give 
135169 (390 mg, 92%) as white powder: UV (MeOH) max 292 nm (ε 12 600), min 251 (ε 2000); 
1H NMR (DMSO-d6)  4.15 (s, 1 H, CCH), 4.92 (s, 2 H, CH2), 7.35-7.42 (m, 5 H, Ph), 8.31 (s, 1 
H, H6), 11.71 (br. s, 1 H, NH); 13C NMR (DMSO-d6)  50.8 (CH2), 76.1, 83.7, 97.2, 127.5, 127.8, 
102 
 
128.6, 136.4, 149.5, 150.0, 162.1. GC-MS (tR 26.63 min) m/z 226 (19, M+), 91 (100), no peak at 
m/z 224 (M-2)+; HRMS calcd for C13H11N2O2 [M + H]+ 227.0815, found 227.0805. 
Procedure B. NH4F (1.05 g, 28.1 mmol) was added to a stirred solution of 142 (645 mg, 2.16 
mmol) in MeOH (25 mL) and the resulting suspension was refluxed until TLC showed total 
consumption of 142 (10 h). The reaction mixture was allowed to cool down to ambient 
temperature and was filtered off. The mother liquor was evaporated and the residue was column 
chromatographed (CHCl3) to afford 135 (330 mg, 67%). 
4-[18O]-1-N-Benzyl-5-ethynyluracil (136). Treatment of 143 (209 mg, 0.70 mmol) by 
Procedure A gave 136 (123 mg, 78%) as a white powder with data identical to the reported above 
for 135, except for GC-MS (tR 26.73 min) m/z, 228 (16, M+), 226 (3, M-2), 91 (100). The 18O/16O 
ratio in 136 (14:86) was calculated from the peak intensities at m/z 228 and 226. HRMS calcd for 
C13H11N2O18O [M + H]+ 229.0857, found 229.0848. 
1-N-Benzyl-5-(Z)-[2-(triphenylgermyl)ethenyl]uracil (144). Alkyne 135168,169 (50 mg, 0.22 
mmol) was dissolved in dry THF (5 mL) and the resulting solution was stirred for 20 min under 
N2 at 0 °C in a screw-capped glass tube. Ph3GeH (73 mg, 0.24 mmol) and Et3B (1M/THF 265 uL, 
0.265 mmol,) were added and the resulting solution was stirred at 0 °C for 7 h. The volatiles were 
evaporated and the resulting bright-yellow liquid was column chromatographed (hexane/EtOAc, 
1:1) to give Z-144 (61 mg, 52%) as a white powder: M.p. 202-204 oC (MeOH); UV (MeOH) max 
296 nm (ε 11 000), min 255 (ε 3500); 1H NMR  4.03 (s, 2H), 6.30 (d, J = 13.5 Hz, 1H), 6.69 
(“d”, J = 7.0 Hz, 2H), 6.84 (s, 1H), 7.09 (“t”, J = 7.5 Hz, 2H), 7.16 (“t”, J = 7.1 Hz, 1H), 7.23-7.35 
(m, 10H), 7.37-7.46 (m, 6H), 8.51 (br. s, 1H); 13C NMR  51.2, 113.7, 128.3, 128.3, 128.4, 128.8, 
129.1, 129.5, 134.8, 135.0, 136.7, 138.7, 141.0, 150.1, 162.4; HRMS calcd for 
C31H2674GeN2NaO2 [M + Na]+ 555.1105, found 555.1113. 
1-N-Benzyl-5-(E)-[2-(triphenylgermyl)ethenyl]uracil (144). Ph3GeH (118.6 mg, 0.38 
mmol) and H2O (25 µL, 25 mg, 1.4 mmol) were added to a stirred solution of 135 (80 mg, 0.35 
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mmol) in toluene (5 mL) at ambient temperature. The resulting mixture was heated 100 oC (oil-
bath) for 12 h and was cooled down to ambient temperature. The volatiles were removed in vacuo 
and the resulting oily residue was column chromatographed (CH2Cl2/EtOAc, 10:1) to give E-144 
(126 mg, 86%) as white solid. Recrystallization from MeOH gave white crystals: M.p. 185-186 
oC; UV (MeOH) max 300 nm (ε 13 900), 251 nm (ε 15 500), min 272 (ε 7100); 1H NMR  4.92 
(s, 2H), 6.56 (d, J = 18.7 Hz, 1H), 7.21 (s, 1H), 7.28-7.30 (m, 2H), 7.33 (d, J = 18.7 Hz, 1H), 
7.35-7.39 (m, 12H), 7.49-7.51 (m, 6H), 8.78 (br. s, 1H); 13C NMR  51.5, 113.8, 127.2, 127.9, 
128.3, 128.6, 129.1, 129.2, 135.1, 135.2, 136.1, 136.9, 141.7, 150.1, 161.8; HRMS calcd for 
C31H2674GeN2NaO2 [M + Na]+ 555.1105, found 555.1111. Anal. Calcd for C31H26GeN2O2 
(531.19): C, 70.09; H, 4.93; N, 5.27. Found: C, 69.82; H, 4.64; N, 5.35. 
1-N-Benzyl-5-[2-(triphenylgermyl)acetyl]uracil (146). Alkyne 135 (50 mg, 0.22 mmol) 
was suspended in dry toluene (5 mL) and the suspension was degassed with N2 for 45 min at 
ambient temperature in a screw-capped glass tube. Ph3GeH (73 mg, 0.24 mmol) and ACCN (10 
mg, 0.041 mmol) were added and the suspension was heated at 85 °C for 2 h (TLC showed 
approximately 80% consumption of 135). The volatiles were evaporated under vacuum and the 
resulting yellow oil was slowly column chromatographed (hexane/EtOAc, 3:2) to give 146 (15 
mg, 13%) followed by Z-144 (31 mg, 27%): The compound 146 was recrystallized from warm 
MeOH to give colorless crystals: M.p. 205-207 oC; UV (MeOH) max 294 nm (ε 10 600), min 255 
(ε 3800); 1H NMR  3.81 (s, 2H), 4.77 (s, 2H), 7.24-7.40 (m, 14H), 7.48-7.54 (m, 6H), 7.79 (br. s, 
1H), 7.85 (s, 1H); 13C NMR  33.1, 52.4, 113.3, 128.3, 128.5, 129.1, 129.3, 129.5, 134.5, 135.2, 
135.3, 149.7, 149.9, 160.7, 194.3; HRMS calcd for C31H2674GeN2NaO3 [M + Na]+ 571.1054, 
found 571.1068; Anal. Calcd for C31H26GeN2O3 (547.2): C, 68.04; H, 4.79; N, 5.12. Found: C, 
68.26; H, 4.60; N, 4.81. 
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Analogous treatment of 135 (40 mg, 0.18 mmol) with Ph3GeH (59 mg, 0.20 mmol) without 
ACCN [100 °C (oil-bath)/10 h] gave an oily residue that was column chromatographed 
(CH2Cl2/EtOAc, 10:1) to give 146 (19 mg, 20%) as a white powder and Z-144 (33 mg, 34%).  
1-N-Benzyl-5-acetyluracil (152). Procedure A. A solution of 146 (15 mg, 0.03 mmol) in 
CH3OH (3 mL) was heated for 12 h at 65 oC (oil-bath). Volatiles were evaporated and the residue 
was column chromatographed (CH2Cl2/EtOAc, 2:1) to give 152218 (6.5 mg, 95%) as a white 
powder: UV (MeOH) max 290 nm (ε 12 200), 226 nm (ε 8100), min 249 (ε 1400); 1H NMR  
2.61 (s, 3H), 5.01 (s, 2H), 7.33-7.41 (m, 5H), 8.28 (s, 1H), 8.59 (br. s, 1H); 13C NMR  30.6, 52.5, 
112.8, 128.3, 129.0, 129.3, 134.3, 150.2, 150.6, 161.2, 193.9. GC-MS (tR 26.87 min) m/z 244 (20, 
M+), 91 (100); HRMS calcd for C13H12N2NaO3 [M + Na]+ 267.0740, found 267.0739. 
Procedure B. H2SO4 (0.5 M; 7 mL) was added dropwise to a stirred solution of 135 (100 mg, 
0.44 mmol) in THF (5 mL) at ambient temperature and the resulting mixture was heated at 70 oC 
(oil-bath) for 7 h. CH2Cl2 (15 mL) was added to the cooled down reaction mixture and the 
separated organic layer was washed with saturated NaHCO3, brine, and was dried over anhydrous 
Na2SO4. Volatiles were evaporated and the residue was column chromatographed (CH2Cl2/EtOAc, 
2:1) to give 152 (95 mg, 88%) with data as reported above. 
1-N-Benzyl-5-(2-deuterioacetyl)uracil (153). Treatment [18 h, 65 oC (oil-bath)] of 146 (10 
mg, 0.02 mmol) as described above for 152 (Procedure A) using MeOD or MeOH-d4 instead of 
MeOH gave 153 (4.2 mg, 94%): GC-MS (tR 26.87 min) m/z 245 (20, M+), 91 (100). 1H NMR 
spectrum of 153 corresponded to this of the above 152 with 1/3 reduction of the integrated 
intensity for the signal from methyl group at 2.61 ppm. 
(E)-1-N-benzyl-5-(1-chloro-2-tosylvinyl)uracil (158). Method A: Fe(acac)3 (3 mg, 0.01 
mmol), Ph3P (3 mg, 0.01 mmol) and tosylchloride 157 (29 mg, 0.15 mmol) was added to a 
stirring solution of 1-N-benzyl-5-ethynyluracil 135 (22.6 mg, 0.1 mmol) in 2 mL toluene at 
ambient temperature. The resulting solution was stirred at 100 oC (oil bath) for 16 h. Volatiles 
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were removed under the reduced pressure and the residue was chromatographed (Hexane : EtOAc 
= 1:1) to give 158 (24.8 mg, 60 %) as white solid. Compound 158 had:1H NMR δ 2.23 (s, 3H), 
4.82 (s, 2H), 6.70 (s, 1H), 7.09 (d, J = 8.1 Hz, 2H), 7.32-7.18 (m, 5H), 7.41 (d, J = 8.4 Hz, 2H), 
7.42 (s, 1H), 8.99 (s, 1H); 13C NMR δ 21.8, 52.4, 108.9, 128.0, 128.7, 129.1, 129.4, 130.1, 134.2, 
134.5, 136.7, 139.7, 145.4, 145.8, 150.1, 159.6; HRMS calcd for C20H18ClN2O4S [M + H]+ 
417.0670, found 417.0664. 
Method B: FeCl3·6H2O (108 mg, 0.4 mmol), TBHP (80 µL, 0.4 mmol; 5-6 M in Hexane) 
and tosylhydrazide 159 (52.2 mg, 0.28 mmol) was added to a stirring solution of 1-N-benzyl-5-
ethynyluracil 135 (45.2 mg, 0.2 mmol) in 2 mL CH3CN at ambient temperature. The resulting 
solution was stirred at 80 oC (oil bath) for 4.5 h. Volatiles were removed under the reduced 
pressure and the residue was chromatographed (Hexane:EtOAc = 1:1) to give 158 (64.9 mg, 65 %) 
as white solid with the same spectroscopic data as above. 
(E)-1-N-benzyl-5-(1-bromo-2-tosylvinyl)uracil (160) and 1-N-benzyl-5-(1,2-
dibromovinyl)uracil (161) FeBr3 (118.2 mg, 0.4 mmol) and TBHP (80 µL, 0.4 mmol; 5-6 M in 
Hexane) and tosylhydrazide 159 (149.1 mg, 0..8 mmol) was added to a stirring solution of 1-N-
benzyl-5-ethynyluracil 135 (45.2 mg, 0.2 mmol) in 2 mL CH3CN at ambient temperature. The 
resulting solution was stirred at 80 oC (oil bath) for 4.5 h. volatiles were removed under the 
reduced pressure and the residue was chromatographed to give 160 (37.8 mg, 41 %) as well as 1-
N-benzyl-5-(1,2-dibromovinyl)uracil 161 (8.2 mg, 12%). Compound 160 had 1H NMR δ 2.40 (s, 
3H), 4.99 (s, 2H), 7.09 (s, 1H), 7.27 (d, J = 8.0 Hz, 2H), 7.40-7.45 (m, 5H), 7.58 (s, 1H), 7.58 (d, 
J = 8.2 Hz, 2H), 9.29 (s, 1H); 13C NMR δ 21.8, 52.4, 110.4, 128.0, 128.6, 128.7, 129.1, 129.4, 
130.1, 134.5, 136.6, 137.8, 145.1, 145.4, 150.2, 159.6. 
Compound 161 had 1H NMR δ 4.69 (s, 2H), 6.54 (s, 1H), 6.99 (s, 1H), 7.04-7.13 (m, 5H), 
8.93 (s, 1H); 13C NMR δ 51.9, 109.0, 112.1, 112.5, 128.3, 129.0, 129.4, 134.6, 145.3, 150.4, 
159.7. 
106 
 
2,3,5-Tri-O-acetyl-5-(1-chloro-2-tosylvinyl)uracil (165). FeCl3·6H2O (108 mg, 0.4 mmol), 
TBHP (80 µL, 0.4 mmol; 5-6 M in Hexane) and tosylhydrazide 159 (52.2 mg, 0.28 mmol) was 
added to a stirring solution of 2,3,5-tri-O-acetyl-5-ethynyluridine 162 (78.9 mg, 0.2 mmol) in 2 
mL CH3CN at ambient temperature. The resulting solution was stirred at 80 oC (oil bath) for 4.5 h. 
After cooled down to room temperature, volatiles were removed under the reduced pressure and 
the residue was chromatographed (Hexane : EtOAc = 1:1 → 4:6) to give 165 (80 mg, 68%) as 
white solid. 1H NMR δ 2.12 (s, 3H), 2.14 (s, 3H), 2.18 (s, 3H), 2.42 (s, 3H), 4.37-4.47 (m, 3H), 
5.36-5.41 (m, 1H), 5.44 (t, J = 5.5 Hz, 1H), 6.10 (d, J = 5.3 Hz, 1H), 6.94 (s, 1H), 7.32 (d, J = 8.1 
Hz, 2H), 7.71 (d, J = 8.2 Hz, 2H), 7.82 (s, 1H), 8.63 (s, 1H); 13C NMR δ 20.6, 20.7, 21.0, 21.8, 
63.2, 70.4, 73.4, 80.7, 88.0, 109.4, 128.1, 130.2, 135.3, 136.7, 139.6, 141.6, 145.5, 149.2, 159.6, 
169.6, 169.7, 170.5; HRMS calcd for C24H25ClN2NaO11S [M + Na]+ 607.0760, found 607.0755. 
2,3,5-Tri-O-acetyl-1-(-D-arabinofuranosyl)-5-(1-chloro-2-tosylvinyl)uracil (166). 
FeCl3·6H2O (108 mg, 0.4 mmol), TBHP (80 µL, 0.4 mmol; 5-6 M in Hexane) and tosylhydrazide 
159 (52.2 mg, 0.28 mmol) was added to a stirring solution of 2,3,5-tri-O-acetyl-1-(-D-
arabinofuranosyl)-5-ethynyluracil 123 (78.9 mg, 0.2 mmol) in 2 mL CH3CN at ambient 
temperature. The resulting solution was stirred at 80 oC (oil bath) for 4.5 h. After cooled down to 
room temperature, volatiles were removed under the reduced pressure and the residue was 
chromatographed (Hexane : EtOAc = 1:1 → 4:6) to give 166 (77 mg, 66%) as white solid. 1H 
NMR δ 2.11 (s, 3H). 2.15 (s, 6H), 2.41 (s, 3H), 4.22-4.28 (m, 1H), 4.41 (dd, J = 4.2, 12.0 Hz, 1H), 
4.48 (dd, J = 6.3, 12.0 Hz, 1H), 5.13 (dd, J =1.3, 2.7 Hz, 1H), 5.45 (dd, J = 1.5, 4.0 Hz, 1H), 6.30 
(d, J = 4.0 Hz, 1H), 6.84 (s, 1H), 7.33 (d, J = 8.1 Hz, 2H), 7.75 (d, J = 8.3 Hz, 2H), 7.80 (s, 1H), 
9.36 (s, 1H); 13C NMR δ 20.8, 20.9, 21.8, 62.6, 74.3, 76.5, 81.3, 85.0, 109.8, 128.1, 130.2, 134.2, 
136.7, 138.5, 141.5, 145.5, 149.1, 159.3, 169.2, 169.7, 180.8; HRMS calcd for C24H26ClN2O11S 
[M + H]+ 585.0940, found 585.0918. 
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3,5-Di-O-acetyl-5-(1-chloro-2-tosylvinyl)uridine (167). FeCl3·6H2O (540 mg, 2 mmol), 
TBHP (400 µL, 2 mmol; 5-6 M in Hexane) and tosylhydrazide 159 (372 mg, 2 mmol) was added 
to a stirring solution of 3,5-di-O-acetyl-2'-deoxy-5-ethynyluridine 163 (336 mg, 1 mmol) in 6 mL 
CH3CN at ambient temperature. The resulting solution was stirred at 80 oC (oil bath) for 4.5 h. 
After cooled down to room temperature, volatiles were removed under the reduced pressure and 
the residue was chromatographed (Hexane : EtOAc = 1:1 → 4:6) to give 167 (400 mg, 76%) as 
white solid. 1H NMR δ 2.12 (s, 3H), 2.16 (s, 3H), 2.27-2.37 (m, 1H), 2.42 (s, 3H), 2.58 (ddd, J = 
1.7, 5.5, 14.3 Hz, 1H), 4.30-4.35 (m, 2H), 4.46 (td, J = 2.3, 5.0 Hz, 1H), 5.27 (d, J = 6.4 Hz, 1H), 
6.35 (dd, J = 5.5, 8.5 Hz, 1H), 6.89 (s, 1H), 7.32 (d, J = 8.0 Hz, 1H), 7.69 (d, J = 8.3 Hz, 1H), 
7.88 (s, 1H), 8.83 (s, 1H); 13C NMR δ 21.02, 21.04, 21.8, 28.8, 38.2, 64.0, 74.4, 83.1, 85.7, 109.2, 
127.9, 130.2, 134.7, 136.7, 139.9, 141.5, 145.6, 149.3, 158.9, 170.5, 170.6; HRMS calcd for 
C22H24ClN2O9S [M + H]+ 527.0886, found 527.0863. 
2'-deoxyl-5-(1-chloro-2-tosylvinyl)uracil (168). FeCl3·6H2O (108 mg, 0.4 mmol), TBHP 
(80 µL, 0.4 mmol; 5-6 M in Hexane) and tosylhydrazide 159 (52.2 mg, 0.28 mmol) was added to 
a stirring solution of 5-ethynyl-2'-deoxyuridine 164 (50.5 mg, 0.2 mmol) in 2 mL CH3CN at 
ambient temperature. The resulting solution was stirred at 80 oC (oil bath) for 4.5 h. After cooled 
down to room temperature, volatiles were removed under the reduced pressure and the residue 
was chromatographed (CHCl3 : MeOH= 9:1 → 85:15) to give 168 (60.8 mg, 69%) as white solid. 
1H NMR MeOD-d6 δ 2.25-2.34 (m, 1H), 2.38 (ddd, J = 13.4, 6.0, 4.1 Hz, 1H), 2.45 (s, 3H), 3.78 
(dd, J = 12.0, 3.5 Hz, 1H), 3.84 (dd, J = 12.0, 2.9 Hz, 1H), 3.99 (dd, J = 6.3, 3.0 Hz, 1H), 4.37-
4.53(m, 1H), 6.31 (t, J = 6.4 Hz, 1H), 7.23 (s, 1H), 7.39 (d, J = 7.8 Hz, 2H), 7.69 (d, J = 7.8 Hz, 
2H), 8.31 (s, 1H); 13C NMR MeOD-d6 δ 21.6, 41.8, 62.7, 72.0, 87.0, 89.3, 109.7, 129.1, 131.0, 
136.0, 138.3, 142.0, 143.9, 146.8, 151.3, 161.6; HRMS calcd for C18H19ClN2NaO7S [M + Na]+ 
465.0494, found 465.0493. 
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(E)-5-(1-amino-2-tosylvinyl)-1-N-benzyluracil (169a). (E)-1-N-benzyl-5-(1-chloro-2-
tosylvinyl)uracil 158 (41.6 mg, 0.1 mmol) was dissolved in NH3/MeOH (3 mL) at 0 oC (ice bath). 
After kept stirring for 24 h, volatiles was removed under the reduced pressure and the residue was 
dried under the high vacuum pump to give (E)-1-N-benzyl-5-(1-(butylamino)-2-tosylvinyl)uracil 
169a (27 mg, 67%) as white solid. UV (MeOH) λmax = 272 nm; 1H NMR (400 MHz, DMSO-d6) δ 
2.37 (s, 3H), 4.92 (s, 2H), 5.26 (s, 1H), 7.08 (s, 2H), 7.28-7.36 (m, 7H), 7.75 (d, J = 8.2 Hz, 2H), 
8.35 (s, 1H); 1H NMR (400 MHz, DMSO-d6 + D2O) δ 2.35 (s, 3H), 4.90 (s, 2H), 5.24 (s, 1H), 
7.28-7.36 (m, 7H), 7.73 (d, J = 8.2 Hz, 2H), 8.28 (s, 1H); 13C NMR (101 MHz, DMSO) δ 21.2, 
51.6, 106.9, 125.7, 127.6, 128.1, 128.9, 129.8, 136.5, 142.3, 142.9, 157.1, 150.0, 150.7, 162.3; 
HRMS calcd for C20H19N3NaO4S [M + Na]+ 420.0994, found 420.0939. 
(E)-1-N-benzyl-5-[1-(n-butylamino)-2-tosylvinyl]uracil (169b). n-Butylamine (100µL, 1 
mmol) was added to a stirring solution of (E)-1-N-benzyl-5-(1-chloro-2-tosylvinyl)uracil 158 
(41.6 mg, 0.1 mmol) in 3 mL of MeOH at ambient temperature. After kept stirring for 2 h, white 
precipitates showed up. The solid was collected by vacuum filtrated, wash with cold MeOH and 
dried under the high vacuum pump to give 1-N-benzyl-5-[1-(butylamino)-2-tosylvinyl]uracil 
169b (32 mg, 71% )as a mixture of two regioisomers with ratio 15:85 (Z:E). 1H NMR (400 MHz, 
DMSO-d6) δ 0.75 (t, J = 7.3 Hz, 0.45H), 0.85 (d, J = 7.3 Hz, 2.55H), 1.08-1.14 (m, 0.3H), 1.26-
1.36 (m, 2H), 1.42-1.47 (m, 1.7H), 2.33 (s, 2.55H), 2.33 (s, .45H), 2.89 (dd, J = 6.8,12.0 Hz, 
1.7H), 2.96 (dd, J = 6.6, 13.1 Hz, 0.3H), 4.87 (s, 1.7H), 4.91 (s, 0.3H), 7.19 (d, J = 8.0 Hz, 2H), 
7.24-7.42 (m, 6), 7.47 (d, J = 8.2 Hz, 2H), 7.67 (s, 1H), 11.41 (s, 1H); 13C NMR (101 MHz, 
DMSO-d6) δ 13.7, 19.7, 20.9, 42.8, 50.7, 93.0, 125.6, 125.8, 127.3, 127.5, 127.7, 128.5, 128.6, 
129.1, 129.5, 136.7, 141.4, 143.2, 150.6, 161.4; HRMS calcd for C24H28N3O4S [M + H]+ 
454.1795, found 454.1793. 
(E)-1-N-Benzyl-5-(1-(propylthio)-2-tosylvinyl)uracil (169c). n-Propylthiol (90µL, 1 mmol) 
and Et3N (279 µL, 20 mmol) were added to a stirring solution of (E)-1-N-benzyl-5-(1-chloro-2-
109 
 
tosylvinyl)uracil 158 (41.6 mg, 0.1 mmol) in 3 mL of MeOH at ambient temperature. After the 
reaction mixture was kept stirring for 2 h, white precipitates showed up. The solid was collected 
by vacuum filtrated, wash with cold MeOH and dried under the high vacuum pump to give 1-N-
benzyl-5-[1-(propylthio)-2-tosylvinyl]uracil 169c (28.1 mg, 62 %) as white solid. 1H NMR (400 
MHz, DMSO-d6) δ 0.92 (t, J = 7.3 Hz, 3H), 1.50-1.59 (m, 2H), 2.38 (s, 3H), 2.80 (t, J = 7.2 Hz, 
3H), 4.92 (s, 2H), 6.48 (s, 1H), 7.31-7.41 (m, 7H), 7.60 (d, J = 8.3 Hz, 2H), 7.86 (s, 1H), 11.56 (s, 
1H); 13C NMR (101 MHz, DMSO) δ 13.2, 20.6, 21.1, 33.6, 50.6, 108.9, 122.0, 127.1, 127.4, 
127.8, 128.6, 129.5, 136.7, 138.8, 143.68, 143.73, 147.6, 150.4, 160.7; HRMS calcd for 
C23H25N2O4S2 [M + H]+ 457.1250, found 457.1229. 
1-N-benzyl-5-(2-tosylacetyl)uracil (184). Fresh prepared sulfinic acid 183 (156 mg, 1.0 
mmol) was added to a stirring solution of 1-N-benzyl-5-ethynyluracil 135 (45.2 mg, 0.2 mmol) in 
1,2-dichloroethane (DCE, 2 mL) at ambient temperature. A balloon filled with oxygen was 
connected to the flask, followed by the addition of pyridine (66 µL, 64.9 mg, 0.82 mmol). The 
resulting solution was stirred at 45 oC for 4h. Then the reaction mixture was cooled down to room 
temperature and volatiles were removed under the reduced pressure. The oily residue was column 
chromatographed (Hexane : EtOAc = 1:1) to give 184 (39.8 mg, 50 %) as white solid. 1H NMR δ 
2.42 (s, 3H), 4.98 ("s", 4H), 7.29 (d, J = 8.0 Hz, 2H), 7.34-7.31 (m, 2H), 7.45-7.37 (m, 3H), 7.79 
(d, J = 8.3 Hz, 2H), 8.23 (s, 1H), 8.46 (s, 1H); 13C NMR δ 21.8, 52.9, 65.4, 112.0, 128.58, 128.61, 
129.4, 129.6, 129.9, 133.9, 137.0, 145.3, 149.6, 151.7, 160.5, 183.8; HRMS calcd for 
C20H19N2O5S [M + H]+ 399.1009, found 399.1017. 
1-N-benzyl-5-(2-benzyl-2-tosylacetyl)uracil (188). Sodium hydroxide (8 mg, 0.2 mmol) 
was added to a stirring solution of 1-N-benzyl-5-(2-tosylacetyl)uracil 184 (20 mg, 0.05 mmol) in 
MeOH (2 mL) at ambient temperature. After stirring for 5 min, benzyl bromide (9.4 mg, 6.5 µL, 
0.055 mmol) was injected to the clear solution via the syringe. The resulting solution was stirred 
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at ambient temperature for 16 h. Volatiles were removed under the reduced pressure and the 
residue was dissolved in EtOAc (5 mL) and washed with 5 % HCl solution, saturated NaHCO3 
and brine. The volatiles was removed under the reduced pressure and the residue was column 
chromatographed (Hexane : EtOAc = 6:4) to give 188 (10 mg, 50 %) as white solid. Compound 
188 Had 1H NMR δ 2.41 (s, 3H), 3.14 (dd, J = 3.5, 13.9 Hz, 1H), 3.44 (dd, J = 11.6, 13.9 Hz, 1H), 
4.91 (d, J = 14.7 Hz, 1H), 4.95 (d, J = 14.7 Hz, 1H), 6.57 (dd, J = 3.5, 11.2 Hz, 1H), 7.03-7.05 (m, 
2H), 7.09-7.15 (m, 3H), 7.26-7.30 (m, 4H), 7.38-7.41 (m, 3H), 7.80 (d, J = 8.3 Hz, 2H), 8.17 (s, 
1H), 8.83 (s, 1H); 13C NMR δ 21.8, 32.7, 52.9, 71.4, 112.6, 126.9, 128.6, 128.7, 129.0, 129.3, 
129.4, 129.5, 129.9, 133.9, 135.3, 136.2, 145.4, 149.6, 151.6, 161.0, 187.0; HRMS calcd for 
C27H25N2O5S [M + H]+ 489.1479, found 489.1458. 
2,3,5-Tri-O-acetyl-5-(α-azido)vinyl uridine (198). TMSN3 (46 mg, 0.4 mmol) and H2O (7 
µL, 0.4 mmol) were added to a stirring solution of 2,3,5-tri-O-acetyl-5-ethynyl uridine 135 (78.7 
mg, 0.2 mmol) in 2 mL of DMSO at ambient temperature. Followed by the addition of Ag2CO3 
(5.5 mg, 0.02 mmol), the suspension was heated and stirred at 80 oC for 1.5 h. After cooled down 
to roon temperature, the volatiles were removed under the reduced pressure and oily residue was 
dilute with EtOAc, washed with H2O, and brine. Organic layer was dried over anhydrous Na2SO4 
and column chromatographied (Hexan:EtOAc = 1:1) to give white solid 198 (47 mg, 54%). 1H 
NMR  2.08 (s, 3H), 2.13 (s, 3H), 2.18 (s, 3H), 4.21-4.47 (m, 3H), 5.09 (d, J = 2.2 Hz, 1H), 5.22-
5.42 (m, 2H), 6.12 (d, J = 5.8 Hz, 1H), 6.37 (d, J = 2.2 Hz, 1H), 7.76 (s, 1H), 9.57 (s, 1H); 13C 
NMR 20.50, 20.56, 20.65, 63.5, 70.1, 72.9, 80.5, 87.1, 102.5, 113.7, 137.2, 146.2, 149.6, 160.5, 
169.81, 169.83, 170.7; HRMS calcd for C17H19N5NaO9 [M + Na]+ 460.1075, found 460.1062. 
2,3,5-Tri-O-acetyl-5-{α-[(5aR,6R,6aS)-1,4,5,5a,6,6a,7,8-octahydrocyclopropa[5,6] 
cycloocta[1,2-d][1,2,3]triazol-6-yl]methanol}vinyl uridine (200). (1R,8S,9S)-
Bicyclo[6.1.0]non-4-yn-9-ylmethanol 199 (9.6 mg, 0.064 mmol) was added to a solution of 2,3,5-
Tri-O-acetyl-5-(α-azido)vinyl uridine 198 (28 mg, 0.064 mmol) in 2 mL of MeOH at ambient 
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temperature. The resulting clear solution was stirred for 8 h and the volatiles were removed under 
the reduced pressure to give clear oily residue. Followed column chromatography (CHCl3 → 
CHCl3 : MeOH =100 → 95:5) gave corresponding product 200 as a mixture of two regioisomers 
as a white solid (80%, 30 mg, 0.051 mmol). 1H NMR  0.99-1.12 (m, 2H), 1.17-1.22 (m, 1H), 
1.48-1.60 (m, 2H), 2.067-2.073 (d, 3H), 2.10 (s, 3H), 2.137-2.142 (d, 3H), 2.22-2.29 (m, 2H), 
2.61-2.67 (m, 1H), 2.87-2.94 (m, 2H), 3.17-3.22 (m, 1H), 3.68-3.74 (m, 2H), 4.13-4.15 (m, 1H), 
4.16-4.27 (m, 2H), 5.23-5.26 (m, 2H), 5.51 (s, 1H), 5.78 (d, J = 4.5 Hz, 1H), 5.81 (d, J = 4.9 Hz, 
1H), 6.55 (d, J = 4.0 Hz, 1H), 6.95 (d, 1H), 9.38 (s, 1H); 13C NMR δ 14.2, 19.8, 19.92, 19.94, 
20.1, 20.5, 20.6, 21.0, 21.5, 21.6, 22.4, 22.5, 22.6, 22.77, 22.81, 23.5, 25.9, 26.0, 31.7, 53.6, 59.79, 
59.81, 63.17, 63.20, 70.5, 73.0, 73.1, 80.4, 89.2, 89.6, 110.9, 111.0, 119.7, 119.8, 134.0, 135.1, 
135.2, 139.1, 138.3, 144.7, 144.8, 149.0, 149.1, 160.4, 169.68, 169.69, 169.8, 169.9, 170.60, 
170.62; HRMS calcd for C27H34N5O10 [M + H]+ 588.2300, found 588.2312. 
5-{α-[(5aR,6R,6aS)-1,4,5,5a,6,6a,7,8-octahydrocyclopropa[5,6]cycloocta[1,2- 
d][1,2,3]triazol-6-yl]methanol}vinyl uridine (201). Compound 200 (30.6 mg, 0.05 mmol) was 
dissolved in NH3/MeOH (3 mL) at 0 °C (ice bath), and the resulting solution was stirred 
overnight. Volatiles were removed under the reduced pressure and the residue was column 
chromatographed (CHCl3:MeOH, 9:1→ 8:2) to give 201 (15 mg, 64%) as white solid. UV 
(MeOH) λmax = 283 nm; 1H NMR (DMSO-d6)  0.84-0.89 (m, 2H), 0.94-1.00 (m, 1H), 1.49-1.58 
(m, 2H), 2.02-2.11 (d, 2H), 2.55-2.61 (m, 1H), 2.80-2.84 (m, 2H), 3.00-3.05 (m, 1H), 3.37-3.41 
(m, 1H), 3.46-3.48 (m, 2H), 3.78-3.81 (m, 2H), 3.84-3.90 (m, 1H), 4.32 (t, J = 4.59 Hz, 1H), 4.84 
(dt, J = 5.25, 8.38 Hz, 1H), 5.11 (s, 1H), 5.38 (s, 1H), 5.44 (d, J = 4.41 Hz, 1H), 5.75-5.77 (m, 
1H), 6.27-6.31 (m, 1H), 7.34-7.43 (m, 1H), 11.65 (s, 1H); 13C NMR (DMSO-d6) δ 18.61, 18.64, 
18.7, 18.9, 20.85, 20.90, 21.3, 21.8, 22.5, 22.87, 22.97, 25.5, 25.6, 48.6, 54.9, 57.35, 57.38, 60.97, 
61.03, 69.95, 69.99, 74.03, 85.0, 88.2, 88.4, 109.7, 116.3, 116.4, 134.3, 134.4, 135.3, 135.4, 
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138.89, 138.92, 143.59, 143.63, 149.69, 149.71, 160.8, 141.5; HRMS calcd for C21H27N5NaO7 [M 
+ Na]+ 484.1803, found 484.1810. 
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5. CONCLUSION  
I have developed a method for efficient transfer of one, two, or three phenyl groups from 
chloro(phenyl)germanes to the Pd catalyzed aryl halides to give the access to various biaryls. 
These cross-coupling reactions were mediated by TBAF and facilitated by adding of measured 
amount of water in toluene as solvent. The TBAF promoted Pd-catalyzed cross-coupling of 
organogermanes have been attempted to extend to the 5-halo pyrimidine nucleoside analogues for 
the synthesis of 5-aryl derivatives by transfer of phenyl groups from the germane center. 
However, during the coupling of 5-halo uracil with chloro(phenyl)germanes in toluene, in 
addition to the desired 5-phenyluracil product (formed in small quantity), an unexpected mixture 
of 5-(o,m,p-methylphenyl)uracil has been observed as the major product. In order to investigate 
the formation of such unexpected 5-aryluracil derivatives, which were formed by direct activation 
of toluene (simple arene) without necessary of using organometallic component, I have further 
studied the reaction of 1-N-benzyl-5-iodouracil with regular arenes.  
To further apply the organogermane substrates to cross-coupling reaction with 5-halouracil, I 
have also developed a method to selective transfer of phenyl group(s) from allyl(phenyl)germanes 
in Pd catalyzed cross-coupling processes. I have shown that selective cleavage of allyl-Ge bond 
upon treatment with SbF5/C can serve as an alternative method for the generation of active 
coupling species fluoro(phenyl)germanes in situ, followed by the Pd-catalyzed cross-coupling 
with aryl halides in the presence of TBAF gave various biaryls.  
I have demonstrated that TBAF-mediated Pd-catalyzed direct arylation of 5-halouracil and 
uracil nucleosides with simple arenes (e.g., benzene, toluene, and anisole) and electron rich 
heteroarenes (e.g., furan, thiophene, and pyrrole) in DMF undergoes smoothly to give 5-arylated 
analogues in high to excellent yields. This methodology has been extended to other enolizable 
heterocyclic systems, such as 3-bromo-2-pyridone. Similarly, the base-promoted Pd-catalyzed 
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direct arylation of 5-halouracils also proceeds with the π-excessive heteroarenes in the presence 
of pivalic acid.  
It is worth to mention that the TBAF-promoted direct C-H arylation protocol developed here 
differs from the existing routes to 5-aryluracils as outlined below. First, our protocol eliminates 
organometallic precursors required in Suzuki, Hiyama or Stille couplings. Secondly, no ligands or 
any other additives are required for the direct arylation to proceed smoothly. Thirdly, it is 
efficient with a variety of uracils and uracil nucleosides, which are important and the basis of the 
DNA or RNA. In addition, the protocol does not induce glycosidic bond cleavage, avoiding a 
major drawback with other methodologies.  
In my research efforts to study the chemistry of 5-ethynyl pyrimidine nucleosides, I have 
shown that the trialkyl or triphenylgermanes add across a triple bond of 5-acetylene pyrimidine 
via radical or thermal hydrogermylation. Interestingly, Z-vinylgermanyl products were obtained 
exclusively in good yields at elevated temperature; while, the E isomers are formed exclusively 
with the addition of “measured” amount of water. During the hydrogermylation of 5-
ethynyluracil nucleosides with triphenylgermane in toluene, unexpected 5-[2-
(triphenylgermyl)acetyl]uracil nucleosides were isolated up to 20 % along with the desired 
vinylgermane products. The 4-[18O]-1-N-benzyl-5-ethynyluracil was synthesized to clarify the 
formation of the unexpected β-germyl ketone as well as confirming the origin of the oxygen in 
the 5-acetyl moiety. A plausible mechanism had been proposed for the formation of the 
unexpected β-germyl ketone on the basis of literature, NMR spectroscopy and HRMS 
fragmentation analysis, which indicates that the origin of the oxygen atom in the 5-acetyl moiety 
is from the residual oxygen in the reaction solution. Interestingly, thermodegradation of the β-
ketogermyl uracil analogues in MeOH give 5-acetyluracil nucleosides in quantitative yield via 
hydrolysis of the O-germyl substituted enols. Bromodegermylation of the 5-
[(trimethyl)vinyl]germyl substrates with NBS produced 5-(2-bromovinyl) analogues with the 
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retention of the stereochemistry in high yields. However, Pd-catalyzed cross-coupling reaction of 
5-[(trimethyl)vinyl]germyl substrates with aryl halides gave corresponding products in only 10-
30%.  
I have also demonstrated that hydrosulfonylation of 5-ethynyluracil nucleoside analogues 
with either sulfinic acid or sulfonylhydrazide in the presence of iron catalyst give 5-(β-halo)vinyl 
sulfonyl uracil nucleoside analogues in moderate to high yield. It is worth mentioning that only 5-
E-(β-chloro)vinyl sulfonyl products are obtained when the reactions were performed in the 
presence of FeCl3. Moreover, when the reactions are carried out in the presence of FeBr3, a 
mixture of E/Z isomers is obtained with the ratio of 15:85 as well as the 5-(α, β-dibromo)vinyl 
substrate in small quantity. I have showed the 5-(β-halo)vinyl sulfonyl analogues can serve as 
excellent Michael acceptors and various of nucleophiles (e.g., n-butylamine, propanethiol, 
ammonia) have been added across the double to give the corresponding β-substituted 
vinylsulfones in high yields. Triethylamine was required as a catalyst for the addition of thiol due 
to the week nucleophilicity. Similarly, 1-N-benzyl-5-(2-sulfonylketo)uracil has been synthesized 
via the direct aerobic difunctionalization of 5-ethynyl substrate with sulfinic acid in the presence 
of pyridine in moderate yield. I have also demonstrated that hydroazidation of the acetyl 
protected 5-ethynyluridine with TMSN3 in the presence of silver salt and catalytic amount of 
water produced novel 5-(α-azido)vinyluridine derivatives. Comparing to the light sensitive 5-
azidouridine with half-life of 4 h in the 3% DMSO/water solution, the 5-(α-azido)vinyluridine 
turned out to be fairly stable. These 5-(α-azido)vinyluridine analogues have been showed to be an 
excellent substrates for the strain-promoted click reaction with cyclooctyne to provide novel 5-(α-
1,2,3-triazole)vinyluridine as a possible fluorescence probe.  
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